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The number of people with type 2 diabetes mellitus (T2DM) is increasing rapidly 
in Africa, straining already overstretched health systems. The association between 
hyperglycaemia first detected in pregnancy (HFDP), which includes both diabetes 
mellitus in pregnancy (DIP) and gestational diabetes mellitus (GDM), and the later 
development of T2DM and cardiovascular disease risk in the mothers and possibly 
overweight in their children is well recognised. This thesis contributes to the largely 
unexplored body of work on the prevalence of T2DM and CVD risk factors in African 
women after HFDP and the relationship between HFDP and childhood overweight and 
obesity. The thesis investigated: 1) the prevalence of T2DM and impaired glucose 
metabolism in African women of childbearing age; 2) the prevalence of T2DM and 
cardiovascular disease risk factors in women within 6 years after HFDP, and 3) the 
influence of maternal blood glucose levels during pregnancy and overweight and 
obesity in the offspring at the preschool age. 
Methods 
A systematic review and meta-analysis of all studies published from January 
2000 to 2017 was carried out to estimate the prevalence of T2DM and impaired glucose 
regulation states. In the PROgression to Diabetes study (PRO2D), women diagnosed 
with GDM using the 2008 National Institute for Health and Care Excellence (NICE) 
criteria during 2010 and 2011 at a major referral hospital and their offspring were 
reviewed up to 6 years later. Relevant maternal and foetal/neonatal data were routinely 
collected during pregnancy and birth. The women were recalled for an assessment of 
T2DM (OGTT and HbA1C) and other cardiovascular risk factors (insulin resistance, 
dysglycaemia, dyslipidaemia and obesity) and their offspring for overweight/obesity. The 
women were reclassified into DIP and GDM using the WHO 2013 criteria for the 




The pooled prevalence of T2DM was; 7.2% (95% CI 5.6% to 8.9%), impaired 
fasting glycaemia, 6.0% (95% CI 4.2% to 8.2%) IGT, 0.9% to 37.0% from 39 studies in 
27 African countries, and 53 075 participants. The response rate for the PRO2D was 
44.2% (final sample n=220). At follow up, almost half of the women, [48% (95% CI 
41.2–54.4)], had T2DM, 83% in the DIP subtype and 31% with GDM had T2DM. The 
type of treatment  [insulin (OR 25.8, 95% CI 3.9–171.4, p = 0.001), oral antidiabetic 
drugs (OR 4.1, 95% CI 1.3–12.9, p = 0.018)], fasting glucose(OR 2.7, 95% CI 1.5–4.8, 
p = 0.001), OGTT 2-hour glucose (OR 4.3, 95% CI 2.4–7.7, p < 0.001), during 
pregnancy;  current anthropometry [waist circumference (OR 1.1, 95% CI 1.0–1.1, p = 
0.007), hip circumference (OR 0.9, 95% CI 0.8–1.0, p = 0.001), BMI (OR 1.1, 95% CI 
1.0–1.3, p = 0.001)]) were associated with T2DM. The prevalence of CVD risk factors 
was:  insulin resistance 75% (95%CI 65.9-82.3), dyslipidaemia 74.6% (95%CI 68.3-
79.9), dysglycaemia 62.3% (95%CI 55.6-68.5), and raised blood pressure 41.4% 
(95%CI 35.0-48.0) and metabolic syndrome 60.9% (95%CI 54.3- 67.2). Of the 443 
neonates exposed to HFDP during pregnancy, almost one-third [29.6% (95%CI 25.5 – 
34.0)] were large-for-gestational-age (LGA) at birth and just over a fifth [21% (95%CI 
15.4 – 27.8)] were either overweight or obese at preschool age. A strong association 
was found between maternal fasting glucose at HFDP diagnosis and birth weight z-
score (OR 1.11, 95%CI 1 -1.22, p=0.046), maternal postprandial 2-hour glucose during 
the third trimester and weight z-score at birth (OR 1.23, 95%CI: 1.07 - 1.42, p = 0.005) 




The high prevalence of T2DM and CVD risk factors in relatively young women 
and overweight and obesity in their offspring within 6 years of the index pregnancy 
demonstrates the need for context-specific interventions to prevent HFDP, to optimise 









This PhD thesis is the culmination of a dream that I had after graduating with my 
Master’s degree in Clinical Epidemiology at Stellenbosch University. I was aware that 
the prevalence of non-communicable diseases was on the rise and I wanted my 
doctoral studies to contribute to a better understanding of cardiometabolic diseases, 
particularly diabetes, on the African continent.  
After some enquiries, I was invited for an interview with Professors Naomi Levitt 
and Krisela Steyn at the Chronic Disease Initiative for Africa (CDIA). During the 
interview, I spoke about my passion for epidemiology and the need to focus on the 
growing burden of non-communicable diseases (NCDs) which were already competing 
for health resources in Africa. Unbeknown to me, they already had a project on 
gestational diabetes which required a PhD student; that was the beginning of my 
doctoral studies. 
The diabetes tsunami is sweeping across the world at an alarming pace. The 
numbers of people with diabetes each year outstrip all previous projections made by the 
International Diabetes Federation. In low-to-middle-income-countries (LMIC), which 
includes African countries, the increase in diabetes prevalence is steeper and is being 
driven by a combination of nutrition and demographic transitions. Premature deaths 
from diabetes are also higher in the LMICs, compared to high-income countries (HIC). 
Yet, most of the people with diabetes have type 2 diabetes, which is preventable.  
      Gestational diabetes (GDM) not only offers us a window of opportunity to prevent 
type 2 diabetes in one individual but also offers us a chance to prevent diabetes and 
cardiovascular disease in future generations. If we manage to understand the 
epidemiology of GDM, we may be able to slow down the seemingly unstoppable tide of 
ever-increasing numbers of people with diabetes in the LMICs. In Africa, however, the 
unknowns far outstrip the knowns. We still have not answered basic epidemiology 
questions. How many women are affected by GDM? What are the risk factors of GDM 
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in Africa? How do we best detect women with GDM? How do we encourage women to 
continue the lifestyle change that they do successfully during pregnancy, into the 
postpartum era.? How many women progress to type 2 diabetes after GDM? Are the 
women with GDM more vulnerable to CVD compared to those without GDM? The 
project that my thesis became a part of, at the CDIA, the IINDIAGO project, focused on 
reducing the risk of type 2 diabetes and CVD in women after gestational diabetes. This 
thesis would subsequently contribute to the formative work for the IINDIAGO project.  
 
One of the biggest problems we currently have is that there are varied diagnostic 
criteria for GDM in different regions and countries, to the extent that a woman with GDM 
will be classified as not having GDMby simply flying from one country to another, and 
vice versa. As will become apparent later, this issue also affected how my PhD studies 
progressed. In brief, the women who we included in our study were diagnosed using 
one criterion and by the time we finished following them up, the new criteria now used in 
South Africa classified them somewhat differently! This is one of the reasons why the 
title of the thesis changed from ‘Type 2 diabetes and cardiovascular risk factors in 
women 5 to 6 years and offspring overweight and obesity after gestational diabetes, in 
Cape Town, South Africa’ to ‘Type 2 diabetes, cardiovascular risk factors and offspring 
overweight and obesity after hyperglycaemia first detected in pregnancy, in Cape Town, 
South Africa”. 
 
This thesis is organised as follows: 
Part A. Introduction 
This section comprises of chapters 1, 2 and 3 and includes the rationale, 
background of the study, literature review, aims and objectives and the methods used in 
the studies. Chapter 1 gives the rationale and a brief background of the thesis. A review 
of the literature relevant to the body of work of the thesis is in Chapter 2. The aims and 
objectives of the thesis are presented in Chapter 3, followed by an overview of the 





Part B. Empirical chapters 
 
Chapter 4 contains a systematic review and meta-analysis of the prevalence of 
T2DM in African women of childbearing age, using studies published during the period 
2000 to 2016. Data which may be used for monitoring and studying trends in the 
prevalence of diabetes in this critical demographic are presented. Chapters 5, 6 and 7 
are the result of studies undertaken in women with HFDP in Cape Town, South Africa. 
In Chapter 5, the medium-term progression to T2DM after HFDP and risk factors 
associated with postpartum T2DM are investigated. In chapter 6 the prevalence of CVD 
risk factors and insulin resistance in the same women after 6 years is described. This is 
the only published paper at present that quantifies the burden of CVD risk factors in 
these women, who are still young, with a mean age of37 years, in Africa. Chapter 7 is a 
paper which describes the link between HFDP and the developmental origins of 
cardiometabolic disease (in this case, the proxy outcomes are overweight and obese) in 
the offspring.  
Chapter 4: Prevalence of type 2 diabetes mellitus in women of childbearing age 
in Africa during 2000–2016: A systematic review and meta-analysis. 
Chapter 5: Progression to type 2 diabetes mellitus and associated risk factors 
after hyperglycaemia first detected in pregnancy: A cross-sectional study in Cape Town, 
South Africa. 
Chapter 6: Chivese T, Norris SA, Levitt NS. High prevalence of cardiovascular 
risk factors and insulin resistance 6 years after hyperglycaemia first detected in 
pregnancy in Cape Town, South Africa. BMJ Open Diabetes Res Care. 2019 Nov 
1;7(1). 
Chapter 7: The influence in a South African cohort of maternal blood glucose 
during pregnancy on weight outcomes at birth and preschool age in offspring exposed 






Part C. Integrated discussion and conclusion 
 
This chapter (chapter 8) contains a discussion that brings together all the findings 
from the thesis. Also discussed in this section are implications for policy and clinical 
practice and implications for research. Finally, the limitations and strengths of this 
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Nothing has such power to broaden the mind as the ability to investigate systematically and 














CHAPTER 1. BACKGROUND 
1.1. Rationale and problem statement 
Diabetes is a growing problem in sub-Saharan Africa, yet there are many areas 
where knowledge is limited. These areas include the prevalence, risk factors and 
outcomes of diabetes in women of childbearing age, who are uniquely affected by 
diabetes in several ways. Firstly, diabetes in women during pregnancy increases the 
risk of transmission of diabetes and other cardiometabolic diseases to their offspring 
and possibly to the offspring’s future children. Further, apart from childbearing and 
childrearing, women assume multiple and increasingly complex roles in both their 
families and their communities. These include being unpaid caregivers for members of 
the family when they get sick, as well as breadwinners and housekeepers. Therefore, a 
diagnosis of diabetes does not affect the woman only but has wide-ranging 
consequences on her family and society. Apart from preventing diabetes in women of 
childbearing age, it is important to plan for the provision of and prioritisation of 
resources for diabetes care. To do that, there is a need to establish the extent of the 
burden of diabetes in African women of childbearing age. This includes information 
about the prevalence of diabetes and impaired glucose regulation. Estimates of 
diabetes prevalence in women of childbearing age will also enable an assessment of 
trends of the disease in this demographic and progress in meeting targets for the 
reduction of the prevalence of diabetes. 
Hyperglycaemia first detected in pregnancy (HFDP) is one of the strongest risk 
factors for type 2 diabetes mellitus (T2DM) in the postnatal period. Further, HFDP may 
also contribute to an increased risk of cardiovascular disease (CVD) and in the offspring 
exposed during pregnancy, a higher risk of cardiovascular disease in adulthood. The 
risk for T2DM and CVD after HFDP varies widely across populations and differs with 
the different criteria that are used to diagnose HFDP in different contexts. This pattern 
has also been observed in the risk for cardiometabolic disease, including overweight 
and obesity, in offspring from HFDP complicated pregnancies. In Africa, there are 
limited data on either T2DM and CVD outcomes in women after HFDP or 
cardiometabolic outcomes in the offspring. However, many studies have shown that the 
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prevalence of HFDP is high – and in many cases underdiagnosed – due to the 
limitations within health systems. This thesis aims to contribute to the understudied 
areas of the prevalence of T2DM in women in Africa of childbearing age and the 




Non-communicable diseases (NCDs) have become the main causes of illness and 
death worldwide, accounting for up to 72% of all deaths (1). The number of people 
affected by diabetes mellitus (diabetes), one of the four major NCDs, has quadrupled 
from 108 million in 1980 to 463 million in 2019 and is projected to reach 700 million by 
2040 (2). The prevalence of diabetes globally is expected to increase from 8.8% in 
2017 to 9.9% in 2045 (2). Diabetes is attributable for at least 5% of all premature deaths 
(death before the age of 70 years) (2). This may well be an underestimate, as diabetes 
is a major cause of CVD and, to a lesser extent, kidney failure and infectious diseases, 
and some of the deaths in these categories are attributable to diabetes (1). Therefore, 
the expected increase in the numbers of people with diabetes will also translate into a 
consequent increase in CVD and other diseases.  
Although there are different types of diabetes, 90% of people who have it have type 
2 diabetes (T2DM) (3) which is preventable. If the sustainable development goal (SDG) 
number 3.4 (4) which aims to reduce premature death from NCDs is to be achieved, 
more efforts need to be put towards prevention as the treatment costs are already 
beyond many nations. One way of doing this is by preventing diabetes in those groups 
of people who are at high risk of developing it. Various diabetes prevention 
programmes (DPPs) (5) in countries such as India (6) and China (7) have demonstrated 
a reduced risk of developing T2DM in people with intermediate states of carbohydrate 
intolerance. However, in Africa, the absence of quality research evidence on the most 
cost-effective interventions hampers efforts in reducing the diabetes epidemic (8). 
The true burden of diabetes in Africa and its related complications is not known 
because of the lack of quality data from many countries and thus estimates are based 
on data from relatively few countries (9). Even though the prevalence of diabetes in 
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Africa is lowest amongst the IDF regions, the number of adults with diabetes, compared 
to other regions, is expected to increase the most, by 143% from 19.4 million in 2019 to 
47 million by the year 2045 (2). Besides, the IDF estimates that Africa has the highest 
prevalence of undiagnosed diabetes, of 69%, compared to other IDF regions (2), partly 
because of fewer resources committed to screening and diagnostic services in health 
systems which are already overburdened by infectious diseases such as malaria, HIV 
and TB (10). A consequence of the high prevalence of undiagnosed diabetes is a 
higher incidence of complications as people with undiagnosed diabetes may seek 
healthcare only when diabetes-related complications have appeared (11). It is perhaps 
not surprising that the proportion of premature death attributable to diabetes is highest 
in Africa (77%), with several southern African countries registering proportions of more 
than 80% (2).  
In a continent where resources for diabetes treatment are limited, prevention should 
be prioritised. There are presently sparse data from trials that have investigated 
diabetes prevention in Africa. Quality research is required from Africa to inform policy 
about interventions that are cost-effective in reducing the risk for diabetes in the 
population as a whole and in groups that are at high risk.  
Diabetes affects women differently compared with men. In many African 
communities, women are expected to be caregivers to their families and assume the 
burden of care if other family members are ill (12). Further, apart from pregnancy and 
immediate postnatal complications, if a woman develops diabetes before or during 
pregnancy there is a high risk of transgenerational transmission of diabetes to her 
offspring (12). There is mounting evidence showing that intrauterine exposure to 
hyperglycaemia increases the offspring’s risk for overweight and obesity, diabetes and 
other cardiometabolic diseases (13, 14). Further, research shows that this risk can be 
transmitted to other generations after the initial exposed generation (12, 15). It is, 
therefore, possible that health trajectories of future generations can be influenced in a 
positive direction by optimising the cardiometabolic health of women before, during, 
and after the pregnancy. The WHO, in its current efforts against NCDs and in 
recognition of the unique position in which women of childbearing age are placed, 
recommended a gender-specific approach to the prevention, treatment and 
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management of NCDs such as diabetes in its Montevideo Declaration in 2017 (16).  
Quality data about the extent of the T2DM burden in African women of childbearing age 
are, however, lacking (2) and this makes evidence-based policymaking difficult.  
HFDP is a known risk factor for the development of T2DM and includes diabetes 
mellitus first detected in pregnancy (DIP) and gestational diabetes mellitus (GDM) (17). 
The WHO adopted the 2010 recommendations of the International Association of 
Diabetes and Pregnancy Study Group (IADPSG) (18) in its 2013 guidelines (17) and 
subdivided HFDP as either GDM or DIP. These changes came as a result of the 
findings of the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study, a 
multi-country study with 25 505 participants from nine countries, which found that even 
the milder maternal blood glucose levels during pregnancy were associated with 
adverse foetal outcomes (19). The HAPO study, however, did not include an African 
cohort and this may limit the application of these guidelines to the African context. 
The IDF estimates that the worldwide prevalence of HFDP was 15.8% during 2019, 
with the highest prevalence reported in South East Asia (2). In Africa, 10.4% of an 
estimated 3.4 million live births are affected by HDFP every year, although data are 
missing from most African countries (2). Data from one recent meta-analysis estimated 
that the prevalence of HFDP was 13.6% (20). There is, however, wide heterogeneity in 
HFDP estimates across African countries from a low of 2.3% in semi-rural Kenya (21) 
to a high 32% in urban Cameroon in 2017 (22). Recent epidemiological surveys in 
South Africa’s Gauteng province suggest that HFDP prevalence could be as high as 
26% in Johannesburg (23). These data imply that as many as one in every four 
pregnancies are affected by hyperglycaemia that is only discovered during the 
pregnancy. Because most provinces in South Africa use risk-factor-based screening for 
HFDP, it is estimated that this may miss more than half of HFDP cases (23). This 
means that many women with HFDP are untreated, with the consequent raised risk for 
T2DM and CVD after the pregnancy for the mother and her offspring. 
Systematic reviews, primarily based on data from high-income countries, have 
reported that women with previous HFDP have a seven-fold risk of developing T2DM 
(24, 25), double the risk of CVD (24) compared to women with normal glucose 
metabolism in pregnancy and their offspring have a raised risk of future overweight and 
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obesity (26). Most of the studies included in these systematic reviews used criteria 
which did not differentiate between women with DIP and GDM, thus more research 
evidence is required to investigate the effects of the different HFDP types on both 
maternal and offspring outcomes. As far as it is known, no published studies in Africa 
to date have investigated these outcomes. Unlike the high-income countries, Africa is 
affected by high rates of food insecurity and both under and over-nutrition tend to co-
exist in many communities, and even in the same households (27-29). This makes it 
difficult to compare research findings from other continents to Africa. 
 
1.3. Chapter summary 
 
The rationale for this thesis and the description of the background to the major areas 
covered in it is provided in this chapter, as is a description of the diabetes problem in 
women of childbearing age and how they are uniquely affected by diabetes. Also 
discussed are gaps in research on HFDP in African women and some of the research 
that was carried out in addressing some of these gaps. The literature on the areas 
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CHAPTER 2. LITERATURE REVIEW 
2.1. Chapter introduction 
 
In this chapter, a comprehensive review of research on diabetes in women of 
childbearing age, the burden of T2DM and CVD due to hyperglycaemia first detected in 
pregnancy (HFDP), and the effect of HFDP on childhood overweight and obesity in 
their exposed offspring is discussed. The chapter explores the topic of diabetes mellitus 
in women of childbearing age and HFDP in the context of Africa, particularly in South 
Africa. The chapter ends with a brief discussion on T2DM and CVD outcomes in 
women after HFDP and on the cardiometabolic risk in their exposed offspring. The 
empirical chapters 4, 5, 6 and 7 also contain discussions on the relevant literature, so 
care has been taken not to repeat some of those in this literature review. The chapter is 
based on comprehensive searches for studies, published mainly during the period 2000 
to 2019, in all major electronic databases including Scopus, MEDLINE and EMBASE 
through Pubmed, ISI World of Science, Scopus, the Cochrane Library and Google 
Scholar. 
2.2. Diabetes mellitus 
 
Diabetes is one of the greatest threats to human health around the world, with 
an estimated global prevalence of 9% in 2019 (1) and 1.5 million deaths directly related 
to diabetes in 2012 (2). Globally, diabetes prevalence has more than doubled from 
4.6% in the year 2000 to 9.3% in 2019 (1). If current trends continue, without successful 
interventions, the total number of people with diabetes is expected to increase from 463 
million in 2019 to 700 million by 2045 (1). This implies an absolute increase of 51% in 
the number of people living with diabetes and will require significant investment in 
health resources being availed for the treatment of diabetes. Unsurprisingly, the 
greatest expected increases in both diabetes prevalence and the numbers of people 
living with diabetes are in the low-to-middle-income countries, as shown in Fig 2.1, 
which are at various stages of epidemiological transitions. The IDF African region, for 
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example, is expected to undergo a 143% increase in the number of people living with 
diabetes, from 19.4 million in 2019 to 47 million in 2045 (2).  
 




Reproduced with permission from the International Diabetes Federation Atlas, 9th Edition 
(1)  
Diabetes mellitus is a group of metabolic conditions characterised by raised blood 
glucose and either a malfunction of or damage to pancreatic β-cells (3). Diabetes has 
several causes which include genetic defects, autoimmunity, inflammation, insulin 
resistance, epigenetic and environmental factors (3). In 2019, the WHO introduced a 
new classification, based on aetiology, which grouped diabetes mellitus as type 1 
diabetes (T1DM), type 2 diabetes (T2DM), hybrid forms of diabetes, specific forms of 
diabetes, unclassified diabetes and hyperglycaemia first detected in pregnancy (HFDP) 
(3). Hyperglycaemia first detected in pregnancy (HFDP) is categorised into either 
diabetes in pregnancy (DIP) or gestational diabetes mellitus (GDM) and has a 
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worldwide prevalence of around 16% (1, 4). T1DM is one of the most severe forms of 
diabetes, accounts for about 5% of all diabetes cases, usually requires insulin for 
survival, and results in decreased life expectancy by around 11 to13 years in the high-
income countries (HICs) (5, 6). The outcomes for T1DM are worse for people living in 
the LMICs, for example, sub-Saharan Africa, where diagnostic and treatment services, 
including insulin availability, are still not adequate (7). In 70-90% of people, T1DM is 
characterised by autoantibodies against insulin-producing pancreatic β-cells and the 
exocrine pancreas itself (8, 9) in genetically susceptible individuals and is diagnosed in 
individuals between the ages of 5-15 years (8).  
The majority (more than 90%) of all people with diabetes have T2DM (10), which is 
caused, in most people, by obesity driven β-cell dysfunction which can either be insulin 
resistance or deficiencies in insulin secretion (3). T2DM occurs mostly in adults and 
was previously rare in children and young adults, but prevalence is increasing in 
parallel with the rising prevalence of obesity in children and young adults (11). Although 
data are lacking from many countries, Australia recorded a 27% increase in the 
prevalence of childhood T2DM during the period 1990-2002 (12) while in India 25% of 
people with T2DM during the period 2000-2006 were below the age of 25 years (13).  
The WHO 2019 classification of diabetes (3) introduced a new category: hybrid 
forms of diabetes in which clinical features found in both T1DM and T2DM exist. This 
new category includes the groups formerly classified as ketosis-prone T2DM and latent 
autoimmune diabetes in adults (LADA), now being referred to as “slowly evolving auto-
immune mediated diabetes”. Ketosis-prone diabetes is usually diagnosed when a 
patient presents with ketosis and severe insulin deficiency but usually the patient 
recovers and does not require insulin (14). Slowly evolving auto-immune mediated 
diabetes is the second most common form of diabetes with a prevalence between 5 to 
10% worldwide (15). Patients with slowly evolving immune-mediated diabetes present 
with symptoms of T2DM but have Glutamic Acid Decarboxylase autoantibodies, 
typically observed in patients with T1DM (16). This form of diabetes usually slowly 
evolves into an insulin-requiring form, hence the name ‘slowly evolving auto-immune 
mediated diabetes’. The fourth category of diabetes consists of different specific forms 
of diabetes. These include monogenic diabetes, caused by defects in specific genes, 
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diseases of the exocrine pancreas, endocrine disorders from hormones that antagonise 
insulin secretion, drug-induced and infection-related diabetes (3).  
2.3. Consequences of diabetes 
 
Diabetes results in damage to both small (17) and large blood vessels (18) and 
leads to a high risk of damage to organs that are vulnerable to both microvascular 
(kidneys, eyes and nerves) and macrovascular dysfunction (the brain and the heart) 
(18).  
Diabetic retinopathy is the most common microvascular complication of diabetes 
and is attributable for 64% of impaired visual acuity and 27% of blindness prevalence, 
worldwide (17). Diabetic nephropathy prevalence increases with diabetes severity and 
leads to end-stage kidney disease and kidney death (19). The risk for nephropathy also 
increases with the duration of diabetes, for example, the United Kingdom Prospective 
Diabetes Study found a prevalence of microalbuminuria of 7.3% at the time of diabetes 
diagnosis, which increased to 28% at 15 years follow-up (20). Cardiovascular 
autonomic neuropathies affect both autonomic and somatic nervous systems and affect 
between 31% to 73% of people with diabetes (21). Although these neuropathies are 
classified under microvascular complications, they may lead to myocardial infarction, 
coronary heart disease, cardiac arrhythmias and sudden death (21).  
Diabetes is the strongest risk factor for cardiovascular disease (CVD), with an odds 
ratio of 4.4, when compared to individuals without diabetes (22). Macrovascular 
complications such as coronary heart disease, carotid artery disease and peripheral 
vascular disease are more prevalent in people with diabetes, compared to the general 
population with coronary heart disease being the most prevalent (prevalence of 21%) 
complication (23).  Findings from several Mendelian randomisation studies have 
demonstrated that diabetes has a causal association with coronary heart disease (24). 
In keeping with the higher prevalence of CVD in people with diabetes, mortality from 
CVD is almost double in people with diabetes, compared to those without (22). 
Although diabetes prevalence does not differ between the genders, women with 
diabetes, compared to men with diabetes, have a higher risk for myocardial infarction 
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and stroke (25), heart failure, peripheral artery disease, overall CVD and double the 
mortality from CVD (26).  
Diabetes is a major cause of mortality and accounts for approximately 11% of global 
mortality (2). This is partly due to diabetes complications and their strong association   
with CVD. Data from a meta-analysis of 57 studies showed that half of the people with 
diabetes, 50.3% (95%CI 37.0 – 63.7), die of CVD (23). Although recent data show a 
steady decrease in mortality from vascular diseases among people with diabetes in 
high-income countries (HIC) (27, 28), the opposite is happening in the low-to-middle-
income countries (LMIC) (29). Further, estimates from the International Diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Federation (IDF) show that more than 60% of diabetes-related-deaths in LMICs are 
premature deaths, i.e., among people aged 20 to 70 years (2).  
Diabetes affects the functioning of communities in many other ways, apart from the 
increased burden of disease, complications, and death. The high rate of undiagnosed 
diabetes in the LMICs results in higher rates of complications and increased disability 
leading to significant impairment of quality of life (30). While diabetes-related health 
expenditure for adults varies widely between regions and countries, overall, 
expenditure rose from just over USD200 million in 2006 to over USD750 million in 2019 
(1). The high disparities in spending may impact outcomes for affected people, with the 
average expenditure per person almost 40 times higher in the HICs compared to the 
low-income countries (USD5 339 vs USD138 per person per year) (1). Health systems 
in the LMICs may not be well equipped to provide for the diagnosis and treatment 
needs for the exponential increase in the number of people with diabetes, over and 
above the existing challenges in their health systems (31). Although data are sparse, 
out of pocket expenses for diagnosis and treatment may add a significant lifetime 
economic burden on individuals living in LMICs.    
 
2.4. Diabetes mellitus in Africa 
 
In Africa, the raw prevalence of diabetes is 6% and the distribution of diabetes 
phenotypes appears to be similar to other regions with up to 90% of all people with 
diabetes having T2DM (2). Compared to other IDF regions, Africa has the lowest age-
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adjusted diabetes prevalence of diabetes, perhaps due to lower urbanisation, a 
population still dominated by the younger age groups and relatively lower levels of 
obesity (1). However, African countries are undergoing epidemiological transitions, 
driven by the combined effects of rapid urbanisation, a demographic transition towards 
older populations and a nutrition transition (32). During the period 1980 to 2014, the 
prevalence of diabetes more than doubled in both men (from 3.4% to 8.5%) and 
women (from 4.1% to 8.9%) (33), and the IDF expects Africa to have the greatest 
increase in the number of people living with diabetes from 19 million in 2019 to 47 
million in 2045 (2). The African region also had the highest estimated prevalence of 
undiagnosed diabetes (69%) during 2019 (1). Late diagnosis of diabetes increases the 
risk of complications and, ultimately, the cost of treating diabetes. Of concern is that, 
compared to other regions, spending on diabetes in Africa is estimated to be around 20 
times lower (1), which may result in poor diagnostic and screening services and poor 
quality of care.  
Rigorous population-based data are still lacking from many African countries but the 
available data show that the distribution of diabetes varies by region, with the highest 
prevalence reported from North Africa (1). A systematic review of studies conducted 
during the period 1999 to 2011 showed that the prevalence of T2DM in North Africa 
ranged from 2.6% in rural Sudan to 20% in urban Egypt (13). A separate systematic 
review of sub-Saharan African studies found that T2DM prevalence ranged from 1% in 
rural Uganda to 12% in urban Kenya during the same period (14). In 2019, South Africa 
had both the highest age-standardised prevalence (12.7%) and the highest number of 
people living with diabetes (4.6 million) in sub-Saharan Africa (1). Notably, prevalence 
estimates vary considerably between and within countries depending on the screening 
method used, rural/urban location and diagnostic criteria used.  
Diabetes was estimated to account for 6% of overall mortality in Africa in 2017(34). 
However, 77% of all diabetes-related deaths in Africa were in people below the age of 
60 years, the highest proportion of premature deaths due to diabetes in the world (34). 
The burden of disease due to diabetes, when assessed using disability-adjusted life 
years (DALYs), is highest in sub-Saharan Africa compared to other regions (35). Sub-
Saharan Africa also experienced the greatest increase (126%) in DALYs due to 
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diabetes during the period 1990 to 2017 (35). This increase in DALYs is largely 
explained by population growth and the demographic transition into older populations 
(35). A closer look at sub-Saharan Africa shows that southern Africa has a higher 
burden of diabetes, compared to other regions of sub-Saharan Africa, with a crude rate 
of 1927 DALYs (compared to Central– 1233, Western – 887 and Eastern – 915) (35). 
Preventive interventions are urgently needed to reduce the effect of the increase in 
both prevalence and numbers of people in need of diabetes treatment on already 
overstretched health systems. 
Africa has several challenges that may worsen the prevalence of T2DM (36). The 
prevalence of overweight and obesity, the strongest known risk factor for T2DM, has 
increased greatly across many African countries, with the average BMI in women 
increasing from 22kg/m2 in 1980 to 25kg/m2 in 2014 (33). At a population level, data 
from Africa for the period 1980 and 2014 show a strong correlation between both mean 
BMI and diabetes prevalence and absolute BMI change and change in diabetes 
prevalence (33). The prevalence of obesity and overweight is not uniform across the 
African countries, but data from a cross-sectional survey of four countries showed high 
prevalence ranging from 46% in adults in rural Uganda to 85% in teachers in South 
Africa (37). 
Data from meta-analyses of observational studies and Mendelian randomisation 
studies have shown that the association between various proxies of adiposity such as 
body mass index (BMI), weight gain, waist and hip circumference and T2DM is causal 
(38). At a mechanistic level, increased adiposity, especially central adiposity, leads to 
increased intra-abdominal visceral fat which has a disruptive effect on insulin 
metabolism and consequently leads to T2DM (39). Many African countries already 
have high levels of obesity and overweight and indications are that this will translate 
into a higher prevalence of T2DM in the future.  
Undernutrition has also been associated with diabetes, albeit before the 1970s in 
some parts of Africa and Asia, but it is now rare. Also named fibocalculous diabetes, 
starvation-related diabetes was found in individuals with a history of undernutrition. This 
type of diabetes was characterised by calcification of the pancreas, chronic pancreatitis 
and malfunction of the exocrine pancreas (36). Apart from starvation, exposure to 
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disease such as malaria was also thought to contribute to fibocalculous diabetes 
through impairment of beta-cell function (40). 
In addition to adiposity, and other known risk factors such as genetic susceptibility 
(41), family history (42), unhealthy diets, low levels of physical activity, increased 
sedentary time, smoking and HFDP (38), other risk factors may be driving the diabetes 
pandemic in Africa. Sub-Saharan Africa is host to more than two-thirds of all people 
living with HIV, of which around 60% are on antiretroviral therapy (ART) (43). While the 
wide coverage of ART has increased the life expectancy of people living with HIV to 
nearly the same as that of people without HIV (44), higher prevalence of diabetes has 
been reported in people on HIV ART (45, 46). The increased prevalence of diabetes in 
people on ART may be partly explained by the combination of ART-related body fat 
redistribution (47) and HIV-related chronic inflammation (48), although data are not 
conclusive and more rigorous research is needed. Although the incidence of HIV 
appears to be slowing down in many sub-Saharan African countries, HIV prevalence 
will continue rising due to the increased life expectancy in people living with the virus. 
More research evidence is required to investigate the effect of ART on diabetes and 
CVD risk, and on the best interventions to reduce the risk for these conditions in people 
living with HIV.   
2.5. Diabetes in South Africa 
 
South Africa had the highest age-adjusted prevalence of diabetes, 12.7%, and the 
highest number of people living with diabetes, 4.7 million, in sub-Saharan Africa during 
2019 (1). Similar to other African nations, diabetes prevalence is higher in urban 
settings compared to rural areas and more than half of people with diabetes in South 
Africa are not aware of their status (1). The burden of diabetes has increased 
significantly in South Africa during the past few decades as can seen in Fig. 2.2. 
Previous estimates showed a crude prevalence of diabetes of 5.5% in the year 2000 
(49) which increased to approximately 9% in adults South Africans in 2009 (50). Data 
from the South African National Health and Nutrition Examination Survey (SANHANES) 
showed a crude prevalence of 9.5% during 2012 (51). Notably, the prevalence of 
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diabetes is higher in people of older age (52), and varies with ethnicity and rural/urban 
locations, with the highest prevalence reported in urban areas. The crude prevalence of 
diabetes was highest in South Africans of Indian descent in urban KwaZulu Natal, 32%, 
in a study in 2016 (53), followed by a prevalence of 24% in South Africans of mixed 
ancestry during 2012, and lowest (12% to 13%) in black South Africans during 2012 
and 2016, respectively, (54, 55) and 4.6% in rural KwaZulu Natal in 2008 (56). Data 
from the other provinces show a similar distribution in terms of prevalence, and ethnic 
and rural/urban differences (51).  
 
Fig 2.2. Change in the prevalence of diabetes mellitus in South Africa 
during the period 2000 – 2012 
 
 Bradshaw 2007 (49) - a meta-analysis of 5 studies, diagnosis criteria not clear. 
Bertram 2013 (50) - a meta-analysis of 4 studies published between 2008-2012. Diabetes 
diagnosed using WHO 1998 criteria.  
Shisana 2015 (51) – nationwide representative sample (South Africa National Health and 
Nutrition Examination Survey). Diabetes diagnosed using HbA1c≥6.5%. 
 
Although current data show an already high burden of diabetes in South Africa, the 
prevalence of diabetes may increase more, in tandem with the demographic transition 
and an epidemiologic transition driven by the increase in the prevalence of obesity. 


























increasing proportions of older people, who are at greater risk of diabetes, compared to 
children and young adults (57). The population age structure of South Africa has 
changed gradually, towards smaller proportions of young children while proportions of 
young and older adults have increased during the period 1996 to 2016 as can be seen 
in Fig 2.3.   




Data are from Statistics South Africa national censuses from 1996- 2011 and the 2016 
community survey. For 1996, the percentage in each gender adds up to 100%, for the years 
2001, 2011 and 2016, the total percentage is 50% for each of the genders.  
  
While the next census will be during the year 2021, data from the Statistics South 
Africa’s Community Survey of 2016 show a gradual transition towards higher 
proportions of young adults and older people in the population structure (Fig 2.2 last 
frame). Besides, Fig 2.4 below shows that the proportions of adults with age ≥ 30 years 
(adults at high risk of diabetes) have increased steadily from 36.65% to 41.1% during 
the 15 years from 1996 to 2011. If this trend continues, the prevalence of diabetes in 
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South Africa will most likely increase as the proportion of the population that is 
vulnerable to diabetes increases.  
 
Fig. 2.4. Change in the proportion of the population≥30 years of age in 
South Africa during 1996-2011 
  
 
Data were calculated from the Statistics South Africa national censuses of 1996, 2001 and 
2011.   
South Africa is among the leading the Africa countries with high prevalence of adults 
who are either overweight or obese (58). The prevalence of overweight and obesity has 
increased in both males and females during the last 2 decades. Data from successive 
national representative samples (59-61) show a steady increase in the proportion of 
men and woman who are either overweight or obese during the period 1998 - 2013. 
Perhaps more worrying is that while the prevalence of overweight has risen steadily, 
but slowly, during the period, the prevalence of obesity has risen more steeply (Fig 
2.5). As of 2013, 69% of South African women over the age of 15 years were either 






































One study of nurses in Limpopo province (61) found an even higher prevalence of 
overweight and obesity in both genders, although these data may not be nationally 
representative. The strong association between obesity and diabetes may mean that 
South Africa is yet to reach the peak of the diabetes epidemic.  
Fig. 2.5. Changes in overweight and obesity prevalence in males and 
females in South Africa during the years 1998 to 2013 
  
 
Data from Puone 2002, Sartorius 2015, Ng 2014 and Goon 2013 (57-60). Data are from 
nationally representative studies, except Goon 2013 (60), a study of male and female nurses in 
Limpopo province, South Africa.  
The diabetes epidemic in South Africa adds to a health system that already has 
multiple challenges which are well described in literature (31). South Africa has 
relatively poor health outcomes, evidenced by maternal and child mortality rates that 
are still unacceptably high, given the country’s level of economic development (62). The 
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inequality from the long-term effects of colonialism and apartheid policies, an inefficient 
health system and the crippling effect of the HIV and TB epidemics (63). This is 
compounded by the related high prevalence of poverty, persisting lack of access to 
clean water and sanitation and high levels of unemployment (63). Although, in general, 
access to health services has improved over the last two decades, formerly 
disadvantaged ethnic groups are still the worst affected by poverty, unemployment, and 
lack of access to clean water and sanitation (63). The structural weaknesses in the 
health system are further exacerbated by a lopsided healthcare financing system where 
public and medical-schemes-dominated- private-healthcare systems coexist (64). Even 
though South Africa spends over 8% of its gross domestic product on healthcare, 
higher than the global average, the health financing model is inefficient. In this 
fragmented two-tiered healthcare financing system, 80% of the population is dependent 
on a free public healthcare system that has only half a share of the human and financial 
resources. For people living with chronic diseases such as diabetes, this system may 
lead to long term impoverishment. For the poor, recent data show that the incidence of 
catastrophic health spending on diabetes is as high as 25%, with more women being 
disproportionately affected (65). Even though diabetes treatment is free in the public 
healthcare system, individuals still must pay for transport costs and may lose days of 
work. It remains to be seen how the proposed National Health Insurance (64) will 
improve the healthcare funding and ultimately, health outcomes for people with 
diabetes. 
Apart from structural challenges, South Africa is undergoing a complex 
epidemiological transition characterised by multiple burdens of disease. This multiple 
disease burden includes persisting infectious diseases, mainly HIV and TB, rising 
prevalence of non-communicable diseases such as diabetes and CVD, co-existence of 
under-and-over nutrition, persisting high burdens of maternal and child mortality and 
high levels of injury and violence (63). The country is host to the largest number of 
people living with HIV, globally, 7.9 million people in 2017, with an estimated 
prevalence of 14%, of which 62% are on ART (66). Notably, the high coverage of ART 
has reduced mortality due to HIV and increased life expectancy which also influences 
the demographic transition, while ART may result in increased diabetes risk as 
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discussed earlier. South Africa is also one of the world’s high-burden-TB countries with 
an estimated TB incidence of 520 per 100 000 during 2018 and a high TB case fatality 
ratio of 22% (67). In addition to a high burden of infectious diseases and maternal and 
child mortality, South Africa also has one of the highest burdens of trauma in Africa due 
to interpersonal violence (31). Diabetes imposes an additional burden on this already 
overstrained health system and prevention may play crucial role in managing the 
diabetes epidemic in South Africa. 
The burden of disease and mortality due to diabetes has increased with the 
increasing diabetes prevalence in South Africa during the past few decades, although 
data from national surveys are sparse. During the year 2000 diabetes was directly 
responsible for 2.6% of all deaths (68) and 1.6% of the total DALYs (49). In 2009, an 
estimated 73 000 DALYs were due to diabetes and its non-fatal complications while 
there were 2000 amputations and 8000 cases due to diabetes (50). Data on these non-
fatal complications during the other years is lacking, although it may be assumed that 
the complications have increased due to the increase in the prevalence of diabetes.  
Data from Statistics South Africa (69–72) show that the proportion of deaths due to 
diabetes has doubled from 3.3% to 5.7% during the decade 2007-2017 (Fig 2.5). 
Diabetes was the tenth leading underlying cause of death in South Africa in the year 
2000 (49) but has become the second leading cause of death after TB since 2012 (Fig 
2.6). Notably, data from death notifications do not show the excess mortality from CVD 
and renal failure that may be due to diabetes. If the excess mortality is considered, the 
true mortality and morbidity burden due to diabetes are likely to be higher than 
suggested by the data from the death notifications. Up-to-date epidemiological data are 









Fig 2.6. The proportion of deaths due to diabetes– findings from death 
notifications from 2007 to 2017 
   
Data are from the Statistics South Africa Mortality and causes of death: Findings from death 
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2.6. Diabetes in African women of childbearing age in Sub-Saharan Africa 
and South Africa 
According to the WHO, the childbearing age in women is between the ages of 15 
and 49 years (73). Women of childbearing age contribute substantial proportions to 
both the total populations and the total population of women (Fig. 2.6) (74). Out of the 
total world population of 7.7 billion in 2019, women aged 15 to 49 years numbered 1.9 
billion, contributing half (49.9%) of the total population of women and a quarter (24.8%) 
of the global population. In Africa, out of a population of 1.3 billion, the proportion of 
women aged 15-49 years mirrored the global pattern (Fig. 2.7), although slightly lower 
(48.3% of the total population of women and 24.2% of the total African population). I 
Compared to the global population distribution, in South Africa, women of 
childbearing age contribute higher proportions to both the total population of women 
(53.5%) and the overall population (27.2%). In the Western Cape and the Cape 
metropole, the population distribution mirrored that of the country (75). South Africa has 
nine provinces and the Western Cape province (estimated population of 6.3 million 
during the 2016 community survey) is the fourth most populous after Gauteng, KwaZulu 
Natal and the Eastern Cape (75). The province is made up of five main districts, 
including the Cape Town City Metropole, where 63.8% of the people live (75). Most of 
the people in the province are of mixed ancestry, a term used to describe a 
heterogeneous group of people who have diverse Khoisan, Bantu-speaking African, 
Asian and European ancestry. Similar to black South African women, women of mixed 
race are also affected by poverty and inequality as they were also discriminated against 
during colonialism and, later, apartheid. There is still no consensus about the best 
socially acceptable term to describe people of mixed-race ancestry without the racial 
implications engendered during apartheid.  
Although women of childbearing age have seen their participation in the economy 
and education increase drastically since the advent of democracy in South Africa in 
1994 (76), they are still greatly disadvantaged. Most South African women of 
childbearing age are of black ethnicity, in line with the general population distribution, 
and are more likely to be poor and either unemployed or employed in poorly paying 
jobs (76). For example, in 2015, 42% of black women were in low skilled jobs 
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compared to 1.4% of white women (71). The ethnic imbalance is also reflected with 
other formally marginalised groups, such as people of mixed ancestry who are 
predominant in the Western Cape province (71). Women, unlike their male compatriots, 
work predominantly in pink-collar jobs and tend to earn less than men (71). Despite 
improvements in gender equality, most women are still expected to play multiple roles 
in their families, including childbearing, child-rearing, caregiving to ill members of the 
family, housekeeping and being breadwinners (76).    
  
Fig 2.7. Proportions of women of childbearing age compared to the total 
population of women (brown colour) and the total population (blue) 
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The prevalence of diabetes in women of childbearing age in Africa is not known, 
partly due to the unavailability of quality data from many countries. Data from the IDF 
show that the prevalence of diabetes across all age groups during 2019 was slightly 
higher in women in general compared to men in Africa, (Fig 2.8) (1). In South Africa, the 
prevalence of diabetes in women is slightly higher than that in males and follows the 
same age and ethnic distributions seen in the general population (51).    
 
Fig 2.8. Diabetes prevalence by age and gender in Africa during 2019 
  
 
Reproduced with permission from the International Diabetes Federation Atlas, 9th Edition 
(1)  
Across most of sub-Saharan Africa, the prevalence of overweight and obesity 
among women of childbearing age, the strongest known risk factor for T2DM, increased 
greatly, in fact, tripled in some cases, in many African countries during the period 1993-
2014 (77). Cultural perceptions of overweight and obesity as symbols of wealth may 
worsen the prevalence of obesity and hinder preventive measures. In South African 
women the prevalence of obesity increased drastically during the decade 2002 to 2012, 
as was previously shown in Fig 2.5 (58-61). Data from the SANHANES showed that 
69% of women were either overweight or obese, and more than two-fifths (42%) of 
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women were obese in 2012 (51). This may mean women may have a higher 
prevalence of diabetes in the future, driven by the higher prevalence of obesity (33, 78). 
Apart from the direct effects of the disease, women with diabetes are affected by 
psychosocial factors, including psychosocial stress (79). Factors such as low education 
status, low socioeconomic status, low income and poorly paying jobs, psychosocial 
stress, occupational stress and sleep disturbances are associated with both diabetes 
and obesity in women (79-81). In many studies the associations are often bidirectional, 
i.e., psychosocial factors leading to a high risk of diabetes and vice versa (79, 82).  
Psychosocial stress may be exacerbated by gender imbalances in many societies and 
greater demands and responsibilities during childbearing and childrearing. In many 
African communities, apart from expected housekeeping roles, childbearing and being 
primary caregivers for children, women tend to assume complex roles which include 
being breadwinners and unpaid caregiver for unwell family members (83, 84). Non-
communicable disease (NCDs) in general and diabetes in particular, impose a burden 
on women and their families, as the care is long term and requires a change in lifestyle, 
apart from treatment. Thus, if a woman of childbearing age is diagnosed with diabetes 
or other NCDs, the effects are not limited to the woman alone, but her family is also 
affected. One study in Tehran found that the total, physical and mental health-related 
quality of life (HRQoL), decreased significantly after the diagnosis of diabetes, not only 
for the woman but for her partner and children (82). In sub-Saharan Africa, the role of 
psychosocial factors in the risk of diabetes and the prognosis after diagnosis with 
diabetes in women of childbearing age remains understudied.  
In terms of clinical outcomes, women seem to have worse outcomes than men. 
Women with diabetes have a higher risk for CVD (85), myocardial infarction and stroke 
(34). Overall mortality from diabetes is almost twice for women compared to men, and 
the ratio is highest during the reproductive age groups of 20 to 49 years (Fig 2.9) (1). 
Again, the higher mortality could be partly attributable to a higher risk of CVD in women 
with diabetes. The higher risk for CVD and mortality in women with diabetes is in sharp 
contrast to the well-established lower risk for CVD in women compared to men during 
the childbearing age (86). In Central Europe, women with diabetes were found to have 
higher levels of LDL-cholesterol and higher levels of both systolic and diastolic blood 
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pressure (87). There are limited data on the distribution of CVD risk factors between the 
genders from Africa, except prevalence of obesity, a common risk factor for T2DM and 
CVD, which is higher in women of childbearing age compared to their male 
counterparts (78). Besides, hyperglycaemia in pregnancy increases the risk for both 
diabetes and CVD and may contribute to the higher mortality in women during 
childbearing age.  
 
Fig 2.9. Mortality from diabetes by gender in Africa during 2019 
 
  
Reproduced with permission from the International Diabetes Federation Atlas, 9th Edition 
(1)  
Data from death notifications in South Africa during the decade 2007 to 2017 (69-72), 
show a similar pattern to world data (Fig 2.10), with female proportions of deaths due to 
diabetes ranging between 1.6 to 1.8 times the male proportions (Table 2.1). In South 
African women, diabetes-related mortality has risen sharply during the last decade. 
Diabetes was the second leading cause of death during 2013 and 2014 and has been 
the leading cause of death in South African women since the year 2015 (Table 2.1). 
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Diabetes-related deaths occur mostly in the older age groups, (50 to 64 years and over 
65 years), although the data on proportions of deaths in women of childbearing age are 
not available.   
Fig 2.10. Percentage of deaths attributable to diabetes, by gender, in 
South Africa during the period 2007 to 2017 
  
 
Data are from the Statistics South Africa Mortality and causes of death: Findings from death 












































Table 2.1. The proportion of mortality due to diabetes in South Africa by 
gender during the period 2007-2017 













2007 2.5 7 4.2 6 1.68 
2008 2.6 7 4.1 6 1.58 
2009 2.8 8 4.4 6 1.57 
2010 3 7 5 6 1.67 
2011 3.2 7 5 5 1.56 
2012 3.4 6 5.6 4 1.65 
2013 3.6 6 6.2 2 1.72 
2014 3.8 6 6.4 2 1.68 
2015 4 6 7.1 1 1.78 
2016 4 5 7.2 1 1.8 
2017 4.1 4 7.3 1 1.78 
Data are from the Statistics South Africa Mortality and causes of death: Findings from death 
notifications: Statistical releases from 2008 (68), 2012 (69), 2015 (70) and 2020 (71)   
 
2.7. Hyperglycaemia in pregnancy and hyperglycaemia first detected in 
pregnancy 
 
Hyperglycaemia in pregnancy (HIP) consists of all forms of raised blood glucose 
occurring during pregnancy. This may include already existing type 1, type 2 diabetes 
and hyperglycaemia first detected in pregnancy (HFDP) and, according to the IDF (1), 
affected 15.8% of pregnancies worldwide during 2019.       
     HFDP contributes to most of the cases of HIP in pregnancy (about 83% IN 2019) 
(1) and is defined as any glucose intolerance diagnosed during pregnancy for the first 
time after ruling out other forms of diabetes (4). HFDP is further categorised as 
gestational diabetes (GDM) and diabetes in pregnancy (DIP). Women with HFDP may 
40 
 
fail to adjust to the metabolic demands of pregnancy which increase after the second 
trimester and coupled with pre-existing chronic insulin resistance, develop 
hyperglycaemia as a symptom of altered glucose metabolism (88).  
The term HFDP was introduced by the WHO in its 2013 guidelines to distinguish 
between women with GDM and those with more severe forms of glycaemia, similar to 
diabetes outside pregnancy (4). The previous WHO criteria of 1999 defined GDM in a 
way that included all women with various degrees of hyperglycaemia. There was a lot 
of heterogeneity in the diagnosis of gestational diabetes mellitus (GDM), before this, 
with some definitions including women with diabetes and women with intermediate 
dysglycaemia as defined outside of pregnancy. Most of the studies that investigated 
GDM before the IADPSG recommendations used definitions that would have included 
women with both GDM and DIP. In this thesis, the term HFDP is applied in studies 
which GDM definitions are used that may have included women with DIP. Notably, the 
guidelines and the criteria for the diagnosis of GDM are still heterogeneous as can be 
seen in Table 2.2. 
GDM was first described in the literature in the early 1950s but the controversy on 
how to diagnose it and which criteria to use has still not been completely resolved. In 
1949, Priscilla White described 439 pregnancies where she classified the degree of 
glycaemia using the letters A to E (89). Her classification took account of the age of 
diabetes onset, duration of diabetes and whether a woman had diabetes complications.  
 
 “Class A, with highest chance for foetal survival, includes patients in whom the  
      diagnosis of diabetes was made upon a glucose tolerance test which deviates but  
     slightly from the normal. Such patients require no insulin and little dietary regulation.” 
 
 
“Class A”, in Priscilla White’s classification would later become known as GDM. In 
1954, a French paper by J. P. Hoet which was translated into English also described 
GDM (90). Although there was increasing awareness of the negative effects of 
hyperglycaemia on pregnancies, the diagnosis criteria for GDM were hotly debated. 
During the mid-1950s, Carrington, Schurman and Reardon in the USA presented data 
from 92 ’prediabetic pregnant women’ who they described as having gestational diabetes 
(91). They used a 2-hour post-load glucose of 170mg/dL (9.4 mmol/L) to classify 
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‘prediabetic pregnant women’. However, in 1957, O’ Sullivan, based on Hoet’s study and 
a large cohort of women whom they followed up, proposed the 3-hour OGTT for women 
with risk factors for GDM. These risk factors were a family history of diabetes, foetal 
overgrowth and glycosuria during the pregnancy. They also proposed a 2-step process, 
starting with a 1-hour 50gm OGTT, and a follow-up 3-hour OGTT for women with 
abnormal 1-hour OGTT (130mg/L). Later, O’ Sullivan and Mahan (a statistician) 
performed 752 OGTTs in women in their second and third trimesters and determined cut-
offs for the diagnosis of GDM using mean plus 2 standard deviations (92). These criteria 
(fasting glucose 5.0mmol/L, 1-hour 9.2mmol/L, 2-hour 8.1mmol/L and 3-hour 6.9mmol/L) 
were based on future risk of diabetes and were subsequently widely used for decades. 
The National Diabetes Data Group (93) modified the 2-step 3-hour OGTT in 1979 and 
further modifications were suggested by Carpenter and Coustan in 1982 (94) (fasting 
glucose 5.3mmol/L, 1-hour 10.0mmol/L, 2-hour 8.6mmol/L and 3-hour 7.8mmol/L). In 
1985, the WHO (95) recommended a 1-step 2-hour OGTT with criteria similar to non-
pregnant individuals of fasting blood glucose of at least 7.8mmol/L and/or 2-hour glucose 
of 11.1mmol/L. The WHO modified its criteria in 1999 (96), while the American Diabetes 
Association (1998) used criteria similar to the Carpenter and Coustan criteria (97).  
Although Pederson (98) and White (89) highlighted the need for diagnostic criteria 
that were based on preventing adverse foetal outcomes, it took six decades to have 
these criteria. The WHO guidelines of 2013 (4) were the result of a consideration of 
evidence from several studies and the recommendations of the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) recommendations on 
the diagnosis and classification of hyperglycaemia in pregnancy (99). Both the WHO 
guidelines and the IADPSG recommendations were based largely on the findings of the 
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) Study, which showed a 
graded continuous relationship between maternal blood glucose levels and several 
adverse pregnancy outcomes (100). The HAPO study followed up 25 505 women with 
fasting blood glucose ≤5.8 mmol/L and/or OGTT 2-hour blood glucose ≤11.1 mmol/L 
measured during the 24-32 weeks of gestation. Maternal blood glucose at 24 to 32 
weeks gestational age was associated with birthweight>90th percentile, cord blood C-
peptide >90th percentile, primary caesarean section and neonatal hypothermia. The 
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HAPO study also showed that maternal blood glucose levels which had previously 
been thought of as ’normal’. were associated with the risk of adverse pregnancy 
outcomes. Notably, the HAPO study did not establish maternal blood glucose cut-offs 
at which adverse events occurred, and this has complicated the search for diagnostic 
cut-offs for GDM, which are still debated. Further, although the HAPO study had 
cohorts from 10 countries in North America, Europe, Asia and Australasia, there were 
no participants from Africa (101). Data from the continent are needed to provide 
insights on the role of maternal hyperglycaemia on adverse pregnancy short- and long-
term outcomes in both the mother and the foetus in a continent with multiple 
challenges. In many African communities, overnutrition and undernutrition frequently 
co-exist, together with the multiple burdens of infectious diseases such as HIV, malaria 
and TB, high maternal and child mortality and the prevalence of non-communicable 
diseases is on the rise. 
While many regional bodies have adopted the WHO 2013 guidelines, there is still no 
consensus on diagnostic criteria for HFDP (102, 103), as can be seen in Table 2.2. 
Debate is still ongoing about when to screen for HFDP, what screening methods to use, 
how to classify women with blood glucose values in the ranges of diabetes outside of 
pregnancy, and the advantages and disadvantages of using lower blood glucose 
criteria for GDM diagnosis (103). There are still no conclusive findings of the costs 
compared to benefits of using lower fasting glucose criteria recommended by the 
IAPDSG which will most likely result in higher numbers of women being diagnosed with 
GDM, and the consequent need for more health resources in pregnancy. One 
difference between the WHO 2013 guidelines and the IADPSG recommendations is on 
the issue of women with blood glucose within the ranges of diabetes outside 
pregnancy. The IADPSG defines these women as having overt diabetes while the 
WHO defines them as diabetes mellitus in pregnancy (DIP). Regardless of the 
terminology used, women with more severe forms of hyperglycaemia in pregnancy are 
at higher risk of adverse pregnancy and have a higher chance of their blood glucose 
not returning to normality after the pregnancy. The Australasian Diabetes in Pregnancy 
Society (ADIPS) (104) adopted the WHO 2013 criteria, while the American Diabetes 
Association (ADA) (105) adopted the IADPSG recommendations. The National Institute 
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for Health and Care Excellence (NICE) maintained its 2008 guidelines in their revised 
guidelines of 2015 (106). In South Africa, the Society for Endocrinology, Metabolism 
and Diabetes of South Africa (SEMDSA) (57) adopted the WHO 2013 criteria in 2017, 
although the terms overt ‘diabetes’ and ‘DIP’ are used interchangeably in the guideline. 
The differences in the criteria used for HFDP also result in heterogeneity in estimates of 
HFDP prevalence across different regions and countries.  
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diabetes and Pregnancy Study Groups; NICE: National Institute for Health and Care 
Excellence.  
 
In the WHO HFDP diagnosis guidelines of 2013 (4), the distinction between the two 
forms of HFDP is mainly through blood glucose levels at diagnosis. GDM is diagnosed 
when the maternal fasting blood glucose is above 5.1 mmol/L but less than 7.0mmol/L 
and/or OGTT 2-hour blood glucose above 8.5 mmol/L but less than 11.1 mmol/L. DIP is 
diagnosed when a woman without a previous diagnosis of diabetes has either fasting 
blood glucose ≥7.0 mmol/L and/or 11.1 mmol/L (4). Women with DIP may have a higher 
risk for adverse pregnancy outcomes, compared to those with GDM, including a higher 
risk of post-partum progression to T2DM, but the lack of studies in this area makes it 
difficult to evaluate the strength of the evidence (4). 
 
2.8. Risk factors for hyperglycaemia first detected in pregnancy 
 
Research evidence suggests that the risk factors for HFDP are largely similar to those 
for T2DM although the contribution of each risk factor to the overall risk of HFDP may 
differ (107, 108). Many observational studies have established various risk factors for 
HFDP which include non-modifiable such as family history and advanced age, 
intermediate such as overweight and obesity and modifiable such as smoking, diet and 
physical activity (109). Genetic and other novel risk factors such as biomarkers have 
also been described recently (109). Most of the studies that investigated risk factors for 
GDM, used definitions that would have encompassed women with DIP, hence this 
review uses the term ‘HFDP’ unless the GDM definition in the study excluded women 
with DIP. Due to the paucity of research, it is not clear whether risk factors for GDM are 
different or differ in their magnitude compared to those for DIP.  
Non-modifiable risk factors in HFDP that have been consistently identified in the 
literature include a history of previous HFDP, ethnicity, family history of diabetes (110), 
advanced maternal age (111) and polycystic ovary syndrome (112). Previous 
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pregnancy outcomes such as having a baby with macrosomia, having a stillbirth and 
having a previous HFDP are also strongly associated with an increased risk of HFDP 
(113). HFDP is also associated with several pregnancy-related complications such as 
gestational dyslipidaemia (114), gestational hypertension (115) and pre-eclampsia 
(116), although these associations are frequently bidirectional and not necessarily 
causal. 
Excess weight in the form of overweight and obesity is perhaps the strongest and 
most consistently identified intermediate risk factor for HFDP (109, 117). Increased 
central adiposity may contribute to the development of HFDP as it is associated with 
chronic insulin resistance which may then be exacerbated during the second and third 
trimesters of pregnancy (117). Excess weight has been measured using various 
proxies in epidemiological studies, including BMI, waist-hip circumference, and mid-
upper arm circumference. BMI, either as a continuous variable or as various categories 
compared to normal BMI (e.g., ≥25kg/m2, ≥30kg/m2 or ≥40kg/m2) is one of the most 
frequently described risk factors for HFDP in the literature (118). The other measures of 
adiposity, i.e., waist circumference (119), waist-hip ratio (119) and mid-upper arm 
circumference (120), have also shown strong associations with the development of 
HFDP and measures of excess weight are frequently used as targets and intermediate 
outcomes in many HFD prevention trials (121). Biomarkers may also be regarded as 
intermediate factors and those associated with increased risk of HFDP are elevated 
chemerin levels during the second trimester (122), elevated mean platelet volume 
(123), low levels of iron and haemoglobin (124) and low vitamin D levels (125). Notably, 
these findings from observational studies have either not been tested by randomised 
controlled trials or have not resulted in therapeutic effect when tested in clinical trials. 
The latter is the case with vitamin D which has been tested in several trials and failed to 
result in either reduced risk for HFDP (126) or reduce risk of adverse pregnancy 
outcomes (127). More research is needed in this area. 
The main modifiable risk factors described in literature, diet and physical activity, 
are also associated with risk of HFDP and although there is wide heterogeneity 
between studies and, frequently, the associations are not independent of overweight 
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and obesity. Some research has shown that the Mediterranean diet is beneficial (128) 
while diets rich in saturated fats, heme iron intake, sugar-sweetened drinks, high 
amounts of refined carbohydrates, and sweets are harmful (129). Lower physical 
activity and sedentary activity have been associated with a higher risk for HFDP (130). 
However, it is worth noting that many lifestyle-change interventions targeting healthy 
diets (131) or those promoting physical activity during pregnancy have failed to reduce 
risk of HFDP (131), except when the intervention was performed throughout the 
pregnancy (132).  
 
2.9. Prevalence of hyperglycaemia first detected in pregnancy in Africa 
 
Results from several meta-analyses suggest that HFDP is prevalent in Africa, with 
meta-analysis estimates of pooled prevalence ranging from 9% (133) to 14% (134) 
although quality data are only available from less than a quarter of the 54 countries. As 
of 2019, data were only available from 33 studies from 12 African countries (133). Most 
of the primary studies have been published from two countries: Nigeria (11 studies) and 
South Africa (8 studies) (133). Four systematic reviews and meta-analysis have been 
published to date, three of which included a mix of women with GDM and DIP (133, 
135, 136) (Table 2.4). The largest and latest of these meta-analyses reported a pooled 
HFDP prevalence of 9% from 33 studies with 31 821 participants. The remaining meta-
analysis, which used strict inclusion criteria of studies using either the WHO 2013, the 
ADA 2015 or the IADPSG 2010 criteria, reported a pooled HFDP prevalence of 13.6% 
from 23 studies with a total of 11 702 participants. The prevalence of GDM appears 
highest in sub-Saharan Africa (14.8%) compared to other regions, particularly in 
Cameroon (137) where one study reported a prevalence of 31% and South Africa (138) 
(25.8%).   
Table 2.3. Summary of systematic reviews and meta-analyses on the 
prevalence of hyperglycaemia first detected in pregnancy in Africa 
Author 
(year) 
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ADA: American Diabetes Association; WHO: World Health Organization; IADPSG: 
International Association of the Diabetes and Pregnancy Study Groups   
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2.10. Prevalence of hyperglycaemia first detected in pregnancy in South 
Africa 
 
The prevalence of HFDP in South Africa is estimated to be between 9% and 25.8%, 
based on data from two cross-sectional studies published in 2018 (138, 140). A total of 
eight studies have examined the prevalence of HFDP in South Africa, to date (Table 
2.5). Most of the studies (n= 3) (138, 140, 141) have been carried out in the Gauteng 
province. Data from other provinces are sparse and dated. The first study was 
published in 1969 (142) and reported a prevalence of HFDP of 8.3% in women without 
risk factors and of Indian descent in Durban, although the criteria used were not very 
clear. Since then, a total of seven studies have been published, at a rate of roughly one 
study per decade. Different screening criteria, diagnosis methods and diagnostic criteria 
were used in these studies and this makes it difficult to compare prevalence or describe 
possible trends. Only one study (143) was carried out in a rural setting and reported a 
prevalence of 8.8% in Limpopo province in 2007 and the rest from urban settings. The 
lowest prevalence (1.8%) was reported in a study in 2010 (141), a retrospective review 
of women who were overweight or obese in urban Johannesburg. The low prevalence 
could be partly explained by the high blood glucose cut-offs the authors used; a fasting 
blood glucose of ≥8.0 mmol/L and/or random blood glucose ≥11.1mmol/L. The highest 
reported GDM prevalence of 25.8% in Johannesburg in 2017 (138) is from a study that 
used universal screening and the IADPSG 2010 criteria. It is not clear why this estimate 
differed widely from the GDM estimate of 9.1% (140) in Soweto at roughly the same 
period. This difference could be partly explained by the inclusion of women with DIP as 
some of fasting glucose values reported by the study were above 7.0mmol/L. 
 
Table 2.4 Summary of studies on the prevalence of hyperglycaemia first 
detected in pregnancy in South Africa  
Author 
(year)   
Region
/locatio
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*Family history, history of miscarriage, obesity, previous macrosomia, glycosuria, previous 
congenital anomaly, Indian ethnicity, age≥35 years   
 
2.11. Management of HFDP in South Africa – from screening to delivery 
 
As with other areas of study concerning HFDP, data from Africa are scarce 
concerning how women are screened for HFDP and managed thereafter. In South 
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Africa, most provinces use a risk factor-based screening, which may leave up to 50% 
with HFDP undiagnosed (138, 146). In the Western Cape, women with any of the 
following risk factors, i.e., family history of diabetes, BMI≥30kg/m2, polycystic ovarian 
syndrome, previous GDM, glycosuria and age≥40 years are screened for HFDP (147). 
It is not clear, however, whether there is consistent screening for all women meeting 
these criteria (147). Between and within provinces, different diagnostic criteria are still 
widely used, with the most widely used being the WHO 1999, the NICE 2008, the 
American College of Obstetricians and Gynaecologists (ACOG) and the IADPSG 2010 
(148). Although the SEMDSA recommended the IADPSG 2010 criteria and the use of 
universal criteria, uptake has been debatable as some clinicians perceive them as 
increasing an already high workload (148). 
The limited available data show that women with HFDP receive adequate care 
during pregnancy, in line with international standards (147, 149). In the Western Cape 
province, all women with HFDP are managed at referral hospitals where they receive 
care from a multidisciplinary team that includes physicians, dieticians and nurses (147). 
The women receive care at dedicated diabetes clinics and are seen and their blood 
glucose checked every fortnight until 32 weeks gestations and every week thereafter 
(149). The management includes individual and group counselling on diet and physical 
activity from the doctor, nurse and dieticians, oral hypoglycaemic agents and insulin 
where necessary (147). Despite the good management during the pregnancy, there are 
gaps in the care for the women after delivery (147). While the current recommendations 
are that the woman must be assessed for diabetes 6 weeks after delivery, available 
data suggest that the proportion of women who go for the 6-week visit is less than 30% 
in South Africa (150). This may be partly because of the fragmentation of postpartum 
care, as care is provided separately, at different health facilities for the mother and her 
offspring (147).  
 
2.12. Type 2 diabetes mellitus and cardiovascular disease after 
hyperglycaemia first detected in pregnancy 
 
Data, primarily from mostly high-income countries, show that women with HFDP 
have a high risk of T2DM and cardiovascular disease after HFDP (108, 151, 152). Only 
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a few studies have been published in LMICs, and these were mostly from China, Brazil 
and India (108). Several systematic reviews and meta-analysis have compared women 
with GDM to women without GDM concerning the risk of T2DM. Again, the definition of 
GDM used in many of above-mentioned studies has included women with DIP. As can 
be seen in Table 6, the risk of progression to T2DM varies considerably between and 
within countries. In a review by Zhu et al. (108), the relative risk for T2DM after HFDP 
ranged from a low of 1.3 in Brazil in 2007 to a high of 47.3 in the USA. Within countries, 
there is also great heterogeneity in risk estimates. For example, in Sweden, the relative 
risk ranged from 3.2 in 1991 (153) to 38.4 (154), in the USA from 3.9 in 2007 (155) to 
47.3 (156) and in Canada, from 10.5 in 2012 (157) to 15.3 (158). The heterogeneity 
may partly be due to different criteria used for diagnosis of GDM and different lengths 
of follow-up used in different studies, with follow-up periods ranging from 1 year to 15 
years. Even when studies with similar lengths of follow-up are compared, the risk of 
progression is different between many of the studies. There are no studies in Africa that 
have investigated the risk of T2DM after HFDP, to date.    
 
Table 2.5. Systematic reviews and meta-analyses on the risk of type 2 
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ADA: American Diabetes Association; WHO: World Health Organization; IADPSG: International 
Association of the Diabetes and Pregnancy Study Groups  
 
  Similar to the risk of T2DM after HFDP, the prevalence of T2DM in women after 
HFDP varies widely from 3.6% in Finland (163) to 52% in India (164) as can be seen in 
Table 2.7. Again, the length of follow-up and HFDP diagnosis criteria vary widely and 
53 
 
may be partly responsible for the heterogeneity in prevalence estimates between 
studies. Only one study in Africa (150) has investigated the progression to T2DM to 
date, at 6-weeks postpartum, in Cape Town in 2018. In this study of 78 participants, the 
authors found that 27% had diabetes six weeks after the pregnancy. The small sample 
size and the short follow-up period limit the conclusions that can be drawn from this 
study.   
 
Table 2.6. Studies on the prevalence of T2DM after hyperglycaemia first 
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The high heterogeneity seen in studies examining the risk of T2DM after HFDP is 
also seen with studies that investigated CVD risk after HFDP as can be seen in Table 
2.6. Three meta-analyses have analysed the association between prior HFDP and risk 
of CVD or its components. Interestingly, the risk for CVD in women after HFDP is 
almost similar to that for women with diabetes, with odds ratios of 1.74 (161) and 1.98 
(162) in separate meta-analyses. In women who did not progress to T2DM, the risk for 
CVD still appears to be high (OR = 1.56), compared to women without a history of 
HFDP (162). Currently, there are no studies which have investigated the association 
between GDM and cardiovascular risk factors in Africa.   
 
2.13. Hyperglycaemia first detected in pregnancy and childhood overweight 
and obesity in the offspring 
 
There is considerable evidence that both higher maternal blood glucose levels at 
the diagnosis of HFDP and the level of glucose control during pregnancy are 
associated with higher foetal birth weight and other measures of adiposity at birth 
(100). Several possible explanations have been put forward to explain the link between 
exposure to hyperglycaemia in pregnancy and offspring adiposity. In the 1950s 
Pederson (98) hypothesised that maternal hyperglycaemia exposure led to foetal 
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overproduction of insulin and, thereafter, overgrowth. This was later refined into the fuel 
mediated teratogenesis hypothesis which proposes that excess fuels lead to 
permanent changes in the foetus (178). Although maternal glucose crosses the 
placenta to the foetus, insulin particles are too large to cross the placental barrier. 
Therefore, the foetal pancreas, which is still developing, is forced to produce more 
insulin than normal. Foetal insulin, apart from regulating blood glucose, also promotes 
foetal growth and adipose tissue production, resulting in overgrowth during pregnancy 
and a higher risk of overweight at birth (178). Apart from excess foetal growth in-utero, 
increased insulin production, increased leptin production in the children exposed to 
hyperglycaemia in pregnancy has also been reported, with children exposed to 
hyperglycaemia having three times cord blood leptin levels compared to the controls 
(179). It is hypothesised that the foetal pancreas is exposed to maternal 
hyperglycaemia at a critical time of its development and that this causes permanent 
impairment of insulin secretion (foetal hyperinsulinemia) (179). Foetal hyperinsulinemia 
continues into childhood hyperinsulinemia which may lead to childhood overweight and 
obesity as shown by data from the Pima Indians, where the 5 to 9-year-old offspring of 
diabetic mothers had higher fasting insulin levels (180) and were heavier at every age 
(181) compared to the offspring of non-diabetic mothers.  
There is increasing evidence linking exposure to maternal hyperglycaemia and long-
term cardiometabolic disease risk in the offspring (165, 182, 183). Besides, higher birth 
weights have been associated with a high risk of adult hypertension (184), 
dyslipidaemia (185), insulin resistance (186), and cardiovascular disease (187). Foetal 
programming for overweight and obesity is another way in which maternal 
hyperglycaemia is thought to exert long-term effects. Maternal hyperglycaemia may 
cause permanent adaptive changes in the foetal genome which, in turn, affects the 
child throughout their life course (188). These adaptive changes in the foetal genome 
may permanently change the physiology and metabolism of the foetus and, 
consequently, induce changes in postnatal metabolism where the offspring will have a 
higher tendency to accumulate fat (189). 
Despite the scientific plausibility for the association between maternal blood glucose 
and childhood overweight and obesity, data from observational studies are not 
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conclusive about the association between GDM and childhood overweight and obesity. 
The HAPO follow-up study (165) did not find a significant association between a GDM 
diagnosis and child BMI at a median age of 11.4 years. An earlier systematic review of 
12 studies, in 2011 (190), found that the odds ratios for the association between a 
GDM diagnosis and risk of childhood and overweight ranged from 0.7 to 6.3. The 
authors noted that most of the studies that found a significant association between 
GDM and childhood overweight and obesity may not have adjusted for maternal BMI. A 
later systematic review and meta-analysis of 25 studies and 308 455 infants (191), 
published in 2020, similarly found no differences in BMI in infants at ages 1 to -6 
months, 7 to 12months and 13 to 24 months. It is also possible that treatment for GDM 
may be the reason why the expected association is often not seen. In Africa, there are 




In this chapter, the epidemiology of diabetes mellitus and HFDP in Africa and South 
Africa has been reviewed. Women of childbearing age constitute about 27% of the 
population of South Africa, play several important roles in their societies, and are 
uniquely affected by diabetes. Diabetes in women of childbearing age increases the 
risk of intergenerational transmission of cardiometabolic disease to the offspring. For 
women with T2DM, the prognosis is worse than in similarly aged males. Available data 
suggest that up to a quarter of South African women are affected by HFDP, which 
increases the risk of T2DM and CVD in the women and may increase long term 
cardiometabolic risk in their offspring. Even data from other regions suggests that 
women with HFDP have a higher risk of T2DM and CVD after the pregnancy the risk 
estimates are heterogeneous between and within countries. In Africa, again, there are 
no data at present on either risk of T2DM and CVD or their prevalence after HFDP. 
This chapter has highlighted several areas that have not been investigated in Africa, 
particularly the medium- and long-term effects of HFDP on the mother and child. The 
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CHAPTER 3. AIMS, OBJECTIVES AND OVERVIEW OF 
METHODS 
3.0. Chapter Outline 
 
This chapter starts with a description of the aims and objectives of the thesis, 
followed by an overview of the methods for the two components of the body of work of 
this thesis: a systematic review and meta-analysis and a primary study. The 
manuscripts in the chapters that follow give additional detailed descriptions of the 
methods used in each specific study.    
3.1.1. Aim 
 
The study aims to add to the body of knowledge on the prevalence of T2DM in 
African women of childbearing age, and the medium-term cardiometabolic outcomes of 
HFDP in both the mother and her exposed offspring. 
 
3.1.2. Specific Objectives 
 
1. To estimate the prevalence of T2DM and impaired glucose metabolism in women of 
childbearing age in Africa as reported in studies published during the period January 
2000 to December 2016, using a systematic review and meta-analysis. 
2. To estimate the proportion of women who progress to T2DM within 6 years of HFDP, 
and factors associated with risk of postpartum T2DM, in Cape Town, South Africa. 
3. To investigate the prevalence of and factors associated with CVD risk factors in 
women 6 years after HFDP, in Cape Town, South Africa.  
4. To investigate the association between maternal blood glucose concentrations 
during HFDP and offspring weight at birth and preschool age and overweight and 




3.2. Overview of methods of the systematic review and meta-analysis 
 
The systematic review was carried out according to the Preferred Reporting Items 
for Systematic reviews and Meta-Analysis guideline (PRISMA) (1). The study protocol 
for the systematic review (Appendix 3.1), with full details of the methods used, was 
registered online on PROSPERO, the International prospective register of systematic 
reviews (http:www.crd.york.ac.uk/PROSPERO, registration number: 
CRD42015027635) on 6 November 2015 and published in a peer-reviewed 
international journal (2). Since the methods are well described in Appendix 1, this 
chapter provide a brief description.  
The systematic review and meta-analysis was performed according to this protocol 
except that the age range inclusion of women was changed to 15-54 years. The reason 
for this change was that many studies used starting from 15 – 24, 25 – 34, 35 – 44 and 
45 – 54 years. Comprehensive searches for published and unpublished studies of all 
the major electronic databases, and the World Health Organization STEPWise country 
reports for STEP 3 was carried out. Eligible studies were published from 2000 to 2016, 
included women of African women of childbearing age and should have used the World 
Health Organization (WHO) guidelines of 1999 (3) or equivalent criteria for the 
diagnosis of type 2 diabetes.  
The analysis of the primary outcome (prevalent diabetes) was done in two steps: (a) 
identification of data sources and documenting estimates and (b) application of the 
random-effects meta-analysis model to aggregate prevalence estimates and account 
for between-study variability in calculating the overall pooled estimates and 95% CI for 
diabetes prevalence. Heterogeneity, systematic biases and publication bias were 
assessed using established methods. 
 
3.3. Overview of the PRO2D Study 
 
The PROgression to type 2 Diabetes study (PRO2D Study) is a study whose main 
purpose was to study maternal and offspring cardiometabolic outcomes 5-6 years after 
HFDP. During the study women who were diagnosed with GDM at one of the 3 major 
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tertiary hospitals in the Western Cape were recalled, together with their offspring, 5-6 
years later. Notably, the women were originally diagnosed using the NICE 2008 criteria 
(4), which included both women with DIP and GDM, when assessed using the WHO 
2013 criteria (5). Therefore, a decision was made to refer to them as women with HFDP 
instead of GDM only. During the pregnancy, clinical data were collected routinely from 
the women and at birth. At the time of follow-up, the women were assessed for T2DM, 
insulin resistance and CVD risk and the children were assessed for overweight and 
obesity. Since the women were still young (mean age 37 years), CVD was not 
assessed directly but we assessed them for the following risk factors; obesity, central 
obesity, raised blood pressure, dysglycaemia and dyslipidaemia.  
The methods for the PRO2D are described in each of the manuscripts in Chapters 
5, 6 and 7, the first two are published already (6, 7). In this chapter, an overview of the 
PRO2D study and its context will be discussed as well as aspects that may not have 
been discussed fully in chapters 5, 6 and 7.    
 
3.3.1. The PRO2D Study Setting 
 
The PRO2D Study was carried out at Groote Schuur hospital, one of the three main 
tertiary hospitals in the Western Cape province of South Africa. The Western Cape 
province, the fourth biggest province of South Africa in terms of population size, is in 
the southernmost part of the Africa continent (8). The province consists of a mixture of 
several towns, some semi-rural settlements and many farming areas. The economy of 
the Western Cape is diverse, from agriculture, tourism, finance, technology and 
manufacturing. The province is a big tourist attraction with one of the 8 wonders of the 
world, Table Mountain, situated a few kilometres from the Cape Town central business 
district.    
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Fig 3.3.1. The Western Cape province geographical position in Africa  
 
Map from www.westerncape.gov.za  
  
The estimated population of the Western Cape was 6.3 million people in 2019, with 
almost two-thirds (4 million) of the population residing in the Cape Town metropole (9). 
People of mixed ancestry, controversially referred to as “Colored”, a legacy of 
apartheid, form the majority (42.4%) of the population followed by people of Black 
ethnicity (38.6%) and people of White ethnicity (15.7%) (9). Similar to other South 
African provinces, the legacy of apartheid is still evident in the towns and cities of the 
Western Cape. This can be seen in the way residential areas are predominantly 
occupied by people of each of the major ethnicities, even though the restriction on inter-
racial mixing is over. Just over half (51%) of the population of the province are women 
and the most common language is Afrikaans (46%, followed by isiXhosa (31% and 
lastly English (19%) (9). Most of the residents of the Western Cape belong in the low-
income group. The average annual household income in 2016 was R29 400.00, 
roughly equal to USD2000.00 (9). An estimated 16.6% of households live in informal 
housing and 38% of households had women as the head during 2016 (9). During 2016, 
96% of households had access to tap water, 89% had reliable refuse removal, 98% had 
access to electricity and 95% had access to flush toilets (9). During 2016, the 
employment rate was 50% with 78% employed in the formal sector (9).  
Apart from the Cape Town metropole, there are 5 other main districts in the 
province and a total of over 25 district hospitals (8). The West Coast district has an 
economy based on a mixture of farming, including rooibos tea, manufacturing and the 
Port of Saldanha Bay and includes the towns of Saldanha Bay, Malmesbury, 
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Clanwilliam, Vredenburg and Mooresburg. The Cape Winelands district produces about 
70% of South Africa’s wines and includes the towns of Paarl, Wellington, Franschoek 
and Stellenbosch. The Overberg district is on the Southernmost tip of the African 
content and consists of the towns of Cape Agulhas, Swellendam, Hermanus, 
Bredasdorp and Caledon. The Garden Route district is an important tourist attraction 
and consists of the towns of Plettenberg Bay, Mossel Bay, Oudtshoorn, George, 
Calitzdorp and Knysna. The Central Karoo is the largest district in the province by land 
mass but has the smallest population, and consists of the towns of Prince Albert, 
Beaufort West and Laingsburg. Patients from these districts are referred to any of the 
three tertiary hospitals (Groote Schuur, Tygerberg and Red Cross Memorial Children’s 
Hospital) when they require specialized or complicated care (8). The Red Cross 
Memorial Children’s hospital is the only tertiary level specialist paediatric hospital in 
South Africa (8). Women with complicated pregnancies from the Southern suburbs of 
the Cape Town metropole are referred to Mowbray Maternity hospital, a secondary 
level referral facility (8). 
During the period 1 September 2010 to 31 August 2011, women with GDM, as it 
was diagnosed at that time, in the Cape Town metropole were treated at the Mowbray, 
Groote Schuur and Tygerberg hospitals, depending on their location. The Groote 
Schuur hospital is situated about 5km from the Cape Town city central business district 
and has a colourful history, including being the hospital where the first human 
transplant was done (8). The name “Groote Schuur” means “The Great Barn” in Dutch. 
Officially opened in 1938, the hospital is a teaching hospital of the University of Cape 
Town, is part of the public health sector and serves most people from low-income 
settings (10). The hospital is the second biggest in the Western Cape province, after 
the Tygerberg, with roughly 900 beds. The hospital has a dedicated diabetes clinic in 
the department of obstetrics and gynaecology, where pregnant women with all forms of 







Fig 3.3.2. The Groote Schuur hospital 
  
  
3.3.2. The PRO2D Study Methods 
 
Routine data were collected during the pregnancy, on all women who had different 
forms of diabetes in pregnancy during the period 1 September 2010 to 31 August 2011, 
as part of separate research (11) and a database created. From this database, all the 
women who were categorized as having gestational diabetes mellitus (GDM) at the time 
of diagnosis, were selected for a follow-up cross-sectional study, together with their 
offspring from the HFDP complicated pregnancy. The follow-up study was carried out 
during the period 1 January 2016 to 31st January 2017. This cross-sectional study was 
used to answer the objectives 2,3 and 4 in the thesis. Data from both the pregnancy 
period and the follow-up measurements were used to assess the association between 
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maternal blood glucose during the pregnancy and foetal weight outcomes at birth and 
preschool age (ages 5-6 years). 
3.4. Summary of the chapter 
 
In this chapter, the aims and objectives and the methods used in this research were 
discussed. The methods are also described well in manuscripts which are part of this 
thesis (Appendix 1, Chapter 5, 6 and 7). Therefore, an overview of the methods used in 
the systematic review and meta-analysis and the PRO2D study is given, together with 
the context of the PRO2D Study. In the next chapter, the results of the systematic 
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"To acquire knowledge, one must study; but to acquire wisdom, one must observe." ~ 










CHAPTER 4. PAPER 1 
 
The prevalence of type 2 diabetes mellitus in women of childbearing age 
in Africa during 2000-2016: A systematic review and meta-analysis 
Roles of the candidate and co-authors 
The candidate, together with Professors Norris, Levitt and Kengne conceptualized 
the study and the study protocol. The candidate drafted the study protocol and 
registered it on PROSPERO and led its publication. The candidate, with the help of a 
librarian, searched for the studies. The candidate extracted data and carried out risk of 
bias analysis with the help of Dr Mahmoud Werfalli, Dr Itai Magodoro and Mr Rekayi 
Chinhoyi. The candidate carried out the data analysis with the help of Professor Andre 
Kengne and the 2 supervisors. The candidate drafted the initial, revisions and final 
manuscript with the help of Professors Kengne, Shane Norris and Naomi Levitt. The 
candidate led the publication and was the corresponding author.  
 
Publication status 
The study protocol (Appendix 1) is published at 
https://bmjopen.bmj.com/content/bmjopen/6/12/e012255.full.pdf, with the following 
citation:  
Chivese T, Mahmoud W, Magodoro I, Kengne AP, Norris SA, Levitt NS. Prevalence 
of type 2 diabetes mellitus in women of childbearing age in Africa during 2000-2016: 
protocol of a systematic review and meta-analysis. BMJ Open. 2016;6(12): e012255-
2016.   
The systematic review and meta-analysis is published at 
https://bmjopen.bmj.com/content/bmjopen/9/5/e024345.full.pdf with the following 
citation:  
Chivese T, Werfalli M, Magodoro I, et al. Prevalence of type 2 diabetes mellitus in 
women of childbearing age in Africa during 2000–2016: a systematic review and meta-







This research aimed to estimate the prevalence of T2DM, impaired fasting glucose 
and impaired glucose tolerance, in African women of childbearing age.   
4.1.2. Study design 
Systematic review and meta-analysis of relevant African studies published from 
January 2000 to December 2016. 
4.1.3. Data sources 
We searched several databases, including EMBASE, MEDLINE, CINAHL, grey 
literature and references of included studies. 
4.1.4. Setting 
Studies carried out in African communities or any population-based studies were 
included.  
4.1.5. Participants 
We included studies, carried out in Africa, with non-pregnant women of childbearing 
age. Studies must have been published between the years 2000 and 2016.   
4.1.6 Outcomes 
The primary outcome was prevalent T2DM. The secondary outcomes were impaired 
fasting glucose and impaired glucose tolerance.   
4.1.7. Data extraction and synthesis 
Two reviewers independently extracted data and, using the adapted Hoy risk of bias 
tool, independently assessed for risk of bias. We used random-effects meta-analysis 
models to pool prevalence estimates across studies. We used Cochran’s Q statistic and 
the I2 statistic to assess heterogeneity.  
4.1.8. Results 
A total of 39 studies from 27 countries were included, totalling 52 075 participants, of 
which 3813 had T2DM. The pooled prevalence of T2DM was 7.2% (95%CI 5.6-8.9%) 
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overall and increased with age. The pooled prevalence was 6.0% (95%CI 4.2% - 8.2%) 
for impaired fasting glycemia while the prevalence of impaired glucose tolerance ranged 
from 0.9% to 37.0% in women aged 15-24 years and 45-54 years respectively. 
Substantial heterogeneity across studies was not explained by major studies 
characteristics such as period of publication, rural/urban setting or whether a study was 
nationally representative or not.  
4.1.9. Conclusion 
This review highlights the need for interventions to prevent and control diabetes in 
African women of childbearing age, given the significant prevalence of T2DM and 
prediabetes.  
PROSPERO registration number: CRD4201502763 
4.2. Strengths and limitations of this study 
 
This research has included many population-based surveys from a broad range of 
African countries than previous systematic reviews has been carried out rigorously and 
transparently. This is one of the first reviews to investigate the prevalence of T2DM, IFG 
and IGT in African women of childbearing age, a key population in the fight against the 
rise of noncommunicable diseases in Africa. One limitation of the research is that 
gender stratified data are not reported in many studies of T2DM prevalence, making 
them unusable in the current meta-analysis. Further, this review has limitations in that 
the methods of screening for dysglycaemia and representativeness of the data in some 
of the included studies were not very satisfactory. There was substantial heterogeneity 










Worldwide, the estimated number of people with diabetes has quadrupled from 108 
million people in 1980 to 422 million in 2014 [1] and is projected to reach 640 million by 
2040 [2]. It is predicted that the greatest increase in numbers will occur in Africa, where 
in 2014, 14.2 million adults aged 20 to 79 years had diabetes, with over two thirds 
unaware of their diabetic status [3]. In African women in general, T2DM prevalence 
more than doubled, from 4.1% in 1980 to 8.9% in 2014 [4]. The rapid increase in 
diabetes has led to calls by the International Diabetes Federation (IDF) for the 
establishment of national diabetes programs to better deliver prevention and control 
solutions [5]. In line with the United Nations Sustainable Development Goal (SDG) 3.4, 
aiming to reduce premature mortality from NCDs by one third by the year 2030 [6], 
identifying special at-risk populations and delivering context-appropriate interventions is 
one of the most important strategies in combating the T2DM epidemic. Up to 70% of 
people with intermediate states of impaired glucose metabolism [impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT)] progress to T2DM within a decade 
[3]. To date, most diabetes prevention programs have focused on people with IGT 
although some have intervened in another group at risk i.e. women with previous 
gestational diabetes (GDM). However, data on intermediate states of impaired glucose 
metabolism such as GDM, IFG and IGT are scarce in Africa. Overweight and obesity, 
the biggest single attributable risk factor for T2DM, is increasing in all African women, 
with the age-standardized BMI having increased from 21.9kg/m2 in 1980 to 24.9kg/m2 
in 2014, possibly implying future obesity-driven T2DM increases in women [4]. In 2017, 
the WHO, recognizing the differential effects of non-communicable diseases (T2DM 
included) on gender, recommended a gender-based approach in prevention and 
treatment policies, in the Montevideo Roadmap 2018-2030 [7].   
African women are affected by diabetes in more ways than their male counterparts, 
often assuming unpaid caregiver roles for affected family members in addition to taking 
care of their own diabetes/themselves [7]. Further, if a woman with diabetes becomes 
pregnant, her unborn child is at an increased risk of developing T2DM in adulthood [9], 
thereby accelerating the intergenerational risk of T2DM. Mapping the prevalence of 
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T2DM in this population is important as it has implications for future trends and 
monitoring of the T2DM burden in Africa.   
The World Health Organization [WHO] defines women of childbearing age as 
women aged between 15 and 49 years [8]. Apart from the IDF estimates, several 
systematic reviews have investigated the prevalence of T2DM in Africa [1,10,11], but 
none have examined the T2DM prevalence in women of childbearing age, nor the 
prevalence of IFG and IGT in women of this age-group despite their contribution to the 
risk of both GDM and T2DM. While two systematic reviews [12,13] have examined 
GDM prevalence on the continent, reporting a prevalence ranging from 0% to 14%, the 
reviews highlighted the sparse data on GDM prevalence and the absence of active 
GDM screening programs in most African countries. As T2DM and impaired glucose 
metabolism affect both maternal and child health, it is important to understand the 
prevalence of T2DM and its distribution in African women of childbearing age to inform 
better planning of preventive interventions and treatment and monitoring strategies.  
This systematic review aimed to address the research question: what is the 
respective prevalence of T2DM, impaired fasting glucose, and impaired glucose 
tolerance in African women of childbearing age between 2000 and 2016? The T2DM 
estimates from this systematic review will complement those of the IDF to enable 
assessment of progress towards reaching the Global Action Plan for NCDs and SDG 
3.4 [14] in women of childbearing age.   
4.4. Methods 
The study protocol of this review is registered on PROSPERO (CRD42015027635) 
and published in a peer-reviewed journal [15]. We searched for eligible studies, 
published during the period 1 January 2000 to 31 December 2016, with the aid of an 
expert librarian, from the following databases; MEDLINE via PubMed, EMBASE via 
OVID, ISI Web of Science, Cochrane Central, Global Health, Scopus, CINAHAL, 
POPLINE, AfricaWide, Google scholar as well as grey literature databases such as 
OpenSigle. All the databases were searched using an African search filter. Besides, we 
hand-searched the reference lists of included studies and asked experts for any studies 
they knew of. We wrote to authors requesting non-reported data. The search strategy is 
shown in Appendix 4.1.  
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4.4.1. Eligibility criteria 
We included population-based cross-sectional studies, published since the year 
2000 as older studies would not have used the WHO 1998 T2DM diagnosis guidelines, 
that assessed the prevalence of T2DM in at least 100 African women of childbearing 
age, in any language. We excluded case-control studies, hospital-based studies and 
studies on migrant Africans. For the meta-analysis, we included only studies that 
reported age and gender-specific prevalence.  
 
4.4.2. Study selection, quality assessment and data extraction 
 
After the retrieval of articles and sorting duplicates, three reviewers (TC, IM and 
MW) independently screened the titles, abstracts and, if necessary, full articles for 
inclusion. The reviewers resolved any differences by discussion and consulted the 
fourth reviewer in the case of disagreement. The three reviewers assessed each 
included study for risk of bias and internal and external validity using the tool by Hoy et 
al. [16] as adapted by Werfalli et al. [10]; Supplementary Table 4.1.   
Four reviewers (TC, MW, IM and LC) independently extracted from the selected 
articles, two reviewers per study. The investigators compared their findings and any 
differences were resolved through discussion. We extracted data on study 
characteristics including the first author’s name, date of publication, country where the 
study was conducted, the number of participants included and proportion of participants 
who were women of childbearing age, diagnostic method and diagnostic criteria, 
sampling method, response rate, and unadjusted T2DM prevalence estimates.   
 
4.4.3. Primary and secondary outcomes 
The primary outcome was T2DM, defined as; fasting plasma glucose of at least 7.0 
mmol/L, fasting blood glucose of at least 6.1 mmol/l, 2-hour Oral Glucose Tolerance 
Test (OGTT) plasma glucose of 11.1 mmol/L, or an existing T2DM diagnosis [17]. The 
secondary outcomes were IGT (fasting blood glucose less than 6.1 mmol/L and 2-hour 
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OGTT blood glucose of at least 7.8 mmol/L but less than 11.1 mmol/L and IFG (fasting 
blood glucose greater than 6.1 mmol/L but less than 7.0 mmol/L).  
 
4.4.4. Data synthesis and analysis 
 
We compiled a summary of extracted data in a table and a narrative synthesis of all 
the 80 included studies. We then conducted a meta-analysis with the studies that 
provided age and gender specific diabetes prevalence. Our population of women of 
childbearing age was defined as African women between the ages of 15 – 49 years, per 
WHO definition. However, in this review, we used the upper cut-off of 54 years as most 
studies used age groups starting from 15 – 24, 25 – 34, 35 – 44 and 45 – 54 years.    
We pooled the T2DM prevalence using the statistical software STATA 15 [18], and 
metaprop package [19]. We applied the random effects meta-analysis framework as we 
expected variability in the prevalence estimates from different studies. The package first 
models the prevalence estimates using the exact binomial distribution and then applies 
the Freeman-Turkey double arcsine variance stabilising transformations, normalising 
the estimates before pooling and then back transforming the estimates. The pooled 
estimates are then computed using the procedure described by Dersimonian and Laird 
[20].   
We assessed heterogeneity between studies using Cochran’s Q statistic [21] and 
estimated the percentage of total variation across studies due to true between-study 
differences rather than chance, using the I2 statistic [22]. We explored sources of 
heterogeneity through subgroup analysis using study-level characteristics. Besides, we 
assessed the presence of publication bias by examining the funnel plots, supplemented 
with formal statistical testing using the Egger test [23], and the Begg’s test [24] for 
publication bias.   
4.4.5. Patient involvement 
We did not involve patients in the development of the research question, 





4.5.1. Search results 
 
The flow chart of the search is shown in Figure 4.1. Out of a total of 6046 studies 
identified via searches, 129 remained after removing irrelevant studies and duplicates. 
A further 41 studies were identified through screening of references of included studies 
(13 studies) and from the WHO STEPWise country reports on the WHO website (28 
studies). The final number of studies included was 80, of which only 39 studies were 
included in the meta-analysis as they reported age-group and gender-specific diabetes 
outcomes. Forty-one studies were included in the narrative description only because 
either they did not report age group-specific data (38 studies) or reported only the 
percentage of participants with T2DM but did not report the raw frequencies (3 studies). 
There were two major age groups systems used by authors, 25 studies (64%) used the 
format: 15-24, 25-34, 35-44 and 44-54 years, 7 (18%) used the format: 20-29, 30-39 
and 40-49 years. We merged some age groups into either of the two systems 
depending on which systems they were most related to, for example, the age group 18-
25 was merged with 15-24 while the age group 20-29 was merged with the 18-29 
years. The remaining 7 studies (18%) used other age groups which were very different 
from the two main systems described above [15-29, 30-44 years (4 studies), 25-44 
years (2 studies) and <50 years (1 study)] and we did not attempt to merge them into 








Fig 4.1. Flow chart showing search, selection of and final included studies 
 
  
4.5.2. Characteristics of included studies 
Appendix 4.2 shows the list and characteristics of all the 80 included studies from 
39 countries. Most of the studies were from Nigeria, 14 (18%), South Africa, 8 
(10%), Tanzania, 5 (6%), Cameroon, 4 (5%) Kenya, 4 (5%), Tunisia, 3 (4%); 10 
countries contributed 2 eligible studies while the remaining 23 countries each 
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contributed a single study. Most studies were published during the years 2014, 12 
(15%), 2013, 11(14%) and the year 2015, 9 (11%) and 2016, 7 (9%). Forty-five 
studies, i.e., 56%, were conducted in both urban and rural populations, 19 (23%) in 
urban settings only, 14 (17%) in rural settings only and one study [25] did not clearly 
state the setting. The reported response rate ranged from 40% [26] to 100% [27]. Of 
the 81 studies, 31 (38%) were nationally representative studies, with 28 of these 
being WHO STEPWise surveys and one national demographic and health survey 
from Namibia [28]. Appendix 4.2 contains the characteristics of the included studies.  
Almost three-quarters of the studies, (n = 59 (74%) used fasting plasma glucose, 
20 (25%) used the 2-hour OGTT, while 2 studies used the HbA1C for the diagnosis 
of T2DM. There were a total of 197 848 participants in the included studies of which 
the proportion of all women included ranged from 21% [29] to 100% [27]. The 
prevalence of T2DM in both sexes in the included studies ranged from 0.8% [30] to 
33% [31], while the T2DM prevalence in all women in the studies ranged from 0.5% 
[30] to 36% [31]. Figure 4.2 shows the map of pooled T2DM prevalence for each 
country, in women of age 15-54 years. Regarding the risk of bias, 74 92.5%of the 
included studies scored a low risk, 3.8% scored moderate risk and the remaining 












Fig 4.2. Map showing pooled T2DM prevalence in African women aged 






4.5.3. T2DM prevalence in women aged 15 – 54 years 
A total of 39 studies, from 27 countries, with 52 075 women of childbearing age, 
of which 3 813 had T2DM were included in the meta-analysis. The T2DM 
prevalence in women aged between 15-54 years ranged from 1% in Uganda 
(Uganda STEPS 2011) to 29% in South Africa (31). The pooled prevalence was 
7.2% (95%CI 5.6% – 8.9%, n = 39 studies), with significant heterogeneity (I2 = 98%, 

























Fig 4.3. Forest plot of T2DM prevalence in African women aged 15-54 
years, from studies published during the period 2000-2016. 
 
 
  NB: Studies must have used WHO 1999 or equivalent guidelines for the diagnosis 
of T2DM  
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4.5.4. Prevalence of T2DM by age group 
The lowest pooled T2DM prevalence was found in the 15 - 24 years age group 
(2.0% 95%CI 1.0% - 3.4%, n = 11 studies, I2 83.2%, p < 0.001) and the 25 – 34 
years age group (3.0%, 95%CI 1.7-4.5%, n = 24 studies, I2 90.0%, p < 0.001). The 
highest pooled T2DM prevalence was observed in the 45 – 54 years age group 
(13.1% 95%CI 9.8-16.8%, n = 23 studies, I2 94.3%, p < 0.001) (Table 4.1 and 
Table. 4.A). T2DM prevalence significantly increased with age, compared to the 15 – 
24 years age group, with a higher prevalence observed in the following age groups; 
30 – 44 years 35 – 44 years, 40 – 49 years and 45 – 54 years (p < 0.001) (Table 1).  
Table 4.1. Summary of sub-group meta-analysis of T2DM, IFG and IGT 
in women aged 15-54 years 
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Table 4. A. Pooled T2DM prevalence in different age categories in 
African women aged 15-54 years, from studies published during the 
period 2000-2016 
 
Study and age group 
  
Prevalence estimate Lower 95%CI Upper 95%CI 
   
25-34 
   
Burkina Faso STEPS 2 3.7 2.7 5.1 
Katte 2014 10.3 6.2 15.9 
Kufe 2015 0.9 0.2 2.3 
Amoah 2002 2.1 1.3 3.3 
Guinea STEPS 2009 3.1 1.6 5.4 
Ayah 2013 1.8 0.7 3.9 
Libya STEPS 2009 10.5 7.4 14.4 
Malawi STEPS 2010 3.7 2.5 5.1 
Mauritania STEPS 200 3.5 1.8 6.1 
Niger STEPS 2008 3.7 1.9 6.4 
Ekpenyong 2012 9.7 7 13 
Rwanda STEPS 2015 2.3 1.6 3.3 
Seychelles STEPS 200 3.8 1.4 8.1 
Seychelles STEPS 201 2.5 0.7 6.2 
Peer 2012 6 3.3 9.8 
Prakashandra 2015 13.1 7.2 21.4 
Hird 2015 
 
4.3 1.9 8.4 
Erasmus 2014 0 0 97.5 
Sudan STEPS 2006 12.2 6.5 20.4 
Tanzania STEPS 2012 8.9 7.1 11 
Togo STEPS 2010 0.8 0.3 2 
Zimbabwe STEPS 2005 9.2 6.4 12.6 
Sub-total 
    
Random pooled  ES 3 1.7 4.5 
     
35-44 
    
Burkina Faso STEPS 2 3.8 2.3 5.8 
Katte 2014 9.4 6 13.8 
Kufe 2015 2.2 0.6 5.7 
Amoah 2002 3.9 2.6 5.5 
Guinea STEPS 2009 4.8 2.4 8.5 
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Ayah 2013 4.1 1.9 7.7 
Libya STEPS 2009 10.5 7.5 14.2 
Malawi STEPS 2010 4.8 3.1 6.9 
Mauritania STEPS 200 8.7 5.6 12.8 
Namibia DHS2015 5 3.6 6.7 
Niger STEPS 2008 3.7 1.8 6.6 
Ekpenyong 2012 13 10.4 16 
Rwanda STEPS 2015 3.4 2.4 4.8 
Seychelles STEPS 200 6.4 3.3 11.2 
Seychelles STEPS 201 7.1 3.7 12 
Peer 2012 10.4 6.2 16.2 
Prakashandra 2015 29 23.1 35.4 
Hird 2015 
 
5.6 2.3 11.3 
Erasmus 2014 13.7 8.6 20.4 
Alberts 2005 3.9 2.1 6.6 
Sudan STEPS 2006 14.3 8 22.8 
Tanzania STEPS 2012 11 8.9 13.4 
Togo STEPS 2010 1.3 0.4 2.9 
Zimbabwe STEPS 2005 11.2 8 15.1 
Sub-total 
    
Random pooled  ES 7.1 5.3 9.1 
     
45-54 
    
Burkina Faso STEPS 2 5.6 3.5 8.4 
Katte 2014 14 10 18.9 
Kufe 2015 38.5 20.2 59.4 
Amoah 2002 7 5 9.4 
Guinea STEPS 2009 11.2 6.7 17.3 
Ayah 2013 13.4 7.7 21.1 
Libya STEPS 2009 24.4 18.7 30.9 
Malawi STEPS 2010 6.5 4.3 9.4 
Mauritania STEPS 200 9.2 5.7 13.8 
Namibia DHS2015 6.1 4.4 8.2 
Niger STEPS 2008 4.7 2.4 8.3 
Rwanda STEPS 2015 3.6 2.2 5.3 
Seychelles STEPS 200 14.9 10.1 21 
Seychelles STEPS 201 14.2 9.5 20.1 
Peer 2012 23.2 17.1 30.3 
Prakashandra 2015 37.5 32.3 42.9 
Hird 2015 
 
24.5 17.9 32.2 
Erasmus 2014 21.2 15.2 28.2 
Alberts 2005 11.6 8.3 15.7 
Sudan STEPS 2006 23.8 15.2 34.3 
Tanzania STEPS 2012 10.9 8.4 13.9 
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Togo STEPS 2010 4.5 2.3 7.7 
Zimbabwe STEPS 2005 10.1 6.9 14.1 
Sub-total 
    
Random pooled  ES 13.1 9.8 16.8 
     
15-29 
    
Benin STEPS 2015 10.2 8.3 12.2 
Ethipopia STEPS 2016 5.6 4.7 6.6 
Oti 2013 
 
3.8 2.8 5 
Kenya STEPS 2015 0.3 0.1 1 
Swaziland STEPS 2012 12.8 10.4 15.6 
Bouguerra 2007 0.8 0.3 2 
Uganda STEPS 2014 0.3 0.1 1 
Sub-total 
    
Random pooled  ES 3.6 1.2 7.4 
     
30-44 
    
Benin STEPS 2015 10.1 8.4 12 
Ethipopia STEPS 2016 12 10.5 13.5 
Kenya STEPS 2015 3 2 4.3 
Swaziland STEPS 2012 16.2 13.3 19.5 
Sub-total 
    
Random pooled  ES 9.7 5 15.6 
     
45-59 
    
Benin STEPS 2015 17.7 14.5 21.3 
Ethipopia STEPS 2016 6.6 5 8.5 
Kenya STEPS 2015 6.2 3.8 9.3 
Liberia STEPS 2011 24.4 19.8 29.4 
Ekpenyong 2012 29.4 23.9 35.3 
Swaziland STEPS 2012 28.4 24.9 32.1 
Zanzibar STEPS 2011 8.7 6.4 11.4 
Sub-total 
    
Random pooled  ES 16.1 9.1 24.6 
     
15-24 
    
Katte 2014 1.8 0 9.6 
Guinea STEPS 2009 1.6 0.7 3.3 
Ayah 2013 0 0 1.3 
Mauritania STEPS 200 3.2 1.6 5.9 
Niger STEPS 2008 3.9 2.1 6.5 
Ekpenyong 2012 3.9 2.6 5.7 
Rwanda STEPS 2015 2.3 1.4 3.5 





0 0 1.9 
Togo STEPS 2010 1.3 0.5 2.7 
Sub-total 
    
Random pooled  ES 2 0.9 3.4 
     
30-39 
    
Boronat 2006 2.1 0.6 5.4 
Oti 2013 
 
4.4 2.9 6.3 
Favier 2004 5.9 4.3 7.8 
Alberts 2005 3.1 1 7.1 
Bouguerra 2007 4.4 2.9 6.3 
Sub-total 
    
Random pooled  ES 4.3 3.3 5.5 
     
40-49 
    
Boronat 2006 4.4 1.8 8.9 
Oti 2013 
 
5.8 3.5 9 
Favier 2004 16.3 13.4 19.4 
Erasmus 2001 3.4 0.4 11.7 
Ruhembe 2014 16 9.4 24.7 
Bouguerra 2007 12.3 9.5 15.7 
Sub-total 
    
Random pooled  ES 9.4 5.4 14.2 
     
25-44 
    
Liberia STEPS 2011 16.8 14.5 19.3 
Zanzibar STEPS 2011 2.4 1.5 3.6 
Sub-total 
    
Random pooled  ES 8.4 7.2 9.7 
     
<50 
    
Osuji 2012 4 1.1 10 
     
15-34 
    
Aspray 2000 0.5 0 2.7 
Aspray 2000 2.2 0.9 4.5 
Sub-total 
    
Random pooled  ES 1.4 0.5 2.7 
     
35-54 
    
Aspray 2000 1.5 0.3 4.3 
Aspray 2000 7.9 3.2 15.5 
Sub-total 
    
Random pooled  ES 2.9 1.2 5.2 
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20-40 
    
Ruhembe 2014 4.5 1.8 9.1 
     
30-49 
    
Uganda STEPS 2014 1.6 0.9 2.6 
     
Overall 
 
          
  
Random pooled  ES 7.2 5.6 8.9 
  
4.5.5. Prevalence of T2DM in urban and rural settings 
 
The highest pooled T2DM prevalence was 9.2% (95%CI 5.5-13.7%, I2 97.7%, p < 
0.001) in the 11 studies from urban settings only, 6.6% (4.9-8.6%, I2 98.2%, p < 0.001) 
in the 26 studies with mixed urban and rural participants, and 4.2% (3.3% - 5.2%, I2 
90.7%, p<0.001) in the 2 studies in participants from rural settings only; p=0.1418 






















4.5.6. Prevalence of T2DM by diagnostic methods 
The pooled T2DM prevalence was significantly higher in the 12 studies that used the 
2-hour OGTT (10% 95%CI 6.2- 14.5%, I2 97.7%, p < 0.001), compared to the pooled 
T2DM estimate in the 27 studies that used the FPG (6.1% 95%CI 4.6-7.8%, I2 98.2%, p 



























4.5.7. T2DM prevalence by the period of publication 
The median year of publishing was 2012. The pooled T2DM prevalence for the 18 
studies published during the period 2000 – 2011 was 6.5% (95%CI 4.6-8.6%, I2 98.5%, 
p < 0.001), compared to 7.8% (5.6-10.4%, I2 97.0%, p < 0.001) for the 21 studies 




















Fig 4.7. Prevalent T2DM comparing studies published during 2000-2011 







4.5.8. T2DM prevalence comparing nationally representative and 
local/regional studies 
The prevalence of T2DM was 7.4% (95%CI 5.4- 9.8%, I2 98.3%, p < 0.001) in the 
nationally representative studies compared to 6.9% (4.6-9.6%, I2 98.3%, p < 0.001) in 
regional and local studies; p=0.949) (Table 1 and Figure 4.8).  
Fig 4.8. Prevalent T2DM comparing nationally representative studies and 






4.5.9. IFG prevalence in African women aged 15 – 54 years 
There were 22 studies from 17 countries with IFG data; 4 (18%) were South African, 
2 (9%) were Cameroonian while the rest were individually from the remaining 15 
countries. These studies included 34 483 participants, of which 2128 had IFG. The 
overall IFG prevalence was 6.0% (95%CI 4.2% - 8.2%) (Figure 4). There was significant 
heterogeneity in the pooled estimate of IFG (I2 = 0.96, p <0.001). In sub-group 
analyses, there were no significant differences in the IFG prevalence between different 
age groups (p=0.870), rural and urban studies (p=0.603) and between the studies 
published during the period 2000 – 2011 and the studies published during 2012 – 2016 

















Fig 4.9. Forest plot showing IFG prevalence in African women aged 15-
54 years, from studies published during the period 2000-2016 
  
 
4.5.10. IGT prevalence in African women aged 15 – 54 years 
Six studies reported age and gender categorized data on IGT; 5 of the studies were 
from South Africa and one each from Ghana and Mauritius (Appendix 1). Due to the 
wide variation in IGT between the studies and the few studies available, a meta-
analysis was not performed. The lowest IGT prevalence (0.8%) was in women aged 15-
24 years in South Africa in 2008 while the highest prevalence (37%) was in women 
aged 45-54 years in 2016, both in urban KwaZulu Natal province. In Ghana, IGT 
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prevalence was 7.3% and 13.0% in women aged 25-34 years and 45-54 years, 
respectively while in Mauritius, in 2004, IGT prevalence ranged from 5.9% to 15.9% in 
women aged 20-29 years and 40-49 years, respectively.  
4.5.11. Publication bias assessment 
We found no evidence of publication bias, as shown in Supplementary Figures 10-
12 and using Begg’s and Egger tests; for T2DM (Begg’s p = 0.07, Egger’s p = 0.293) 
and IFG (Begg’s p=0.367, Egger’s p=0.202).  
4.6. Discussion 
 
The implications of diabetes on the health of both the mother and that of the 
offspring have been researched in detail elsewhere [9,32-35], and evidence is mounting 
that this may contribute to the developmental origins of chronic disease in exposed 
offspring, especially metabolic abnormalities, in later life [36-38].  In this systematic 
review, we investigated the prevalence of dysglycaemia in African women of 
childbearing age, as reported in studies published during the period 2000 – 2016. The 
major findings of this systematic review and meta-analysis of 39 studies are an overall 
pooled T2DM prevalence of 7%, and overall pooled IFG prevalence of 6% while IGT 
prevalence ranged from 0.9% to 37%, with substantial heterogeneity in all three 
outcomes.  Subgroup meta-analysis did not explain the heterogeneity observed. 
Further, we found a significantly higher prevalence of T2DM in studies which used the 
OGTT compared to studies which used the FPG for the diagnosis of T2DM.   
To date, ours is the only systematic review that has assessed the prevalence of 
T2DM, IFG and IGT in women of childbearing age in Africa, thus limiting our ability to 
compare our findings with those of existing reviews. Most of the existing reviews have 
investigated the prevalence of T2DM, IFG and IGT either in both men and women or in 
all women. In 2015, the IDF used an analytic hierarchical process which included 
sample representativeness, diagnostic criteria, sample size, and age of study to select 
studies from which to estimate the T2DM prevalence. Only 13 high-quality data sources 
from 12 African countries during the years 2000 to 2015 met the stringent criteria for 
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inclusion [3]. However, there are notable similarities between our data and the IDF data 
for African women of childbearing age. The T2DM prevalence for African women aged 
20 – 54 years from IDF data sources ranged from 0.001% to 32%, compared to our 
reported data which ranged from 0.5% to 36%. In the IDF data, reported T2DM 
prevalence in women aged 20-54 years ranged from 0.1% to 23% in Europe, from 
1.4% to 43% in the Middle East and North Africa region, 1.3% to 34% in the North 
American and Caribbean region, 1.5% to 21.5% in the South and Central America 
region, 1% to 36% in the South East Asia region, while the highest reported T2DM 
prevalence was reported, as expected, in the Western Pacific region (range 0.1% to 
62%).  
There are other published systematic reviews which did not investigate the T2DM 
prevalence in women only but rather in both African men and women [T2DM 
prevalence ranged from 1% to 12% [39,40]. Hilawe et al. 2013, using a systematic 
review and meta-analysis of 36 studies, found a T2DM prevalence in African women 
aged 15 years and above in Sub-Saharan Africa, of 5.9 (95%CI 4.6% – 7.6%), [41] that 
overlaps with our finding of 7% (95%CI 5.6% – 8.9%). Our review differed from that of 
Hliawe in several areas. First, in contrast to Hilawe et al, we included only women from 
15 to 54 years and not under the age of 15 years or women above 54 years.  Second, 
Hilawe et al. included studies from 1984 until 2011- only 23 studies are common to both 
reviews. Third, the diagnostic criteria differ:  the studies included in the Hilawe et al. 
review were based on the WHO or American Diabetes Association diagnostic criteria 
used at the time of the study, while the studies in our review have used a standard 
WHO 1998 criterion.   
More recently, the NCD-Risk Factor Collaboration (NCD-RisC), using more data 
sources [76 reports], and robust methods, estimated the T2DM in 2014 at 8.9% in all 
African women [4]. The difference between our prevalence estimate and the NCD-RisC 
estimate can be partly explained by the inclusion of older women in the later estimate, 
as T2DM prevalence increases with age. For example, Werfalli et al. 2015 [10], using a 
systematic review and meta-analysis, found a T2DM prevalence of 15% in African 
women aged 55 years and above, highlighting the higher prevalence in older women.   
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We are also limited in comparisons of our IFG and IGT estimates with existing 
systematic reviews. Very few primary studies have reported IFG and IGT outcomes 
and, consequently, these are infrequently reported in systematic reviews and meta-
analyses. The IDF’s 2015 report did not report IFG prevalence in Africa but estimated 
the IGT prevalence in African men and women at 7.9% (95%CI 4.8 – 21.7), which is in 
line with our estimate.  Bos et al. 2013, [39] in a systematic review of T2DM in North 
African countries, found an IFG prevalence in all women of 5.1% (n = 1 study) in 
Tunisia, 2.2% in rural Sudan and 13.1% in urban Egypt (n = 5 studies). The review by 
Bos et al. included studies published during the period from 1990 to 2012 and included 
any studies reporting diabetes, regardless of how it was defined.   
We identified 22 studies which reported IFG prevalence while only 6 studies 
reported IGT prevalence. The smaller number of studies reporting IGT reflects that 
most epidemiological studies use the FPG, instead of the OGTT for the diagnosis of 
T2DM, IFG and IGT. The time requirement and labour-intensive nature of the OGTT 
make it an unfavourable tool for diabetes screening in epidemiological studies. 
However, there is mounting evidence that the two impaired glucose regulation states 
are distinct entities, with isolated IFG reflecting impaired insulin secretion while isolated 
IGT reflects impaired insulin sensitivity [42,43]. Furthermore, the use of the FPG only 
for the identification of impaired glucose regulation states could result in up to 20% of 
IGT cases being missed [43]. Several studies have shown that disorders in insulin 
secretion and sensitivity are already present when the FPG is within normal ranges and 
are more likely to be detected as IGT [44,45]. Although it has been suggested (1) that 
HbA1c be used for screening for impaired carbohydrate metabolism, as it is more 
convenient, faster, doesn’t require prior fasting and is becoming more affordable, there 
is no conclusive evidence on the HbA1c cut-off points that correspond to either IFG, 
IGT or both, in African populations.  
Risk factors for T2DM in African women of childbearing age are on the increase, 
driven by the nutrition transition, urbanization and decreasing physical activity [46]. 
Several studies have shown that African women are more insulin resistant than their 
Caucasian counterparts, while antiretroviral therapy for HIV contributes to more fat 
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deposition in affected women [46]. In Sub-Saharan Africa, HIV positive women are 
more likely to be young and overweight or obese [46]. Further, evidence suggests that 
the mean BMI in African women increased from 21.9kg/m2 in 1980 to 24.9kg/m2 in 
2014 [4]. All these factors suggest that we may see a high future diabetes burden in 
African women of childbearing age, compared to the present prevalence.   
Africa is one of the continents where the IDF expects the greatest increases in the 
numbers of people with diabetes to occur between the years 2015 and 2035. African 
health systems are already overburdened by infectious diseases such as HIV, TB and 
malaria while at the same time catering for people already diagnosed with non-
communicable diseases, diabetes included [47]. Prevention of new cases is, therefore, 
a priority. Prevention of diabetes can be achieved using either a population-wide 
approach or a “screen and treat” approach or a combination of both. The population-
wide approach targets everyone through public health policies, for example, the sugar 
tax to help reduce overweight and obesity, advocated by the W.H.O. [48], which has 
already been implemented in several European countries, such as Norway, Ireland and 
the United Kingdom, while in Africa, the tax was introduced in South Africa in 2017.  
On the other hand, the “screen and treat”, used in various Diabetes Prevention 
Programs, involves identifying at-risk groups, such as people with IFG, IGT or GDM, 
and offer targeted interventions, which are usually pharmacological, or lifestyle change 
interventions or a combination of both. Despite the success of various diabetes 
prevention programs [49], in the USA [50], China [51] and India [52], among other 
countries, studies investigating the effectiveness of either pharmacological or lifestyle 
change interventions in delaying or preventing T2DM in African women are scarce. In 
2017, the WHO, in the Montevideo RoadMap on non-communicable diseases [NCDs] 
[7], stressed the double impact of non-communicable diseases such as T2DM, where 
women may become sufferers and unpaid caregivers to family members with chronic 
NCDs. In the same policy document, the WHO advocates for gender-based 
approaches to the prevention of NCDs. The prevention of T2DM in women of 
childbearing age is one such area where a gender-based approach will be appropriate. 
Women with IFG, IGT and GDM are special at-risk populations for T2DM. While we did 
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not investigate the prevalence of GDM in this review, systematic reviews published in 
2014 and 2015 found reported GDM prevalence as high as 14% in African women 
[12,53]. Identifying women with IGT and IFG in Africa is not part of routine care or 
national programs. On the other hand, many African health settings screen women for 
GDM, and perhaps this is a group with which “screen and treat” approaches could be 
used, to prevent or delay future T2DM, particularly in the maternal and child health 
context. Research is needed to investigate the effectiveness of lifestyle, and even 
pharmacological, interventions in delaying or preventing T2DM in African women with 
IFG, IGT and GDM, in the context of limited resources and possibly different modifiable 
environmental risk factors to those in the higher income countries.  
A strength of the current study is that it is based on a larger number of population-
based surveys from a broader range of African countries than previous estimates.  
However, the quality of the included surveys, the inclusion of studies with small sample 
sizes, methods of screening for dysglycaemia and the representativeness of the data 
remain of concern. Of the 39 studies included in our meta-analysis, 20 could be 
described as nationally representative. All the 20 studies, except for the Namibian 
Demographic and Health Survey [28] were WHO STEPWise surveys. Further, we 
acknowledge that variations in economic development may explain some of the 
heterogeneity across the studies and that our estimate may not be representative of the 
prevalence across the African continent due to this. Included studies rarely report data 
on the detection, treatment and control of diabetes/dysglycaemia as well as prevalent 
chronic diabetes complications in the surveyed populations. Therefore, the current 
review is unable to comment on the performance of health systems in preventing and 
controlling diabetes in African women of childbearing age.     
We planned to use the WHO definition of women aged 15-49 years for this review, 
but as most studies utilized the 15-24, 25-34, 35-44, 45-54 years age group system for 
operative reasons, we capped the upper age at 54 years. We likely included a 
proportion of women who were not of childbearing age in the review, and consequently, 





Our study demonstrates that T2DM, IFG and IGT prevalence is high in African 
women of childbearing age. Due to the long and short-term implications, on both the 
mother and child of any form of diabetes, it is imperative to develop interventions 
targeted at at-risk women, within the maternal and child health framework.  
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Global data indicate that women with a history of hyperglycaemia first detected in 
pregnancy (HFDP) are at up to seven times risk of progressing to type 2 diabetes 
mellitus (T2DM), compared to their counterparts who have pregnancies that are not 
complicated by hyperglycaemia. However, there are no data from the sub-Saharan 
African region, which has the highest projected rise in diabetes prevalence globally. 
This study aimed to determine the proportion of women who progress to T2DM and 
associated risk factors, 5-6 years after HFDP, in Cape Town, South Africa.   
 
5.1.2. Methods and Findings 
 
All women with HFDP at a major referral hospital in Cape Town were followed up 5 
to 6 years later using a cross-sectional study. Each participant had a 75gram oral 
glucose tolerance test, anthropometric measurements and a survey were administered.  
Two-hundred-and-twenty participants were followed up. At that time, their mean age 
was 37.2 (SD 6.0) years. Forty-seven percent (95%CI 40.7-53.9) progressed to T2DM, 
5.5% (95%CI 3.1 – 9.4) had impaired fasting glucose, and 11% (95%CI 7.4 – 15.8) had 
impaired glucose tolerance. Of the participants who progressed to T2DM, 47% were 
unaware of their diabetes status. When HFDP was categorized, post hoc, according to 
the WHO 2013 guidelines, progression in the DIP group was 81% (95%CI 70.2 – 89.0) 
and 31.3% (95%CI 24.4 – 39.3) in the GDM category. Factors associated with risk of 
progression to T2DM were; at follow-up - waist circumference (OR 1.1, 95%CI 1.0 – 
1.1, p = 0.007), hip circumference (OR 0.9, 95%CI 0.8 – 1.0, p = 0.001), and BMI (OR 
1.1, 95%CI 1.0– 1.3, p = 0.001), and at baseline – insulin (OR 25.8, 95%CI 3.9 – 171.4, 
p = 0.001) and oral hypoglycaemic treatment during HFDP (OR 4.1, 95%CI 1.3 – 12.9, 
p = 0.018), fasting (OR 2.7, 95%CI 1.5– 4.8, p = 0.001) and oral glucose tolerance test 
2-hour glucose concentration at HFDP diagnosis (OR 4.3, 95%CI 2.4 – 7.7, p < 0.001). 
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Our findings have limitations in that we did not include a control group of women 
without a history of HFDP.  
5.1.3. Conclusions 
 
The progression to T2DM in women with previous HFDP found in this study 
highlights the need for interventions to delay or prevent progression to T2DM after 
HFDP. Besides, interventions to prevent HFDP may also contribute to reducing the risk 
of T2DM.   
5.2. Author Summary 
 
Why Was This Study Done? 
International research shows that when a woman has diabetes detected in 
pregnancy, which may resolve after the pregnancy, she remains at high risk of future 
diabetes.   
However, we do not know what proportion of women progress to type 2 diabetes in 
Africa, as no research has been done before, despite the rapid increase in the number 
of people with diabetes.  
What Did the Researchers Do and Find? 
We recalled 220 women 5-6 years after they had diabetes first detected in 
pregnancy, and tested them for type 2 diabetes, in Cape Town, South Africa.   
We found that almost half of the women, 48%, now had type 2 diabetes. Of the 
women with type 2 diabetes, 47% did not know that they had type 2 diabetes.   
We also found that being obese at follow up and having higher blood sugar 
concentrations at the time the women were tested for diabetes in pregnancy, increased 








What Do These Findings Mean? 
A big proportion of South African women who have diabetes first detected in 
pregnancy may develop type 2 diabetes at an early age and within 6 years after the 
pregnancy.   
  It may be necessary to change their lifestyle after pregnancy, so they can reduce 
the chance of progressing to type 2 diabetes.   
 Screening for type 2 diabetes after the pregnancy needs to be more often so women 
who develop diabetes are treated earlier.   
Further research is needed, as we did not include women who did not have 




Sub-Saharan Africa, compared to other regions, is expected to have the greatest 
increase in the number of people living with diabetes by the year 2040, with more than 
half the people affected unaware of their diabetes status [1]. Since 2015, diabetes has 
already risen to be the second leading cause of death, after tuberculosis, in South 
Africa [2]. The prevalence of obesity, the strongest known risk factor for type 2 diabetes 
has increased, across the world, and, more so in African women, with a recent meta-
analysis showing that in this group, mean BMI increased from 22kg/m2 in 1980 to 
25kg/m2 in 2014 [3]. In South Africa, the combined obesity and overweight prevalence 
increased from 29% to 40% men and 57% to 70% in women during the period 2002 to 
2016 [4,5]. Other drivers of the diabetes epidemic, such as poor nutrition, decreased 
physical activity has also increased during the last two decades, while HIV antiretroviral 
therapy-induced lipodystrophy may also increase risk of diabetes, especially in women 
of childbearing age, who are disproportionally affected by HIV, compared to their male 
counterparts [6]. Because of the current high burden of diabetes and the expected rise 
in diabetes prevalence, it is imperative to identify populations at elevated risk and 
introduce risk-lowering interventions.   
Women with a history of hyperglycaemia first detected in pregnancy (HFDP), 
including gestational diabetes mellitus (GDM), are at high risk of future development 
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ofT2DM [7]. Initially, GDM was defined based on the risk of developing T2DM, but this 
may have resulted in the inclusion of women with undiagnosed diabetes in the GDM 
subgroup. Following the recommendations of the International Association of Diabetes 
and Pregnancy Study Group (IADPSG) [8]  and the publication of the findings from the 
Hyperglycaemia and Adverse Pregnancy Outcomes Study (HAPO Study) [9], a 
multicentre study with participants from 10 countries, the WHO [10], in 2013, defined 
HFDP as either diabetes in pregnancy (DIP) or GDM. According to the WHO, GDM is 
now diagnosed as glucose intolerance in pregnancy with fasting glucose values 
between 5.1-6.9mmol/l or/and oral glucose tolerance test (OGTT) 2-hour glucose 
concentrations between 8.5-11.0mmol/l, while women with blood glucose values 
diagnostic of type 2 diabetes first discovered in pregnancy are classified as having DIP. 
The HAPO Study demonstrated associations between fasting glucose concentrations, 
as low as 5.1mmol/l at HFDP diagnosis and adverse foetal outcomes at birth, while the 
HAPO follow-up study [11], and others [12], showed a high risk for T2DM in women in 
the post-partum period as well as long term and adiposity in their offspring. Notably, 
neither the HAPO study nor the follow-up studies included data from an African cohort. 
Despite the absence of data from African countries, it is expected that lower fasting 
glucose concentration cut-offs for HFDP diagnosis, in addition to increased awareness 
and improved screening as well as increasing calls for universal screening for HFDP, 
may result in a higher prevalence of HFDP worldwide, especially in transitioning 
populations, such as South Africa. In China, for example, a four-fold increase in GDM 
prevalence was noted when universal screening was introduced [13].   
Before the introduction of the term HFDP, most studies used the term GDM to 
describe any hyperglycaemia first detected during pregnancy. In this article we use the 
term HFDP where the studies may have used the term GDM, using older criteria in 
which the DIP subgroup was possibly included. The prevalence of HFDP varies in 
different populations, although this is complicated by the use of different diagnostic 
criteria as well as different screening methods for hyperglycaemia during pregnancy 
[14]. HFDP prevalence from a systematic review of the small number of available 
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studies in Africa ranged from 0 to 14% [15]. Recent studies that used the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) [8] criteria for  
GDM diagnosis reported prevalence of 8.9% in Nigeria [16], 2.9% in Kenya [17] 
and, in South Africa; 9.1% in Soweto [18] and 25.8% [19] in Johannesburg. The 
Johannesburg estimate of 25.8%, may have included women with DIP, and therefore 
could be an estimate of HFDP. Using the conservative Soweto estimate, if 1 in every 11 
pregnancies is complicated by GDM then public health interventions are required to 
prevent or delay T2DM in these women post the index pregnancy, in South Africa. 
However, the paucity of data on the prevalence of and associated risk factors for 
T2DM, in women after GDM, in sub-Saharan Africa and South Africa, may hinder 
effective development and planning of interventions and policies.   
Data from meta-analyses of studies, mostly from high-income countries, show that 
women with previous GDM have up to seven-fold risk of developing T2DM [7,20], 
increased risk of long-term cardiovascular disease [7] and, for the offspring, increased 
risk of immediate adverse perinatal as well as future cardiometabolic disease risk [7], 
compared to those with non-diabetic pregnancies. Further, the risk of progression to 
T2DM is highest during the period 3-6 years post GDM [20]. However, the risk may be 
overestimated as most of the included studies used older GDM criteria which included 
women with DIP. Besides, there is a great degree of heterogeneity in the risk for T2DM; 
relative risks ranging from 2.7 in Germany to 38.4 in Sweden [14]. The estimates of risk 
vary by country and within countries, by ethnicity and region, which may be due to 
differences in the distribution of risk factors of T2DM in different populations. Different 
follow-up times and different study designs may also contribute to the differences in the 
risk estimates.   
Progression to T2DM post HFDP varies widely, from a low 6% in Australian non-
indigenous women [21] to 42% in Indian women [22], using IADPSG criteria. Risk 
factors for progression also vary widely, ethnicity, increased BMI, family history of 
T2DM, increased waist circumference and severity of GDM at diagnosis, being some of 
the most frequently identified [23]. In Africa, apart from a single study that followed up 
77 women up to 12 weeks post HFDP in Cape Town [24], to our knowledge, there are 
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no data on the progression to T2DM post-HFDP or associated risk factors. This study in 
women 5-6 years post HFDP, provides the only data, to date, on the proportion of 
women who progress to T2DM beyond the postpartum period, as well as factors 
associated with risk of progression, in Africa, specifically in Cape Town, South Africa. 
We also investigated the proportion of women who progressed to T2DM in the GDM 




5.4.1. Study design, setting and participants 
 
The study was carried according to an ethics approved study protocol (S1 Doc). 
Data on all women managed for HFDP at Groote Schuur Hospital (GSH) during the 
period 1 September 2010 to 31 August 2011 were routinely collected during the index 
pregnancy [25]. During that time, in the Western Cape province of South Africa, GDM 
screening and diagnosis was based on the provincial guidelines [26]. The screening 
was based on selective risk factors; maternal age≥40 years, BMI≥40kg/m2, previous 
GDM, previous foetal birthweight≥4.5kg, previous unexplained miscarriage, acanthosis 
nigricans and polycystic ovarian syndrome while GDM was diagnosed using the United 
Kingdom National Institute for Health and Care Excellence (NICE) 2008 criteria (fasting 
glucose above 5.5mmol/l and OGTT 2-hour glucose over 7.8mmol/l) [27]. A cross-
sectional study, of the same participants (n = 498) was undertaken 5-6 years later, 
during the period 1 January 2016 to 31 Jan 2017. We contacted and invited participants 
through letters mailed to their last known address, calls to their telephone or cell phone 
numbers in the hospital record or next of kin and finally, home visits when all other 







5.4.2. Study procedures and data collected 
 
On the day of testing, participants underwent a standard 75-gram OGTT after 
fasting for 8-10 hours. Blood was drawn for glycated haemoglobin A1c (HbA1C), and 
glucose and insulin at fasting and 120 minutes post OGTT glucose load. The blood 
samples were kept on ice, aliquoted within 4 hours of collection and stored at -80 
degrees until analyzed. All blood samples were analysed after the recruitment of the 
last participant, at the same time. The time between assay collection and laboratory 
analysis therefore ranged from a few days to 7 months. However, this would not have 
influenced the glucose levels as the storage at -80 degrees Celsius would have 
ensured stability. Participants on treatment for T2DM were not required to do either the 
OGTT or the HbA1C. A trained fieldworker administered a questionnaire (Appendix 5.1) 
to obtain sociodemographic, reproductive history, self-reported personal and family 
medical history and psychosocial health and lifestyle factors such as physical activity 
(modified W.H.O. Global Physical Activity Questionnaire), smoking and diet using a 2-
week food frequency questionnaire.  
Height, weight, waist and hip circumference and blood pressure were measured 
using standardized procedures. Waist-hip ratio was calculated as the ratio of each 
participant’s waist circumference to their hip circumference. BMI was grouped 
according to WHO criteria for underweight (<18.5 kg/m2), normal weight (18.5–24.9 
kg/m2), overweight (25–29.9 kg/m2), obese (30-39.9 kg/m2) and morbidly obese (>40 
kg/m2) [28]. Outcomes for each participant were T2DM, impaired fasting glucose (IFG) 
and impaired glucose tolerance (IGT) using WHO 2006 criteria [29].   
 
5.4.3. Biochemistry and lab analyses 
 
Plasma glucose was measured using the Randox RX Daytona Chemistry Analyzer. 
Glycosylated haemoglobin A1C (HbA1C) was measured using turbidimetric inhibition 
immunoassay (D10TM Haemoglobin A1c Program; Bio Rad Laboratories Inc., 
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Hercules, CA, USA). The precision and trueness of the Randox RX Daytona Chemistry 
Analyzer were verified using the Clinical and Laboratory Standards Institute document 
EP15. Coefficients of variation calculated from running 40 separate samples at 3 
different times were 3.0% for glucose and 1.6% for HbA1c.  
 
5.4.4. Sample size and power 
 
The sample size for this study was based on the main aim, to estimate the 
proportion of participants who progressed to T2DM by the time of follow-up. Most 
studies found a prevalence of T2DM during the first 5 years after GDM diagnosis 
between 20% and 50% [12,30]. Using Open Epi sample size calculator for a proportion 
(http://www.openepi.com/SampleSize/SS), assuming that 35% of our participants would 
have progressed to T2DM and using the range 20% to 50% from literature (i.e. 15% 
either side of our assumed proportion), the minimum sample size required was 154. We 
anticipated difficulties in following-up women in our setting and therefore decided to 
include all women who we could contact and who agreed to participate.   
 
5.4.5. Statistical data analysis 
 
All statistical analysis was carried out using Stata 15 statistical software [31]. For all 
hypothesis testing and comparisons, significance was set at 0.05 while 95% 
Confidence Intervals (95%CIs) were reported for the prevalence of T2DM as well as all 
odds ratios (OR). Means and standard deviations were presented for normally 
distributed measured variables, medians and interquartile ranges (IQR) for variables 
that were not normally distributed while, for categorical variables, frequencies and 
proportions were reported.   
To compare variables between participants who progressed to T2DM and those 
who did not, chi-squared test and Fischer’s Exact (small frequencies) were used for 
hypothesis testing for categorical data, while the t-test for independent groups (or 
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Wilcoxon rank-sum test if data were not normally distributed) were used to compare 
measured data.    
The analysis for factors associated with T2DM at follow up was redone after input 
from journal reviewers, with the main change being using continuous variables (BMI, 
age, waist and hip circumference) in their raw, and not categorized forms. We carried 
out a multiple logistic regression model which included variables which are associated 
with risk of T2DM. Variables included from data measured at follow-up were; age, 
anthropometry (BMI, hip and waist circumference), socioeconomic variables (education 
and employment), comorbidities (self-reported dyslipidaemia and high blood pressure), 
total physical activity from the GPAQ and family history of diabetes. Variables included 
from baseline measurements were OGTT glucose concentrations at diagnosis of HFDP 
and type of treatment for HFDP. Stopping alcohol due to health reasons (n = 58 with 
responses) was not included in the multivariate regression as there were too many 
missing or “not applicable” data. We also did not include waist-hip ratio in the model 
due to the very wide 95% confidence interval. Further OGTT 1-hour glucose at HFDP 
diagnosis was also not included due to its limited clinical utility and as most health 
facilities in South Africa do not measure it. For logistic regression model diagnostics, 
we assessed the following; linearity assumption using the Lowes graph, multicollinearity 
using variance inflation factors, model specification using the C-statistic, and confirmed 
the fit of the model using the Hosmer-Lemeshow goodness-of-fit test. We also checked 
for outliers as well as influential observations.   
This study is reported as per the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guideline (S3 STROBE Checklist).  
 
5.4.6. Ethical considerations 
 
The study received ethics clearance from the Human Research Ethics Committees 
of the University of Cape Town (Ref: 656/2015) (Appendix 5.2) as well as permission to 
research the GSH. Participants gave written informed consent (Appendix 5.3). If found 






Of the 498 eligible women, 220 (44.2%) participated in the follow-up study, 234 
(47.0%) could not be contacted and 44 (8.8%) could not participate (Fig 5.1). There 
were no major differences between participants who were followed up and those lost to 
follow-up, except that participants followed up had a higher mean BMI at booking and a 
lower mean OGTT 2-hour glucose concentration at the time of HFDP diagnosis of 
HFDP (S1 Table).   
 
Fig 5.1. Flow chart of the study 









5.5.1. Characteristics of participants 
 
As seen in Table 5.1, at baseline during the index pregnancy, the mean age was 
30.8 (SD 5.9) years, most participants, 142 (65.4%) were of mixed ancestry, followed 
by 68 (31.3%) who self-identified as Black. More than three-quarters had a first-degree 
family history of diabetes, while most participants were either obese, 96 (44.9%) or 
morbidly obese, 49 (22.9%). Just under a third of the participants, 27.7%, received oral 
hypoglycaemic treatment and 23.6% had insulin therapy for HFDP. At HFDP diagnosis, 
70 participants had FPG ≥7mmol/l or/and 2-hr blood glucose concentrations 11.1mmol/l 
and were retrospectively classified as DIP, and the remaining 150 (68.2%) had FPG 
between 5.6-6.9 mmol/l or/and 2-hr blood glucose concentrations 7.8-11.0mmol/l, 
retrospectively classified as GDM. Our classification of GDM differed from the WHO 
2013 guidelines in that our cohort did not include women with fasting glucose values 
lower than 5.5mmol/l while we included women with OGTT 2-hour blood glucose 
between 7.8-8.4 mmol/l.   
 
Table 5.1. Comparison of baseline characteristics of participants with 
and without T2DM at follow-up 
Variable Level Overall, n 
= 220  
Progressed 




T2DM, N = 
115 
P-value 
Age, years Mean (SD) 30.8 (5.9) 31.5 (6.0) 30.3 (5.7) 0.116 
Ethnicity, n (%)   Black  68 (31.3) 34 (32.7) 34 (30.1) 0.702 
Mixed ancestry 142 (65.4) 67 (64.4) 75 (66.4) 
Other  7 (3.2) 3 (2.9) 4 (3.5) 
Family history of 
diabetes, n (%) 
Yes 169 (76.8) 81 (77.1) 88 (76.5) 0.913 
BMI at booking (n = 
214), kg/m2 
Mean (SD) 34.2 (8.2) 35.2 (7.8) 33.3 (8.5) 0.096 
BMI at booking 
categories, n (%) 
Normal  31 (14.5) 10(9.5) 21(18.3)  
0.134 Overweight 44 (20.0) 
(17.8) 
16 (15.2) 22(19.3) 
Obese 104 (47.3) 56 (53.3) 46 (40.0) 
Morbidly obese 48 (21.8) 23 (21.9) 26(22.6) 
HFDP type, n (%) DIP 70 (31.8) 58 (82.9) 12 (17.1) <0.001 
 GDM 150 (68.2) 47 (31.3) 103 (68.7)  
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Gestational age at 
delivery (n = 215) 
Weeks, median 
(IQR) 
38 (37 – 
39) 
38 (37 – 
39) 
38 (38 – 
39) 
0.001 




61 (27.7) 38 (36.2) 23 (20.0) 0.007 
insulin 52 (23.6) 43 (41.0) 9 (7.8) <0.001 
Glucose metabolism 
at HFDP diagnosis 
(mmol/l) (mmol/l) 
median (IQR) 
FPG 5.8 (5.1 – 
6.7) 
6.4 (5.7 – 
7.2) 
5.6 (4.9 - 
5.9) 
<0.001 




9.8 (8.5 – 
10.6) 
<0.001 
OGTT 2-hours 9.0 (8.3 – 
10.4) 
10.1 (8.6 – 
11.1) 
8.6 (8.1 – 
9.3) 
<0.001 
***n is specified for variables with missing data only. All the other variables have complete 
data  
Table 2 shows the characteristics of the participants at follow-up. At follow-up, the 
mean age of the participants was 37.2 (SD 6.0) years. Most of the participants, 167 
(75.9%), had secondary or matric level education. More than two-thirds of the 
participants were either obese, 96 (44.9%) or morbidly obese, 49 (22.9%).  
 
 
Table 5. 2. Comparison of characteristics at follow-up of participants 
with and without T2DM 
Variable Level Overall, n 
= 220  
Progressed 




T2DM, N = 
116 
P-value 
Age (years) Mean (SD)  37.2 (6.0) 37.1 (6.0) 37.3 (5.9) 0.949 
Education, n (%) Tertiary 30 (13.6) 9 (8.7) 21 (18.3)  
 Secondary and 
matric  
167 (75.9) 80 (76.2) 87 (75.7) 0.017 
 Primary   23 (10.5) 15 (14.6) 6 (5.2)  
Employed, n (%) Yes 108 (49.1) 48 (45.7) 60 (52.2) 0.338 
Marital status, n (%) Married   141 (64.1) 68 (64.8)) 73 (63.5) 0.843 
Hypertension n (%)  Yes  74 (33.6) 42 (40.0) 32 (27.8) 0.056 
On treatment for 
hypertension, n (%) 
Yes 58 (26.4) 35 (33.3) 23 (20.0) 0.025 
Dyslipidaemia, n (%) Yes  29 (13.2) 22 (21.0) 7 (6.1) 0.001 
On treatment for high 
cholesterol  
Yes  26 (11.8) 20 (19.1) 6 (5.2) 0.002 
On ARV treatment, n 
(%) 
Yes 8 (3.6) 4 (3.8) 4 (3.5) 0.896 
Stopped drinking 
alcohol due to health 
Yes 14 (6.4) 9 (8.6) 5 (4.4) 0.038 
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reasons, n (%) (n = 
58) 
GPAQ total physical 
activity, minutes per 
week 







GPAQ total PA, n 
(%) 
≥150mins/week 158 (71.8) 76 (72.4) 82(71.3) 0.859 
Anthropometry  
BMI (kg/m2) Mean (SD) 34.9 (8.7) 35.2 (8.9) 34.7 (8.6) 0.705 
BMI categories, n 
(%) 
Normal 24 (10.9) 14 (13.3) 10 (8.7) 0.329 
Overweight 44 (20.0) 17 (16.2) 27 (23.5) 
Obese 104 (47.3) 48 (45.7) 56 (48.7) 
Morbidly obese 48 (21.8) 26 (24.8) 22 (19.1) 
BMI gain (Follow-up 
– booking BMI) 
(kg/m2) (n=214) 























Waist hip ratio  median (IQR) 0.94 (0.89 
– 0.98) 





      
 
 
     
 
5.5.2. Progression to T2DM 5-6 years post HFDP 
 
At the time of follow up, n = 105, 47.7% (95%CI 41.2 – 54.4) progressed to T2DM, 
of these 47.1% were not previously diagnosed, 12 had IFG (5.5%, 95%CI 3.1 – 9.4) 
and 23 participants (10.5%, 95%CI 7.0 – 15.3) had IGT (Fig 5.2). Using an HbA1c ≥6.5 
and an established T2DM diagnosis, the T2DM prevalence was 49.5% (95%CI 42.8 – 
56.2). When HFDP was categorized, post hoc, according to the modified WHO 2013 
criteria, progression to T2DM in the DIP group was 82.9% (95%CI 72.0 – 90.1), and 







Fig 5.2. Progression to T2DM by the modified WHO 2013 criteria for 
GDM 
 
  *GDM depicts women who would be categorized as GDM under the W.H.O.2013 GDM criteria 
but in this cohort had slightly different cut-offs (fasting glucose between 5.6 and 6.9mmol/l 
and/or 2-hour OGTT between 7.8 and 11.0mmol/l)  
**DIP - depicts women who would be diagnosed as DIP under the W.H.O. 2013 GDM 
criteria (fasting glucose of at least 7mmol/l and 2-hour glucose of at least 11.1mmol/l  
 
 
5.5.3. Comparison of participants with and without T2DM at follow-up 
 
Participants who progressed to T2DM, compared to those who did not progress, 
had significantly higher median glucose concentrations (in mmol/l) at all times of the 
OGTT  at HFDP diagnosis, fasting: 6.4(IQR 5.7 – 7.2 vs 5.6 (IQR 4.9 – 5.9), p < 0.001; 
1-hour: 11.0 (IQR 10.0 – 12.2) vs 9.8 (IQR 8.5 – 10.6), p < 0.001 and 2-hour glucose: 
10.1 (8.6 – 11.1) vs 8.6 (8.1 – 9.3), p < 0.001), and were more likely to be on either oral 
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hypoglycaemic (36.2% vs 20.0%, p = 0.007) or insulin therapy (41.0% v 7.8%, p < 
0.001) during HFDP (Table 5.1 and 5.2).  
At follow-up, compared to participants without T2DM, participants who progressed 
to T2DM were significantly less likely to have a tertiary level education but more likely 
to have primary school level education (tertiary: 8.7% vs 18.3%, primary: 14.6% vs 
5.2%, respectively, p =0.017), more likely to report having dyslipidaemia (21.0% vs 
6.1%, p = 0.001) and to have stopped drinking alcohol for health reasons (8.6% vs 
4.4%, p = 0.038) and more likely to have gained less BMI, in kg/m2, [median 0.0 (IQR -
3.0 – 2.8) vs 1.6 (-1.1- 4.0) respectively, p = 0.019]. Box plots comparing fasting and 
OGTT 2-hour glucose levels at HFDP diagnosis, waist, hip circumference and waist-hip 
ratio at follow-up, by T2DM status at follow up, are shown in S1 Fig, S2 Fig, S3 Fig, S4 
Fig and S5 Fig, respectively.  
 
5.5.4. Factors associated with progression to T2DM 
 
Fig 3 shows the results of multiple logistic regression for variables independently 
associated with T2DM. Baseline variables significantly associated with risk of 
progression T2DM were; fasting glucose at HFDP diagnosis (OR 2.7, 95%CI 1.5– 4.8, 
p = 0.001) and OGTT 2-hour glucose concentration at HFDP diagnosis (OR 4.3, 95%CI 
2.4 – 7.7, p < 0.001), oral hypoglycaemic treatment for HFDP (OR 4.1, 95%CI 1.3 – 
12.9, p = 0.018) and insulin treatment during HFDP, (OR 25.8, 95%CI 3.9 – 171.4, p = 
0.001). The following variables measured at the time of follow-up  were significantly 
associated  with progression to T2DM; having primary school education only, compared 
to tertiary education (OR 16.2, 95%CI 1.1 – 244.3, p = 0.044), self-reported 
dyslipidaemia diagnosis   (OR 72.0, 95%CI 7.6 – 682.6, p < 0.001), self-reported 
hypertension diagnosis (OR 5.0, 95%CI 1.6 – 15.6, p = 0.006), BMI (OR 1.1, 95%CI 
1.0– 1.3, p = 0.001),  waist circumference (OR 1.1, 95%CI 1.0 – 1.1, p = 0.007) and hip 





Fig 5.3. Multiple variable logistic regression of factors associated with 
T2DM 
 
  Model statistics (observations – 200, LR Chi2 – 167.4, p-value – 0.000, Pseudo R2 – 0.54.6 
and log likelihood – 54.6)   
 
5.5.5. Logistic regression model diagnostics 
 
The model consisted of 200 observations after the removal of outliers (n = 17) and 
the omission of participants with missing data (n = 3). In the final model, the p-values 
for the C-statistic (_hatsq) and the Hosmer-Lemeshow statistic were 0.123 and 0.809, 
respectively, confirming good fit for the model. There was no significant collinearity 
since pairwise correlations resulted in variance inflation factors between 1.04 and 1.82. 
The Lowes graph confirmed the linear model assumption. 





Our major findings are that in women 5-6 years post HFDP, only 36.4% had normal 
glucose tolerance; 47.7% had progressed to T2DM, of whom 47% were previously 
undiagnosed, 5.5% had IFG and 10.9% IGT. When we further categorized the HFDP 
post hoc using modified WHO 2013 GDM criteria, progression to T2DM was 83% and 
31% in the DIP and GDM categories, respectively. Factors associated with risk of 
T2DM were fasting and OGTT 2-hour glucose concentration at HFDP diagnosis, oral 
hypoglycaemic and insulin treatment during HFDP and primary school education, BMI, 
waist and hip circumference at follow-up.  
A key consideration for this study is the impact of GDM definition changes on the 
progression to type 2 diabetes. Recommendations of the IADPSG [8], based on 
findings from the HAPO study were adopted by the WHO in 2013 [10], and since then, 
most regional bodies have moved towards adopting the WHO guidelines. 
Consequently, most studies published before 2013 used GDM definitions, such as 
1999 WHO guidelines on the diagnosis of GDM, which included both women with GDM 
and women with DIP and may, therefore, have overestimated the progression to T2DM 
proportion. In S2 Table, we have listed studies that investigated progression to T2DM, 
in the medium to long term post-partum period, published during the period 2000-2019, 
and the proportion of women who progressed to T2DM from each study. Most of these 
studies [32-46] used either the WHO 1999 guidelines or other criteria while only 4 
studies used the IADPSG or equivalent criteria [11,21,22,47], for the diagnosis of GDM. 
Therefore, any comparisons of our findings with published data will need consideration 
of the heterogeneity of HFDP and GDM definitions.  
In the South African context, the T2DM prevalence in our study population is 4 times 
higher than that of South African women overall, 11% [48], and higher than the T2DM 
prevalence in black women aged between 25-74 years, 13.8% [49] or women of mixed 
ancestry aged over 30 years, (28.2%) [50] in Cape Town. South African women with a 
history of HFDP are a vulnerable population and require intervention to delay or prevent 
progression to T2DM. The high proportion of women who progressed to T2DM (48%) 
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could be explained partly by the possibility that, for some of the women, their glucose 
never returned to normality as they were not evaluated 6 weeks post the index 
pregnancy. This highlights the need for postpartum screening in these women. Global 
data indicates that postpartum screening is between 24% and 58% [51] while, in South 
Africa, less than 30% attend the recommended 6 weeks postpartum OGTT [24]. 
Several barriers from both the health system and patient perspectives hinder the 6-
week postpartum screening. The South African health system is overburdened [52] and 
postpartum screening for diabetes at 6 weeks using the recommended 2-hour OGTT 
would add significantly to the burden. While there are no South African data on barriers 
to postpartum screening, other studies have shown that the inconvenience of the OGTT 
and lack of time are the main reasons women do not attend the postpartum screening 
[51]. There is an ongoing debate on the utility of either fasting glucose only or the 
HbA1c for the postpartum screening [51]. Research is required to establish the 
optimum method to replace the OGTT, and for the HbA1C, both optimum timing for 
screening as well as cut-offs for the diagnosis of type 2 diabetes in African women. In 
the Western Cape, after delivery, the women must attend diabetes screening at a 
separate clinic while taking their offspring to a well-baby clinic for vaccination and 
follow-up, which may result in most women prioritizing the baby’s care over theirs. 
Studies investigating the barriers to postpartum screening as well as optimum 
screening methods in South African women are needed.  
We found very different proportions of women who progressed to T2DM between 
the GDM and DIP groups. The proportion of women who progressed to T2DM in the 
GDM group was 31% when we recategorized the women using modified WHO 2013 
criteria. The high proportion of women who progressed to T2DM in the DIP group (83% 
on OGTT alone but 96% on both HBA1c and OGTT), suggests that they may possibly 
have had T2DM before the pregnancy. However, they clearly had more severe glucose 
intolerance during the pregnancy, compared to the GDM group. When HbA1c 
assessment was added, only 3 (4%) of women in the DIP group did not progress to 
T2DM. Further analysis of the DIP group showed discordance between the OGTT 
results and HbA1c; 2 of the 7 participants with either impaired glucose intolerance or 
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impaired fasting glucose had HbA1C levels above 6.5% (7.2% and 8.6%) while 3 out of 
6 participants with normal GTT had HbA1C levels of at least 6.5% (6.5%, 6.5%, and 
6.6%). The remaining 3 participants with normal GTT had HbA1c levels below 6.5%. 
Further, the small proportions of IFG and IGT in our sample at follow up suggests that 
most of the women who will have converted to T2DM had already converted, further 
proof that most of the conversion to T2DM occurs during the first half decade after 
HFDP. Our data, although in a small sample of women with DIP, suggests the need for 
more structured follow-up for assessment for T2DM after the pregnancy.    
Comparisons of our findings with other studies that have investigated progression to 
T2DM is complicated by several issues. Firstly, there are no African studies that have 
investigated progression to T2DM post HFDP, the HAPO studies did not include an 
African cohort. Secondly, and more importantly, the heterogeneous definitions used for 
HFDP and GDM in the published studies (S2 Table) make it difficult to compare 
proportions of women who progressed to T2DM. Lastly, comparisons with published 
data are further complicated by the different study designs and different lengths of 
follow-up from the different studies. The proportion of women who progressed to T2DM 
of 31% in our GDM group, classified according to a modified WHO 2013 criteria, is 
somewhat high, compared to the four studies [11, 21, 22, 47] that used either the 
IADPSG or other criteria almost similar to it. This may be due to the cut-offs we used 
for GDM. Our study population is slightly different in that we did not include women with 
fasting glucose values between 5.1-5.5mmol/l, while we included women with OGTT 2-
hour glucose values between 7.8-8.4mmol/l The women in our study population, in 
terms of diagnostic glucose values, would have been almost similar to those included 
by Chamberlain et al. 2016 [21], where widely different proportions of progression to 
T2DM for indigenous (25.5%) and nonindigenous women (5.7%), at 5 years post-
partum, were reported. The proportion of women who progressed in the indigenous 
women was fairly similar to our study. A study from India, by Gupta et al. [22], in 
women diagnosed using the IADPSG GDM criteria, found that 25% and 42% of women 
aged 20-29 years and 30-39 years, respectively, progressed to T2DM in 5 years. The 
remaining two prospective cohort studies that used the IADPSG criteria for the 
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diagnosis of GDM, had follow-up periods which are very different from ours. In Japan, 
Inoue et al [47] found that 22% progressed to T2DM, 2 years post GDM, while 7.9% 
progression was observed in the HAPO study [11] after a median follow-up of 11.4 
years. It seems that progression to T2DM is heterogeneous, even when similar criteria 
for GDM diagnosis are used.  
Identifying risk factors for the risk of progression to T2DM is a necessary step when 
designing interventions to delay or prevent T2DM. The risk factors for progression in 
our study are largely similar to findings from previous studies; fasting [53] and 2-hour 
OGTT glucose concentration [47,54] at HFDP diagnosis, and, at follow-up, BMI, waist- 
and hip circumference [39,54,55]. Insulin and oral hypoglycaemic treatment during 
HFDP are an indicator of the severity of HFDP and, in our study, 77% of women who 
had insulin treatment were classified as DIP. Of the women with dyslipidaemia, 66% 
were already on treatment for diabetes at the time of follow-up, and it is well known that 
uncontrolled diabetes is associated with higher triglyceride and lower HDL levels [56], 
and the participants with an established diabetes diagnosis were more likely to have 
been screened for dyslipidaemia as part of standard care [57]. While no other long-term 
follow-up studies have shown a similar association between T2DM and education to 
ours, Gante [58], found an association between lower education and persistent post-
partum glucose disorders in Portuguese woman at 6 weeks follow-up. In our study and 
our setting, education is a good indicator of socioeconomic status, and therefore may 
be associated with an inability to access healthier lifestyle options such as better diets. 
Women with lower education may also not be able to access information on reducing 
T2DM risk after HFDP, therefore special interventions may be required for this group.  
Women who progressed to T2DM had lower BMI gain compared to those who did 
not progress to T2DM. A possible explanation for the lower BMI gain in women who 
progressed to T2DM could be that half of these women were already on treatment for 
T2DM. Typically this involves both lifestyle change and pharmacotherapy. On the other 
hand, in the absence of an intervention, women who did not progress to T2DM would 




Preventing T2DM can be achieved through either population-wide approaches such 
as the sugar tax, or interventions targeted at high-risk populations. The latter requires 
the screening and identification of high-risk individuals and offering interventions. 
Various diabetes prevention programs in both high income and low-to-medium income 
countries [46-49] have shown that lifestyle interventions can reduce the risk of T2DM in 
high-risk populations such as people with impaired glucose tolerance, although 
screening for impaired glucose tolerance in a population can be expensive and difficult. 
Our study highlights the notion that women with a history of GDM are an obvious and 
easily accessible target for prevention, diagnosed as part of routine care in the health 
system. An added benefit of this approach is that by targeting these women, there is a 
real chance of decreasing the risk of intergenerational transmission of T2DM to the 
offspring. In South Africa, there are increasing calls for universal screening for GDM 
[18,19], which is costly and adds to the workload of health workers compared to the risk 
factor-based screening which leaves a substantial proportion of women with GDM 
unscreened. Regardless of the screening approach used, research on the efficacy or 
effectiveness of lifestyle interventions in preventing or delaying progression to T2DM in 
women post HFDP, in South Africa, would provide much-needed data.  
Our study has several limitations. We were only able to follow-up 44.2% of women 
after 5-6 years, comparable to other studies [46,47,53] and partly explained by a highly 
mobile population in the Western Cape, where in-and-out migration is common [59]. 
The women who participated were more likely to book 2 weeks early (15 vs 17 weeks), 
had a higher BMI at booking by 2 units (34.6 vs 32.7kgm2), and had lower 2-hour 
OGTT blood glucose at HFDP diagnosis (9.0 vs 12.0 mmol/l), compared to the women 
who were lost to follow-up and therefore not completely representative of our study 
population. Given that we followed up only 31% of women with DIP compared to 40% 
at baseline, it is possible that the conversion to T2DM would have been higher in the 
whole group of 498 women. Due to the design, our study did not follow women up until 
diabetes developed, and therefore we do not have time to development of diabetes as 
well as being unable to establish temporality for any of the risk factors we identified. 
The lack of a control group of women with normoglycemic pregnancies at the same 
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time as our sample is a further limitation. However, when compared to recent T2DM 
prevalence in similar-aged women in the Western Cape, our data indicate a high T2DM 
prevalence in women with a history of HFDP. More robust studies, with control groups, 




Almost half of the women with a history of HFDP progress to T2DM within 5-6 
years, with almost half of them undiagnosed, in Cape Town, South Africa. There is a 
need for postpartum screening and interventions to reduce the risk of progression.  
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Chapter 6. PAPER 3 
 
High prevalence of cardiovascular risk factors and insulin resistance 6 
years after hyperglycaemia first detected in pregnancy, in Cape Town, 
South Africa 
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The study is published at https://drc.bmj.com/content/bmjdrc/7/1/e000740.full.pdf with 
the following citation:  
Chivese T, Norris SA, Levitt NS. High prevalence of cardiovascular risk factors and 
insulin resistance 6 years after hyperglycaemia first detected in pregnancy in Cape 












To investigate the prevalence, and associated risk factors for cardiovascular risk 
factors, 6 years after hyperglycaemia first detected in pregnancy (HFDP), in Cape 
Town, South Africa.   
6.1.2. Research Design and Methods 
 
Data were collected during the index pregnancy from all women diagnosed with 
HFDP at a major referral hospital in Cape Town. Participants were evaluated 6 years 
later, using a cross-sectional study. At follow up participants had a 75gram oral glucose 
tolerance test, fasting lipogram, blood pressure and anthropometric measurements and 
a field worker administered the questionnaire. We used the ATP III criteria for the 
diagnosis of metabolic syndrome and individual risk factors. Insulin resistance was 




At follow up 220 women were reviewed. Their mean age at follow up was 37.2 (SD 
6.0) years. The prevalence of CVD risk factors was: metabolic syndrome - 60.9% 
(95%CI 54.3- 67.2), insulin resistance - 75% (95%CI 65.9-82.3), dysglycaemia - 62.3% 
(95%CI 55.6-68.5), raised blood pressure - 41.4% (95%CI 35.0-48.0), and 
dyslipidaemia - 74.6% (95%CI 68.3-79.9). Women with diabetes in pregnancy, 
compared to those with gestational diabetes during the index pregnancy had a higher 
prevalence of metabolic syndrome (74.3% vs 54.7%, p = 0.010) and dysglycaemia 
(88.6% vs 50.0%, p<0.001) at follow-up. Lower school education attainment, having a 
subsequent pregnancy, waist circumference at follow-up, and fasting blood glucose at 






We found a high prevalence of CVD risk factors found in South African women 
within 6 years of HFDP, which highlights the need to develop and evaluate 
interventions optimising the cardiometabolic health of this vulnerable group. The main 
limitations in our research are the lack of a comparative group of women without HFDP 
and that we did not assess for CVD risk factors before HFDP.   
 
6.2. Significance of this study 
  
What is already known about this subject? 
 
Women with a history of hyperglycaemia first detected in pregnancy (HFDP), which 
includes gestational diabetes, may have a higher risk for CVD, although there are no 
data from Africa.   
What are the new findings? 
 
In this study, we found a high prevalence of CVD risk factors 6 years after HFDP, in 
women, of mean age 37 years, in Cape Town, South Africa.   
 
How might these results change the focus of research or clinical 
practice? 
 
Given their relatively young age, there is a need for research which investigates 
innovative interventions for encouraging women to change their lifestyles after HFDP. 










Non-communicable diseases (NCDs) are the leading causes of illness and death 
worldwide. they account for up to 70% of overall mortality while cardiovascular 
diseases (CVD) and diabetes are responsible for almost 50% of the NCD burden (1). 
The majority of premature deaths from NCDs (85%) occur in low to middle-income 
countries (1) where health systems are struggling to cope with the concurrent problems 
of infectious diseases and emerging NCDs. In South Africa, the rapidly increasing 
prevalence of NCDs contributes to the multiple burdens of disease, comprising 
tuberculosis (TB) and HIV, ongoing malnutrition, and high maternal and child mortality 
(2, 3). Diabetes and CVD have been the second and third leading causes of death in 
the country since 2014.  (4), highlighting the need to prioritize their prevention.  One 
prevention strategy could be through identification of high-risk populations and offering 
tailored interventions.    
Recent South African epidemiological surveys show that at least a quarter of 
pregnant women (26%) have hyperglycaemia first detected in pregnancy (HFDP) (5) 
while almost 10% have gestational diabetes (GDM) (6). This may increase their risk for 
early CVD. However, as the risk factor-based-screening currently being used in South 
Africa is sub-optimal, a significant proportion of pregnant women are not screened for 
HFDP (5, 7). Until recently, GDM was defined as HFDP with a post-partum return to 
normalcy in many guidelines. Further, the criteria used for the diagnosis of GDM have 
varied widely in different countries. However, the WHO 2013 guidelines (8) which were 
largely based on the results of the Hyperglycaemia and Adverse Pregnancy Outcomes 
Study (HAPO) (9) and recommendations of the International Association of Diabetes 
and Pregnancy Study Group (IADPSG) (10), have been adopted by many regional and 
national bodies. These WHO guidelines include the adoption of lower fasting glucose 
cut-offs and the distinction between GDM and diabetes in pregnancy (DIP), where 
blood glucose concentrations are diagnostic of type 2 diabetes mellitus (T2DM).   
Meta-analyses have shown that women with a history of GDM (although these 
studies also included women with DIP, according to the WHO 2013 criteria) have 
double the risk for overall CVD (11, 12) and coronary artery disease in the long term 
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(12) and four times the risk for metabolic syndrome (13), compared to women with 
normo-glycaemic pregnancies (13). There may be population differences in the 
association between GDM and the metabolic syndrome, as the Asian studies did not 
show the association seen with other populations. Although the metabolic syndrome's 
utility as a clinical entity is debatable, it represents a constellation of risk factors for 
CVD, with possible common pathophysiology and common environmental risk factors. 
Insulin resistance, thought to be central in the development of metabolic syndrome 
(14), is also associated with beta-cell deterioration during the immediate post-HFDP 
period (15) and consequent progression to type 2 diabetes (16).    
To the best of our knowledge, there are no published studies on the intermediate 
and long-term burden of CVD in African women post HFDP, despite the increasing 
understanding of the critical role women of childbearing age play in the possible 
intergenerational transmission of and prevention of CVD risk. This study aimed to 
describe the prevalent metabolic syndrome, insulin resistance and individual CVD risk 
factors (raised blood pressure, dysglycaemia, dyslipidaemia, raised waist 
circumference and overweight and obesity) and their risk factors in women 6 years post 
HFDP in Cape Town, South Africa. We also compared the prevalence of metabolic 
syndrome and individual CVD risk factors between GDM and DIP groups, after re-




All women diagnosed and treated for GDM at a major tertiary referral hospital in 
Cape Town, South Africa, between 1 August 2010 and 30 September 2011, were 
eligible for a cross-sectional follow-up study 6 years later. At the time of the pregnancy, 
GDM was defined as any glucose intolerance first detected in pregnancy according to 
the 2008 NICE guidelines (fasting glucose >5.6mmol/l and oral glucose tolerance test 
(OGTT) 2-hour glucose ≥7.8mmol/l) (17). We retrospectively classified these women 
using modified WHO 2013 criteria as HFDP, since the criteria used at the time of the 
pregnancy included women with GDM and those with DIP, and then grouped the 
participants into GDM (fasting glucose 5.6-6.9mmol/l and OGTT 2-hour glucose 7.8-
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11.0mmol/l) and DIP (fasting glucose≥7.0mmol/l and OGTT 2-hour glucose ≥ 11.1 
mmol/l). Between the 1st of May 2016 and the 30th of March 2017, the women were 
invited for follow up assessment via telephone, postal mail and home visits. Women 
with known type 1 or type 2 diabetes were excluded during the pregnancy and pregnant 
women were excluded from the follow-up study.   
 
6.4.1. Study procedures 
 
Pregnancy-related data were collected during the index pregnancy, as part of 
routine clinical care, but the women, as part of this study, were not assessed for the 
following CVD risk factors; central obesity, raised blood pressure and dyslipidaemia, as 
they are affected by the pregnancy. At follow-up, participants were invited to come for 
assessment at the research unit. Trained fieldworkers administered a questionnaire 
(adapted from the WHO STEPWise survey questionnaire (18) to collect 
sociodemographic, breastfeeding and potential risk factor information. The following 
sections of the core WHO STEPWise questionnaire were used: history of chronic 
illnesses, physical measurements, alcohol and tobacco use, in addition to questions on 
reproductive health. Physical activity was assessed using the modified Global Physical 
Activity Questionnaire (GPAQ). Average breastfeeding length was calculated as the 
total months a participant breastfed divided by the number of children she breastfed.   
The fieldworkers carried out anthropometric measurements (height, weight, waist 
and hip circumference) using standard methods (18). Each measurement was repeated 
three times, at least 5 minutes apart, and the average calculated. Height was measured 
to the nearest 0.1cm, using a wall-mounted stadiometer. Weight was measured to the 
nearest 0.1kg, with the participant putting on light clothing, without shoes, on a 
bathroom scale placed on a hard, flat floor. Waist circumference was measured to the 
nearest 0.1cm using a flexible tape, with the participant having one layer of clothing, at 
the midpoint between the lower costal margin and the level of the superior iliac crests. 
Hip circumference was measured to the nearest 0.1cm at the widest part of the hip, 
with a flexible tape held horizontally. Each participant had 3 blood pressure 
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measurements 5 minutes apart while seated comfortably, using an Omron automated 
BP monitor (Omron 711; Omron Health Care, Hamburg, Germany). The average of the 
last two readings was used in analyses.   
Each participant underwent a 75-gram OGTT (unless already diagnosed with 
diabetes) after fasting for 8 to 10 hours. Fasting blood was drawn for glucose, insulin 
and lipids. Besides, blood was drawn at 2 hours for glucose. Participants on treatment 
for high blood pressure raised blood lipids and diabetes were not required to give 
samples or take measurements for the respective conditions. The samples were kept 
on ice until centrifugation within 4 hours of collection and the aliquots stored at minus 




Outcomes were the metabolic syndrome (having ≥3 CVD risk factors) and individual 
CVD risk factors (dysglycaemia, raised blood pressure, dyslipidaemia and central 
obesity), defined according to a modified National Cholesterol Education Program Adult 
Treatment Panel (NCEPATP III) (19). Raised blood pressure was defined as either 
diastolic blood pressure above 85mmHg and/or systolic blood pressure above 
130mmHg. Dyslipidaemia was defined as either triglyceride ≥1.7mmol/L and /or HDL-
cholesterol ≤1.30mmol/L. Dysglycaemia was defined as fasting plasma glucose 
≥5.6mmol/L. BMI was grouped according to WHO criteria for underweight (<18.5 
kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obese (30-39.9 
kg/m2) and morbidly obese (>40 kg/m2) while a waist circumference cut-off of  
≥88cm was used for central obesity (20). We assessed insulin resistance using the 
homeostatic model assessment of insulin resistance (HOMA-IR) using a cut-off of 1.95 
as used in a previous study in obese South African women (21). Participants with 






6.4.3. Biochemistry and laboratory analyses 
 
Plasma glucose was measured using the hexokinase method on a Randox RX 
Daytona Chemistry Analyzer. Enzymatic colorimetric assays were used to measure 
triglycerides, total cholesterol and high-density lipoprotein cholesterol (HDL-cholesterol) 
using the Roche Modular Auto Analyzer while low-density lipoprotein cholesterol (LDL-
cholesterol) was calculated using direct methods. Coefficients of variation calculated 
from running 40 separate samples in duplicate, were 3.0% for glucose,3.1% for 
cholesterol, 3.1% for triglycerides and 3.4% for insulin.   
 
6.4.4. Statistical data analysis 
Stata 15 (22) statistical software was used for all analyses, with p<0.05 for 
significance and 95% confidence intervals (95%CIs) reported for estimates, where 
appropriate. Means and standard deviations are presented for normally distributed 
measured data, medians and interquartile ranges (IQRs) for non-normally distributed 
data and frequencies and proportions for categorical variables. Comparisons of 
participants with metabolic syndrome and those without were done using the Chi-
squared test for categorical data and independent groups t-test (normally distributed 
measured data) or Wilcoxon sum rank test (for measured data that were not normally 
distributed). The prevalence of CVD risk factor was calculated as the proportion of 
participants with the outcome over the total assessed.  
To explore factors associated with metabolic syndrome, multiple variable logistic 
regression was used. Pregnancy-related variables entered into the logistic regression 
models were fasting and 2-hour OGTT glucose levels at HFDP diagnosis and type of 
treatment during HFDP. Variables measured at follow-up included in the logistic 
regression were: socioeconomic (age, ethnicity, education and employment), 
anthropometry (waist and hip circumference, BMI), family history of high blood 
pressure, reproductive health factors (subsequent pregnancy (yes/no) and average 
breastfeeding length in months), total minutes of physical activity per week from the 
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modified GPAQ, smoking (current smoker or not). Stopping alcohol due to health 
reasons and BMI at pregnancy booking was not included in the multiple logistic 
regression due to missing data.  
For each of the following individual CVD risk factors; raised blood pressure, 
dysglycaemia; dyslipidaemia and insulin resistance, separately, we explored risk 
factors using multiple variable logistic regression. Bonferroni adjustment was used to 
compensate for multiple testing by multiplying the individual p-values by the total 
number of outcomes (four). For insulin resistance, only the 108 participants who had no 
diabetes at follow-up and had fasting insulin measurements, were included.   
Logistic regression model diagnostics included: linearity assumption testing using 
the Lowes graph, multicollinearity testing using variance inflation factors (VIF), using a 
cut-off of the square of the VIF above 4, model specification testing using the C-statistic 
link test (_hatsq), and confirmation of the fit of the model using the Hosmer-Lemeshow 
goodness-of-fit test. The area under the receiving operating characteristic (ROC) curve 
and k-fold cross-validation (k=10) were used for model validation. The study is reported 
according to the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) (23) guidelines.   
 
6.4.5. Ethical considerations 
The study was carried out according to the principles of the Helsinki Declaration 
(24). The study was approved by the Human Research Ethics Committees of the 
University of Cape Town (Ref: 656/2015). Informed consent was obtained from all 
participants. Participants who were found to have either hypertension or diabetes were 




Two hundred and twenty participants (44.2%) were followed up (Fig. 6.1). There 
were no differences in any socio-demographic characteristics during the index HFDP in 
those followed up compared to the women lost to follow up. However, compared to 
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participants lost to follow-up, participants assessed at follow-up had higher median BMI 
at booking [34.6 (IQR 28.8 – 41.4) vs 32.7 (IQR 27.6-38.4) kg/m2, respectively] but 
lower median 2-hour OGTT glucose concentrations at HFDP diagnosis [9 (IQR 8.2–10) 
vs 12 (IQR 11.2-12.8) mmol/l, respectively] (Supplemental Table 6.1).  
 
Fig 6.1. Study flow chart 
   
  
Tables 6.1 shows the characteristics of the participants during the pregnancy and at 
follow-up, as well as a comparison by metabolic syndrome status. When the HFDP was 
classified retrospectively using modified WHO 2013 criteria, 70 of the 220 participants 
were classified as DIP while the remaining 150 women were classified as GDM.  
Table 6.1. Characteristics of participants– by the presence or absence of 
the metabolic syndrome 










Number of participants  220 134 86  
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Variables measured at baseline 
Age (years) Mean (SD) 30.8 (5.9) 32.0 (5.7) 29.0 (5.7) <0.001 
BMI at booking (kg/m2) Mean (SD) 34.2 (8.2) 36.2 (7.3) 32.2 (8.5) <0.001 
BMI at booking 
categories, n (%) 
Normal  31 (14.5) 7 (5.2) 24 (27.9)  
 
<0.001 
Overweight 38 (17.8) 17 (12.7) 21 (24.4) 
Obese 96 (44.9) 76 (56.7) 26 (30.2) 
Morbidly obese 49 (22.9) 34 (25.4) 15 (17.4) 
HFDP type, n (%) DIP 70 (31.8) 18 (22.1) 52 (38.8)  
0.010 GDM 150 (68.2) 67 (77.9) 82 (61.2) 
Insulin treatment for 
HFDP, n (%) 
Yes 52 (23.6) 39 (29.1)
  
13 (15.1) 0.017 
OGTT at HFDP diagnosis  
Fasting blood glucose 
(mmol/l) 
Median (IQR) 5.8 (5.1-6.7) 6.1 (5.4-7.1) 5.5 (4.9-6.3) <0.001 
1-hour blood glucose 
(mmol/l) 
Median (IQR) 10.4 (9.2-
11.6) 
10.6(9.5-11.9) 10.0 (8.7-11.2) 0.006 
Insulin treatment for 
HFDP, n (%) 
Yes 52 (23.6) 39 (29.1)
  
13 (15.1) 0.017 
2-hour glucose (mmol/l) Median (IQR) 9.0 (8.3-10.5) 9.1 (8.4-1.0) 8.8 (8.2-9.6) 0.022 
Variables measured at follow-up 
Follow up time (years) Median (IQR) 6.1 (2.8-11.0) 5.6(1.1–9.5) 6.9 (4.8-12.8) 0.002 





167 (75.9) 109 (81.3) 58 (67.4) 
Primary   23 (10.5) 16 (11.9)) 7 (8.1) 
Employed, n (%) Yes 108 (49.1) 57 (42.5) 51 (59.3) 0.015 
Marital status, n (%) Married   141 (64.1) 86 (64.2) 55 (64.0) 0.832 
Family history, n (%) Diabetes 169 (76.8) 103 (76.9) 66 (76.7) 0.983 
Hypertension 156 (70.9) 98 (73.1) 58 (67.4) 0.364 
Stroke and 
heart attack 
96 (43.6) 59 (44.0) 37 (43.0) 0.883 
Stopped drinking 
alcohol for health 
reasons, n (%) 
Yes  14 (6.4) 10 (7.5)) 4 (4.7) 0.486 
Current smoker, n (%) Yes  64 (29.1) 37 (27.6) 27 (31.4) 0.547 






375 (90-1280) 0.274 
Subsequent pregnancy, 
n (%) 
Yes  58 (26.4) 32 (23.9) 26 (30.2) 0.297 
Average breastfeeding 
length (months)  
Median (IQR) 6 (1 – 18) 8 (1 – 18) 6 (1 – 12) 0.332 
Follow-up BMI (kg/m2) Mean (SD) 34.9 (8.7) 36.8 (8.3)  32.0 (8.6) <0.001 
Weight gain (kg) Median (IQR) 2.0 (-4.6 - 9.0) 1.5 (-7.0–9.0) 3.3 (-3.1 – 7.9) 0.511 
Follow-up BMI 
categories, n (%) 
Normal  24 (10.9) 6 (4.5) 18 (20.9)  
 
<0.001 
Overweight 44(20.0) 21 (15.7) 23 (26.7) 
Obese 104(47.3) 70 (52.2) 34 (39.5) 
Morbidly obese 48(21.8) 37 (27.6) 11 (12.8) 
Waist circumference 
(cm) 
Mean (SD) 110.5 (17.6) 115.6 (16.9) 102.3 (15.6) <0.001 
Hip circumference (cm) Mean (SD) 117.3 (16.1) 119.3 (15.7) 113.9 (16.4) 0.008 
Self-reported 
comorbidities, n (%) 
Diabetes  55 (25.0) 45 (33.6) 10 (11.6) <0.001 
Hypertension  44 (20.0) 42 (31.3) 2 (2.3) <0.001 




At booking of the index pregnancy, the participants’ mean age was 30.8 (SD 5.9) 
years, and at follow up; 37.2 (SD 6.0) years. The majority,142 (65.4%), were of mixed 
ancestry. Participants with the metabolic syndrome at follow-up had significantly higher 
mean BMI and age at booking of the index pregnancy and higher fasting and OGTT 1-
hour and 2-hour blood glucose concentrations at diagnosis of HFDP, compared to 
those without metabolic syndrome (Table 6.1). One hundred and five (47.7%) 
participants had diabetes at follow-up and were not assessed for insulin resistance. 
Compared to participants without metabolic syndrome, those with metabolic syndrome 
were had a significantly higher BMI and were significantly less likely to have tertiary 
education (Table 6.1). The anthropometric and biochemical characteristics of the 
participants at follow-up are shown in Supplemental Table S6.2.   
 
6.5.1. Prevalence of CVD risk factors, metabolic syndrome and insulin 
resistance at follow up, and comparison between DIP and GDM  
 
The prevalence of the metabolic syndrome was  60.9% (95%CI 54.3-67.2); and the 
prevalence of the individual CVD risk factors was; insulin resistance - (75.0%, 95%CI 
65.9-82.3), waist circumference≥88cm - 90.4% (95%CI 85.6-93.7), dyslipidaemia - 
74.6% (95%CI 68.3-79.9), dysglycaemia - 62.3% (95%CI 55.6-68.5), obesity - 47.3% 
(95%CI 40.7-53.9), morbid obesity - 21.8% (95%CI 16.8-27.8) and raised blood 
pressure - 41.4% (95%CI 35.0-48.0) (Fig 6.2 & Supplemental Table S6.3). The 
proportions of participants already diagnosed with the CVD risk factors were as follows; 
diabetes – 25.0%, hypertension – 20.0% and dyslipidaemia – 10.9% (Table 6.1). 
Compared to women with GDM, women with DIP had a higher prevalence of both 
metabolic syndrome (74.3% vs 54%, p = 0.010) and dysglycaemia (88.6% vs 50%, 
p<0.001), but the proportions with insulin resistance, and the remaining CVD risk 







Fig 6.2. Prevalence of CVD risk factors and insulin resistance 6 years 




 6.5.2. Factors associated with metabolic syndrome and individual CVD risk 
factors at follow-up – multiple variable logistic regression 
 
After multiple variable logistic regression, fasting blood glucose at HFDP diagnosis 
(OR 1.5, 95%CI 1.1 – 2.0, p =0.006), having secondary and matric education, 
compared to tertiary education (OR 2.5, 95%CI 1.3 – 9.4, p = 0.014)), having a 
subsequent pregnancy (OR 0.4, 95%CI 0.2 – 0.9), and waist circumference (OR 1.1, 
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95%CI 1.0 – 1.1, p <0.001) were independently associated with the metabolic 
syndrome (Fig. 6.3).   
Supplemental Table 4 shows the multiple variable logistic regression of factors 
associated with the individual CVD risk factors. Waist circumference was associated 
with raised blood pressure (OR 1.1, 95%CI 1.0 – 1.1, p =0.036), dyslipidaemia (OR 1.1, 
95%CI 1.0 – 1.1, p = 0.32) and dysglycaemia (OR 1.1, 95%CI 1.0 – 1.1, p <0.001), 
while hip circumference was associated with dyslipidaemia (OR 0.9, 95%CI 0.9 – 1.0, p 
= 0.032) and dysglycaemia (OR 0.9, 95%CI 0.9 – 1.0, p = 0.044). Being employed was 
associated with raised blood pressure (OR 0.3, 95%CI 0.2 – 0.7, p = 0.008).   
 
 Fig 6.3. Multiple variable logistic regression for factors associated with 
metabolic syndrome 
 
  Legend  
Notes: 1. Model statistics (Observations – 218, LR chi2 – 73.5, P-value – 0.000, Pseudo R2 






6.5.3. Logistic regression diagnostics and validation – metabolic 
syndrome outcome 
 
The Lowess graph indicated an acceptable linear relationship. Hip circumference 
(VIF 4.39) was removed from the initial model as it was colinear with waist 
circumference (VIF 3.95) and BMI at follow up (VIF 4.78). The link function was 
correctly specified (p=0.630) and the Hosmer Lemeshow goodness of fit test showed 
that the model fit was acceptable (p=0.444). A few influential cases were identified by 
plotting residual against predicted probabilities, although sensitivity analysis showed no 
differences in model estimates when these cases were omitted. The model validation 
was reasonable, the area under the ROC curve was 0.907 and the Crossfield validation 




In this study of women with a mean age of 37 years and a 6-year prior history of 
HFDP, there was a high prevalence of the metabolic syndrome as well as of the 
individual components, with very low proportions being aware of their disease status. 
When the HFDP was categorized according to criteria that approximated the WHO 
2013 HFDP diagnostic criteria, women with DIP had a higher prevalence of both the 
metabolic syndrome and dysglycaemia compared to those classified as GDM. A high 
waist circumference, lower education attainment, having had a subsequent pregnancy 
at follow-up and fasting blood glucose at HFDP diagnosis were all independently 
associated with metabolic syndrome at follow up. An increase in waist circumference 
was associated with risk of raised blood pressure, dyslipidaemia and dysglycaemia.    
To our knowledge, this is the first to investigate metabolic syndrome, insulin 
resistance and individual CVD risk factors prevalence in African women post HFDP. As 
different study designs, heterogeneous definitions of GDM and different lengths of 
follow-up complicate comparison of our findings with international data, we have 
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attempted to compare our findings with studies that used similar criteria for GDM to 
ours as well as a similar duration of follow up. Our prevalence estimates are similar to 
data from India, where the reported metabolic syndrome prevalence was 55% (25), 
dysglycaemia prevalence 68% (26) and dyslipidaemia 71% (25).  On the other hand, 
our prevalence estimates are much higher than those reported from other countries. In 
China, the prevalence of the metabolic syndrome was 7.5% (27), in Brazil the 
dysglycaemia prevalence was 39.4% (28) and in Ireland, the prevalence of 
dyslipidaemia was 25% (29). The single study that assessed insulin resistance (29), 
found a prevalence of 33.6%, which is less than half of the prevalence in our study.   
We were unable to find studies that compared CVD risk factors at follow-up 
between women with DIP and those with GDM. Given that the DIP group may include 
undiagnosed type 2 diabetes cases, this group’s higher prevalence of dysglycaemia 
compared to that in the GDM group, is expected. The former’s higher metabolic 
syndrome prevalence could be partly explained by the higher proportion of women with 
dysglycaemia as well as diabetes-associated dyslipidaemia. Thus, early intervention 
and screening for CVD risk factors for women in this category are warranted.   
Our study has several limitations. A major limitation was the lack of a control group. 
Despite this, we were able to use prevalence estimate, based on the same criteria for 
our outcomes of interest in women of childbearing age from population surveys in Cape 
Town. In these the prevalence of the metabolic syndrome was 9.9% (30) and 43% (31), 
raised blood pressure 19.9% (30), dysglycaemia 2.2% (32), 17.9% (33) and 32.6% 
(34), dyslipidaemia 46% and insulin resistance (in obese women) 38% (35). Thus, our 
data indicate that women with a history of HFDP in our study have a higher prevalence 
of CVD risk factors than women of childbearing age in Cape Town.  Our findings 
highlight the need to intervene in women post HFDP to reduce risk of CVD risk factors 
and consequent CVD in South Africa. This has the potential to improve more than the 
mothers’ health, it may also reduce the risk of hyperglycaemia in future pregnancies 
and subsequently reduce the potential for intergenerational transmission of CVD risk 
through foetal programming (36).   
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The first intervention could be integrating CVD risk factor screening with the 
recommended post-partum screening for diabetes. Currently, the recommended 6 
weeks post-partum screening for diabetes has a poor uptake, in keeping with 
international trends. In our setting, innovative solutions to the various health system 
and socio-demographic barriers may be required to improve uptake (37). The very low 
numbers of women who were aware that they had CVD risk factors and on treatment is 
a cause for concern. There is need for interventions that sensitize women about their 
higher risk for CVD post HFDP. Social science research about how to effectively 
communicate risk to the women is needed. Combining the post-partum care of the 
mother with that of the baby may offer a window to both screen for CVD risk factors and 
provide an opportunity to engage with the mother to promote change in her modifiable 
CVD risk factors. This post-partum review may need to be extended to include obese 
women, as our data showed that high waist circumference was associated with the risk 
of metabolic syndrome at follow-up. However, this will have health system implications 
because of the high prevalence of obesity in South African women of childbearing age 
(38). The high prevalence of obesity has been attributed to changes in diet and physical 
activity patterns among urban-dwelling South African women (38). Lifestyle change 
should, therefore, be part of a holistic package to prevent CVD risk in these women and 
reduce the consequent cardiometabolic risk in future offspring.  
A further limitation of our study is that we were only able to assess 44% of women 
at follow up, due to the population being highly mobile. The rate of follow up is 
comparable to studies from other low-to-middle income countries (39, 40). As we were 
able to follow-up fewer women with DIP, we may have underestimated the prevalence 
of both metabolic syndrome and dysglycaemia. On the other hand, the women who we 
were able to follow-up had a higher BMI by 2 units compared to those we were not able 
to follow up. Finally, as we did not assess the presence of the metabolic syndrome 
during the index pregnancy, it is difficult to ascertain the effect of HFDP on the risk of 






Given the considerable and growing burden of diabetes and CVD in South Africa, 
the high prevalence of CVD risk factors found in relatively young African women within 
6 years of a previous HFDP highlights the urgent need to develop and evaluate 
interventions optimising the cardiometabolic health of this group.   
Acknowledgements 
 
We thank Ms Chantal Stuart (administration and logistics) and Ms Siphokazi 
Khonkwane (fieldwork) at the Chronic Disease Initiative for Africa for their support 
during data collection at follow-up. We acknowledge Dr Hetta van Zyl for collecting 
pregnancy-related data from participants and Professors Krisela Steyn and Christina 
Zarowsky for help during the conception of the research.    
 
Abbreviations 
Non communicable diseases (NCD), Hyperglycaemia first detected in pregnancy 
(HFDP), gestational diabetes mellitus (GDM), anti-retroviral therapy (ARV), body mass 
index (BMI), cardiovascular disease (CVD), diabetes in pregnancy (DIP), fasting 
plasma glucose (FBG), gestational diabetes mellitus (GDM), global physical activity 
questionnaire (GPAQ), National Cholesterol Education Program Adult Treatment Panel 
(NCEP-ATP III), Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO), high 
density lipoprotein cholesterol (HDL), International Association of Diabetes and 
Pregnancy Study Group (IADPSG), interquartile range (IQR), National Institute for 
Health and Care Excellence (NICE), oral glucose tolerance test (OGTT), odds ratio 
(OR), homeostatic model assessment of insulin resistance (HOMA-IR), Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE), type 2 diabetes 
mellitus (T2DM), 95% confidence interval (95%CI), area under the receiving operating 
characteristic curve (ROC), variance inflation factor (VIF), world health organization 
(WHO)   
  




TC – none declared    
SAN – none declared   




This research was funded by the Chronic Disease Initiative for Africa. We 
acknowledge funding from the International Development Research Centre (IDRC) 
(fund number: 411592) for TC (under the IINDIAGO project). The funders played no 
role in the conception, the conduct or writing up of or the decision to submit this 
research for publication.   
6.8. References 
 
1. World Health Organization. Noncommunicable diseases 2016 [updated 1 June 
2018; cited 2019 27 Jan 2019]. Available from: https://www.who.int/en/news-
room/factsheets/detail/noncommunicable-diseases.  
2. Kabudula CW, Houle B, Collinson MA, Kahn K, Gómez-Olivé FX, Clark SJ, et al. 
Progression of the epidemiological transition in a rural South African setting: 
findings from population surveillance in Agincourt, 1993–2013. BMC public health. 
2017;17(1):424.  
3. Mayosi BM, Benatar SR. Health and Health Care in South Africa—20 Years after 
Mandela. New England Journal of Medicine. 2014;371(14):1344-53.  
4. Statistics South Africa. P0309.3 - Mortality and causes of death in South Africa: 
Findings from death notification, 2016. 2018.  
5. Adams S, Rheeder P. Screening for gestational diabetes mellitus in a South African 
population: prevalence, comparison of diagnostic criteria and the role of risk factors. 
South African Medical Journal. 2017;107(6):523-7.  
6. Macaulay S, Ngobeni M, Dunger DB, Norris SA. The prevalence of gestational 
diabetes mellitus amongst black South African women is a public health concern. 
Diabetes research and clinical practice. 2018; 139:278-87.  
181 
 
7. Coetzee A, Mason D, Hall DR, Conradie M. Prevalence and predictive factors of 
early postpartum diabetes among women with gestational diabetes in a single‐
center cohort. International Journal of Gynecology & Obstetrics. 2018.  
8. World Health Organization. Diagnostic criteria and classification of hyperglycaemia 
first detected in pregnancy. 2013.  
9. HAPO Study Cooperative Research Group, Metzger B, Lowe L, Dyer A, Trimble E, 
Chaovarindr U, et al. Pregnancy Outcome (HAPO) Study Cooperative Research 
Group. N Engl J Med. 2008; 358:991-2002.  
10. International Association of Diabetes and Pregnancy Study Group. International 
association of diabetes and pregnancy study groups recommendations on the 
diagnosis and classification of hyperglycaemia in pregnancy. Diabetes care. 
2010;33(3):676-82.  
11. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of 
cardiovascular disease in women: a systematic review and meta-analysis. 
Diabetologia. 2019.  
12. Li J, Song C, Li C, Liu P, Sun Z, Yang X. Increased risk of cardiovascular disease in 
women with prior gestational diabetes: A systematic review and meta-analysis. 
Diabetes Res Clin Pract. 2018; 140:324-38.  
13. Xu Y, Shen S, Sun L, Yang H, Jin B, Cao X. Metabolic syndrome risk after 
gestational diabetes: a systematic review and meta-analysis. PLoS One. 2014;9(1): 
e87863.  
14. Stern MP. Diabetes and cardiovascular disease: the “common soil” hypothesis. 
Diabetes. 1995;44(4):369-74.  
15. Retnakaran R, Qi Y, Ye C, Hanley AJ, Connelly PW, Sermer M, et al. Hepatic 
insulin resistance is an early determinant of declining β-cell function in the first year 
postpartum after glucose intolerance in pregnancy. Diabetes Care. 
2011;34(11):2431-4.  
16. Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological 
characterization of the development of type 2 diabetes in Hispanic women with prior 
gestational diabetes mellitus. Diabetes. 2010;59(10):2625-30.  
182 
 
17. Guidelines Development Group. Guidelines: management of diabetes from 
preconception to the postnatal period: summary of NICE guidance. BMJ: British 
Medical Journal. 2008;336(7646):714.  
18. World Health Organization. WHO STEPS surveillance manual: the WHO STEPwise 
approach to chronic disease risk factor surveillance. 2005.  
19. Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in 
adults. Executive summary of the third report of the National Cholesterol Education 
Program (NCEP) expert panel on detection, evaluation, and treatment of high blood 
cholesterol in adults (Adult Treatment Panel III). Jama. 2001;285(19):2486.  
20. World Health Organization. Waist Circumference and Waist-Hip Ratio Report of a 




21. Jennings CL, Lambert EV, Collins M, Levitt NS, Goedecke JH. The atypical 
presentation of the metabolic syndrome components in black African women: the 
relationship with insulin resistance and the influence of regional adipose tissue 
distribution. Metabolism. 2009;58(2):149-57.  
22. Stata C. College Station (TX). Stata Press. 2016.  
23. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et 
al. The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. PLoS 
medicine. 2007;4(10): e296.  
24. Helsinki WEU. Do. World medical association declaration of Helsinki. Fortaleza, 
Brazil. 2013 
25. Kale S, Yajnik C, Kulkarni S, Meenakumari K, Joglekar A, Khorsand N, et al. High 
risk of diabetes and metabolic syndrome in Indian women with gestational diabetes 
mellitus. Diabetic medicine. 2004;21(11):1257-8.  
26. Krishnaveni GV, Hill JC, Veena SR, Geetha S, Jayakumar MN, Karat CL, et al. 
Gestational diabetes and the incidence of diabetes in the 5 years following the index 
183 
 
pregnancy in South Indian women. Diabetes research and clinical practice. 
2007;78(3):398-404.  
27. Tam WH, Yang XL, Chan JC, Ko GT, Tong PC, Ma RC, et al. Progression to 
impaired glucose regulation, diabetes and metabolic syndrome in Chinese women 
with a past history of gestational diabetes. Diabetes/metabolism research and 
reviews. 2007;23(6):485-9.  
28. Rivero K, Portal VL, Vieira M, Behle I. Prevalence of the impaired glucose 
metabolism and its association with risk factors for coronary artery disease in 
women with gestational diabetes. Diabetes Res Clin Pract. 2008;79(3):433-7.  
29. Noctor E, Crowe C, Carmody LA, Kirwan B, O'Dea A, Glynn LG, et al. ATLANTIC-
DIP: prevalence of metabolic syndrome and insulin resistance in women with 
previous gestational diabetes mellitus by International Association of Diabetes in 
Pregnancy Study Groups criteria. Acta Diabetol. 2015;52(1):153-60.  
30. Jennings CL, Lambert EV, Collins M, Levitt NS, Goedecke JH. The atypical 
presentation of the metabolic syndrome components in black African women: the 
relationship with insulin resistance and the influence of regional adipose tissue 
distribution. Metabolism: clinical and experimental. 2009;58(2):149-57.  
31. Peer N, Lombard C, Steyn K, Levitt N. High prevalence of metabolic syndrome in 
the Black population of Cape Town: The Cardiovascular Risk in Black South 
Africans (CRIBSA) study. European Journal of Preventive Cardiology. 
2014;22(8):1036-42.  
32. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force 
for the  
33. Management of Dyslipidaemias of the European Society of Cardiology (ESC) and 
European Atherosclerosis Society (EAS) Developed with the special contribution of 
the European Assocciation for Cardiovascular Prevention & Rehabilitation 
(EACPR). Atherosclerosis. 2016; 253:281-344.  
34. Peer N, Steyn K, Lombard C, Lambert EV, Vythilingum B, Levitt NS. Rising diabetes 




35. Erasmus RT, Soita DJ, Hassan MS, Blanco-Blanco E, Vergotine Z, Kengne AP, et 
al. High prevalence of diabetes mellitus and metabolic syndrome in a South African 
coloured population: Baseline data of a study in Bellville, Cape Town. SAMJ: South 
African Medical Journal. 2012;102(11):841-4.  
36. Jennings CL, Lambert EV, Collins M, Joffe Y, Levitt NS, Goedecke JH. 
Determinants of insulin‐resistant phenotypes in normal‐weight and obese Black 
African women. Obesity. 2008;16(7):1602-9.  
37. Nehring I, Chmitorz A, Reulen H, Von Kries R, Ensenauer R. Gestational diabetes 
predicts the risk of childhood overweight and abdominal circumference independent 
of maternal obesity. Diabetic medicine. 2013;30(12):1449-56.  
38. Venkataraman H, Sattar N, Saravanan P. Postnatal testing following gestational 
diabetes: time to replace the oral glucose tolerance test? The Lancet Diabetes & 
Endocrinology. 2015.  
39. Gradidge PJ-L, Crowther NJ. Review: Metabolic Syndrome in Black South African 
Women. Ethnicity & disease. 2017;27(2):189-200.  
40. Gupta Y, Kapoor D, Desai A, Praveen D, Joshi R, Rozati R, et al. Conversion of 
gestational diabetes mellitus to future Type 2 diabetes mellitus and the predictive 
value of HbA1c in an Indian cohort. Diabet Med. 2017;34(1):37-43.  
41. Liu Z-y, Zhao J-j, Gao L-l, Wang AY. Glucose screening within six months 
postpartum among Chinese mothers with a history of gestational diabetes mellitus: 
a prospective cohort study. BMC pregnancy and childbirth. 2019;19(1):134.  
  
  








Chapter 7. PAPER 4 
 
The influence of maternal blood glucose during pregnancy on weight 
outcomes at birth and preschool age in offspring exposed to 
hyperglycaemia first detected during pregnancy, in a South African 
cohort 
 Tawanda Chivese, Magret C Haynes, Hetta van Zyl, Una Kyriacos, Naomi S Levitt, Shane A 
Norris   
Role of the candidate and co-authors 
 
The candidate, together with Professors Norris and Levitt conceptualized the study. 
Professors Norris and Levitt provided overall guidance of the study design, data 
analysis and writing up. The candidate collected the data, with the help of MCH and 
HVZ. The candidate was responsible for data and sample management. The candidate 
carried out the data analysis with the help of the 2 supervisors. The candidate drafted 
the initial, revisions and final manuscript with the help of all the supervisors and UK. 
The candidate led the publication and was the corresponding author. All authors 



















Little is known about the influence of hyperglycaemia first detected in pregnancy 
(HFDP) on weight outcomes in exposed offspring in Africa. We investigated the 
influence of maternal blood glucose concentrations during pregnancy on offspring 
weight outcomes at birth and preschool age, in offspring exposed to HFDP, in South 
Africa.   
7.1.2. Research design and methods 
 
Women diagnosed with HFDP had data routinely collected during the pregnancy 
and at delivery, at a referral hospital, and the offspring followed up at preschool age. 
Maternal fasting, oral glucose tolerance test 1 and 2-hour blood glucose were 
measured at diagnosis of HFDP and 2-hour postprandial blood glucose during the third 
trimester. Offspring were classified as either those exposed to diabetes in pregnancy 
(DIP) or gestational diabetes (GDM). At birth neonates were classified into 
macrosomia, low birth weight (LBW), large for gestational (LGA)age, appropriate (AGA) 
and small for gestational age (SGA)] groups. At preschool age, offspring had height 




Four hundred and forty-three neonates were included in the study at birth, with 165 
exposed to DIP and 278 exposed to GDM. At birth, the prevalence of LGA, macrosomia 
and LBW were 29.6%, 12.2% and 7.5%, respectively, with a higher prevalence of LGA 
and macrosomia in neonates exposed to DIP. At pre-school age, the combined 
prevalence of overweight and obesity was 26.5%. Maternal third trimester 2-hour 
postprandial blood glucose was significantly associated with z-scores for weight at birth 






In offspring exposed to HFDP, there is a high prevalence of LGA and macrosomia 
at birth, and overweight and obesity at preschool age, with higher prevalence in those 
exposed to DIP, compared to GDM. Maternal blood glucose control during the 
pregnancy influences offspring weight at birth and preschool age.  
   
1. What is already known about this subject? 
2.  
Hyperglycaemia first detected in pregnancy (HFDP) includes both gestational 
diabetes mellitus (GDM) and diabetes in pregnancy (DIP). Higher maternal blood 
glucose levels at diagnosis of GDM and during pregnancy are associated with higher 
birth weight, which may result in adverse birth events such as macrosomia and 
shoulder dystocia, although there are no data from an African cohort. Whether HFDP 
still influences weight outcomes during childhood remains inconclusive. Further, little is 
known about the effect of DIP compared to GDM exposure on offspring weight 
outcomes at birth and during childhood.  
 
3. What are the new findings? 
 
We found a high prevalence of large for gestational age (LGA) at birth (30%) and 
overweight and obesity at preschool age (27%) in a South African cohort.  
Offspring exposed to DIP had a higher prevalence of LGA at birth and 
overweight and obesity at preschool age. 
Poor maternal blood glucose control during the pregnancy, represented by 
maternal postprandial 2-hour glucose increased the risk of both LGA and SGA at birth 
and was associated with weight z-score at preschool age.  
 




There is a need for earlier screening for HFDP in this setting, to allow earlier 
detection of DIP and intervention. Improved management of maternal blood glucose 
during pregnancy is needed to reduce both LGA and SGA at birth and overweight and 




The prevalence of childhood overweight and obesity is a public health concern 
globally, with 25% of children under the age of 5 years who are overweight or obese 
being in Africa (1). While childhood overweight and obesity is plateauing in high-income 
countries, in Africa the prevalence in under-fives doubled to 5% during the period 2000 
to 2017 (2) and the prevalence of obesity quadrupled between 1975 to 2016 (3). 
Children who are overweight and obese, tend to remain so in adulthood, with a 
consequent earlier and higher risk for cardiovascular risk factors and cardiovascular 
disease (CVD) (4). As interventions during early life are more effective in reducing the 
risk of adulthood overweight and obesity than those in childhood (3), it is imperative to 
identify and intervene in children at risk of overweight and obesity.  
Developmental Origins of Health and Disease (DOHaD) has shown that maternal 
under-and-overnutrition during pregnancy affect the offspring’s future risk for overweight 
and obesity and consequent cardiometabolic disease (5, 6). Offspring of women with 
hyperglycaemia first discovered in pregnancy (HFDP) may be particularly at risk for 
being large-for-gestational-age (LGA) at birth and overweight and obese during 
childhood, due to exposure to a high glucose uterine environment (7). This has led the 
World Health Organization (WHO) Report of the Commission on Ending Childhood 
Obesity to emphasize the need to improve the diagnosis and management of HFDP (1), 
as one of the strategies to reduce risk of childhood overweight and obesity.  
The World Health Organization (WHO) guidelines of 2013 define HFDP as either 
diabetes in pregnancy (DIP) or gestational diabetes (GDM) (8). Many older guidelines 
and studies have classified both DIP and GDM groups as GDM, although DIP may in 
some cases, imply that the foetus is likely to be exposed to hyperglycaemia for a longer 
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period compared to GDM and consequently, untreated hyperglycaemia for a longer 
period until screening and treatment (9). Data comparing the effect of these two 
subtypes of HFDP on offspring overweight and obesity during childhood are scarce (7).   
Maternal glucose levels at diagnosis of HFDP are linked to neonate weight outcomes at 
birth.  
The Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) Study of 23 216 
participants from 10 countries, demonstrated a linear graded relationship between 
maternal blood glucose at diagnosis of GDM and birth size (10). The major guidelines 
for the diagnosis of HFDP, including the International Association of Diabetes and 
Pregnancy Study Groups (IADPSG) and the WHO 2013 criteria, have since adapted 
their criteria, based on this landmark study. However, the lack of an African cohort in 
the HAPO study may limit the applicability of the findings to the continent, where a high 
prevalence of HFDP has been reported in several countries (11-14) and where 
undernutrition and overnutrition coexistence is prevalent (15). Data from African cohorts 
are needed to compliment the HAPO findings.  
Evidence on whether maternal blood glucose influences overweight and obesity risk 
during early and later childhood remains inconclusive (7). Findings from the HAPO 
follow up study (16) showed no significant associations between GDM and childhood 
overweight and obesity at ages 10-14 years, after adjusting for maternal BMI, but, at 
the same age, there were significant associations with other measures of adiposity 
such as body fat percentage, waist circumference and the sum of skinfolds. Three 
systematic reviews (7, 17, 18) found higher BMI z-scores in children exposed to GDM, 
compared to those from normoglycemic pregnancies, although in some of the included 
studies the association was not statistically significant once adjusted for maternal BMI. 
Arguably, as a child grows older, other factors such as socioeconomic factors, diet and 
physical activity, contribute to a child’s nutrition and the influence of maternal 
hyperglycaemia may lessen. Nevertheless, more research evidence is needed.   
In South Africa, recent epidemiological studies reported prevalence of HDFP and 
GDM of 26% (14) and 9% (13), respectively, suggesting that at least a quarter of 
pregnancies may be complicated by HFDP. Since most provinces in the country use a 
selective risk factor screening approach and consequently may miss up to 50% of 
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women with HFDP, a substantial proportion of children are likely to be exposed to 
untreated HFDP (19). This study was undertaken to contribute to the understudied area 
of the cardiometabolic outcomes of children from HFDP in South Africa and elsewhere 
in Africa. The main aim was two-fold: (i) to investigate the influence of maternal blood 
glucose during pregnancy, and offspring weight at birth and preschool age and to 
investigate the prevalence of overweight and obesity at ages 5-6 years in children 
exposed to HFDP, and (ii) to compare the prevalence of overweight and obesity at birth 
and at follow-up, between children exposed to DIP and those exposed to GDM, in an 
African cohort.  
 
7.3. Research design and methods 
 
A cohort of offspring exposed to HFDP had birthweight measured at birth and was 
followed up at ages 5-6 years. Routine pregnancy and delivery data were collected on 
all mothers diagnosed and managed with HFDP at a major tertiary hospital in the 
Western Cape province of South Africa between 1 September 2010 to 31 August 2011. 
At that time, the National Institute for Health and Care Excellence (NICE) 2008 
guidelines were used to diagnose GDM [fasting blood glucose > 5.5mmol and/or oral 
glucose tolerance test (OGTT) 2-hour glucose > 7.8mmol/l] (20). Five to six years after 
the pregnancy, a cross-sectional study (21, 22) was carried out, where each mother 
was recalled and assessed for diabetes and CVD risk factors. Each mother was asked 
to bring her offspring 5-6 from the index pregnancy. Neonates who had the following 
characteristics at birth were excluded from the analysis: children from multiple births, 
premature, congenital birth disorders, admitted into neonatal intensive care at birth and 
neonates hospitalized with serious conditions.   
7.3.1. Data collected 
 
During the index pregnancy, maternal age, BMI and gestational age at booking, 
maternal HIV status, treatment for HFDP, type of birth delivery and gestational age at 
delivery were routinely collected by the attending clinician. Maternal glucose measures 
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included fasting glucose, OGTT 1-hour and OGTT 2-hour glucose concentrations at 
HFDP diagnosis, and routine fasting and postprandial glucose measurements during 
the third trimester. We retrospectively classified the children into 2 groups, using a 
modified WHO 2013 criteria and maternal blood glucose values at HFDP diagnosis, 
into DIP-exposed (maternal fasting glucose at HFDP diagnosis of at least 7.0mmol/l 
and /or OGTT 2-hour glucose of at least 11.1 mmol/l) and GDM-exposed (maternal 
fasting glucose at HFDP diagnosis of at least 5.5mmol but less than 7.0 mmol/l and/or 
OGTT 2-hour glucose of at least 7.8 mmol/l but less than 11.1 mmol/l). Maternal fasting 
blood glucose and 1 and 2-hour postprandial blood glucose were measured weekly 
during the third trimester, as part of routine clinical monitoring, until delivery, and the 




Birthweight was measured by the attending clinician, who was not part of the study. 
Gestational age at birth was calculated from the first day of the last menstrual period 
and ultrasound estimation. Birthweight z-scores and birthweight percentiles for 
gestational age and gender were computed using the International Newborn Size at 
Birth Standards software (23). Neonates with birthweight percentile<10% were 
classified as small-for-gestational-age (SGA) while those with birthweight> 90% were 
classified as large-for-gestational-age (LGA). Additionally, neonates with 
birthweight<2500 grams were classified as low-birthweight (LBW) and neonates with 
birthweight>4000 grams as macrosomic. At follow-up, trained study staff measured the 
children’s anthropometry in light clothing and without shoes. Height was measured 
eight to the nearest 0.1cm, using a wall-mounted stadiometer. Weight was measured to 
the nearest 0.1kg, using a calibrated digital scale. All measurements were taken in 
duplicate and the average calculated. Z-scores for weight, height and BMI were 
calculated using the WHO Child Growth Standards STATA igrowup package for 
children 5 years old or younger and the WHO Child Growth Standards STATA WHO 
2007 package for children above 5 years (24). Children over the age of 5 years with 
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BMI z-scores above one but less than 2 were classified as overweight while children 
with BMI z-score of at least 2 were classified as obese. Children with BMI z-scores 
below -1 were classified as underweight.  
 
7.3.3. Sample size and sampling 
 
The study sample consisted of 443 eligible neonates at birth and these were all 
included. The same children were eligible for follow-up and thus the sample size at 
follow up consisted of all children who were able to participate in the study, although 
there was significant attrition.  
 
7.3.4. Statistical data analysis 
 
We used STATA 15 (25) and R statistical software (26) for all statistical analyses, 
p<0.05 as a cut-off for significance and reported 95% confidence intervals (CI) for 
prevalence and regression estimates, where applicable. For summarizing data, we 
reported frequencies and proportions for categorical data, means and standard 
deviations (SD) for measured data, such as child anthropometry and ages, if normally 
distributed, and medians and interquartile ranges (IQR) for non-normal data. We 
calculated the prevalence of neonates who were LGA and the prevalence of overweight 
and obesity at preschool age as a proportion of the children with the outcome divided 
by the total assessed.  
We compared z-scores, LGA at birth, and overweight and obesity at preschool age 
between children exposed to DIP and those exposed to GDM during the pregnancy. P-
values for group comparisons were computed using the chi-squared test for categorical 
data and the t-tests for independent groups or Wilcoxon rank-sum test (where data 
were not normally distributed).  
Multiple variable linear regression was used to investigate the association between 
maternal blood glucose concentrations during pregnancy, and weight z-score at birth 
and preschool age and BMI at preschool age. A linear mixed-effects model was used to 
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investigate the effect of maternal blood glucose on longitudinal offspring weight z-score, 
as there were no data for offspring BMI z-score at birth. Multiple variable multinomial 
logistic regression was used to examine the association between maternal blood 
glucose and the categorized outcomes of size at birth (LGA and SGA with AGA as the 
base outcome) and BMI category at preschool age (Overweight and Obesity with 
normal BMI as the base outcome). In all the models the following maternal blood 
glucose variables were included; 1) glucose levels at HFDP diagnosis (fasting blood 
glucose, OGTT 1-hour, OGTT 2-hours) and third trimester mean 2-hour postprandial 
blood glucose. In all models, the following variables were adjusted for, maternal age at 
pregnancy booking, maternal BMI at pregnancy booking, gender and mode of birth 
delivery. In addition, size at birth (LGA or SGA vs AGA) was adjusted for in all models 
at preschool age. Maternal HIV was not included in the analysis due to the low 
prevalence in the study while fasting and 1-hour postprandial blood glucose were 
omitted as they had too much missing data.  
The study is reported according to the Strengthening the Reporting of Observational 




This study protocol (S2 Doc) was approved by the Human Research Ethics 
Committees of the University of Cape Town (Refs: 377/2012 and 656/2015) and 
permission obtained to conduct research at the tertiary hospital. The study was 
conducted according to the ethical principles of the Helsinki Declaration (27). At follow 
up, mothers gave informed consent for their children to participate and each child 
assented before they had their weight and height measured. All the children who were 






Of the 498 women treated for HFDP, 443 (89.0%) had children who were eligible for 
the birthweight assessment. Of these 167 (37.7%) were followed up at ages 5-6 years. 
The remainder were lost to follow-up due to various reasons (Fig 7.1). The only 
differences in the baseline clinical characteristics of children followed up compared to 
those lost to follow up (Supplemental Table 1) were: the lower mean gestational age at 
booking of the pregnancy and smaller proportion of children exposed to DIP in those 
seen as follow up compared to those not followed up [(15 (IQR 12-21) vs 17(IQR 13-
23) weeks, and 29.9% vs 41.7% respectively, p = 0.013].  
 
Fig.7.1. Flow chart of the study 
   
*Preterm – extreme or very preterm: gestational age below 32 weeks (WHO 
classification), and/or birthweight ≤ 1500 grams   
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**Dandy Walker syndrome (n=1), ventriculomegaly (n = 1), Intrauterine growth 
restriction (n=4), short-long bones (n=2), kyphosis (n = 1)  
***hospitalizations (multiple problems (n=2), hypoglycaemia (n=1), hypothermia and 
microencephaly(n=1))  
 
7.4.1. Participant characteristics and comparison between DIP and 
GDM- exposed infants 
Table 7.1 shows maternal and offspring characteristics. At booking of the 
pregnancy, mean maternal age was 30.5(SD 6.2) years, mean maternal BMI was 
34.5(SD 8.6) kg/m2 and median gestational age was 16(IQR 12-22) weeks. Two 
hundred-and-twenty (49.7%) of the 443 infants were female. At HFDP diagnosis, the 
median fasting and OGTT 2-hour blood glucose concentrations were 5.8 (IQR 5.2-6.6) 
mmol/l and 9.1 (IQR 8.3-10.6) mmol/l, respectively, with, as expected, higher 
concentrations in the mothers with DIP, compared to those with GDM (Table 7.1). The 
children’s mean age at follow up was 5.5 (SD 0.5) years, with only 26 (15.5%) being 5 
years old or younger. After classification using modified WHO 2013 criteria, 165 
(37.2%) and 50 (29.9%) were classified as DIP at birth and preschool age, respectively. 
The maternal characteristics at follow up did not differ significantly between the DIP-
exposed and GDM-exposed children (Table 7.1).  
 
Table 7.1. Characteristics of, and comparison between infants exposed 
to GDM and those exposed to DIP 
Variable  Level Overall DIP GDM p-
value 
Pregnancy-related data  N = 443 N = 165 N = 278  
Maternal age at booking (mean (SD)) Years  30.5 (6.2) 31.2 (6.0) 30.1 (6.2) 0.06 
Maternal ethnicity (n (%)) Black  130 (29.4) 57 (34.6) 73 (26.3) 0.064 
Mixed 
ancestry 
313 (70.7) 108 (65.5) 205 (73.7) 




34.5 (8.6) 35.1 (8.3) 34.2 (8.7) 0.35 
Maternal HIV status (n (%)) Positive 27 (6.1) 16 (9.8) 11 (4.0) 0.024 











Maternal gravida  (median 
[IQR]) 
3 (2-4) 3 [2, 4] 3 [2, 4] 0.024 
Maternal parity  (median 
[IQR]) 
3 (2-4) 2 [1, 3] 1 [0, 2] 0.029 
Gestational age at booking (weeks) (median 
[IQR]) 





Fasting glucose (mmol/l) at HFDP 





7.20 [6.2, 8.5] 5.6 [5.0, 5.9] <0.00
1 








8.6 [8.1, 9.4] <0.00
1 
Third trimester postprandial 2-hour 
blood glucose (n = 440) 
(median 
[IQR]) 
5.7 [5.1 – 
6.3] 
5.9 [5.2- 6.6] 5.6 [5.1 – 6.2] 0.031 
Insulin treatment for HFDP (n (%)) Yes 111 (25.1) 88 (53.3) 23 (8.3) <0.00
1 
Oral hypoglycaemics treatment (n (%)) Yes 141 (31.9) 70 (42.4) 71 (25.6) <0.00
1 
Mode of birth delivery (n (%)) Caesarean 
section  
231 (52.4) 96 (58.2) 135 (48.9) 0.074 
Vaginal  210 (57.6) 69 (41.8) 141 (51.1) 
Gestational age at delivery (weeks) Median 
[IQR] 






Infant gender (n (%)) Female  225 (50.8) 88 (53.3) 137 (49.3) 0.467 
Follow up data (age 5-6 years), N = 167 
Child gender (n (%)) Female  80 (47.9) 28 (56.0) 52 (44.4) 0.171 
Child age (years) (Mean 
(SD)) 
5.5 (0.5) 5.7 (0.5) 5.5 (0.5) 0.014 
Maternal education (n (%)) Primary 15 (8.9) 8 (16.0) 7 (6.0) 0.093 
 Secondary 129 (77.3) 37 (74.0) 92 (78.6) 
 Tertiary 23 (13.8) 5 (10.0) 18 (15.4) 
Mother employed (n (%)) Yes 80 (47.9) 23 (46.0) 57 (48.7) 0.878 
Maternal alcohol (n (%)) Ever 
consumed 
72 (43.9) 22 (44.0) 50 (43.9) 1.000 
Maternal smoking (n (%)) Ever 
smoked 
61 (36.5) 17 (34.0) 44 (37.6) 0.789 
NB: n is specified where data are missing  
Abbreviations: BMI, body mass Index, FBG, fasting blood glucose, HFDP, hyperglycaemia 
first detected in pregnancy, OGTT, oral glucose tolerance test, DIP, diabetes in pregnancy, 
GDM, gestational diabetes mellitus  
 
 
7.4.2. Prevalence of LGA at birth and overweight and obesity at 
preschool age, and comparison between exposure to DIP and GDM 
 
The median birthweight of the offspring was 3.3 (IQR 3.0-3.6) kg and their mean 
BMI at preschool age was 16.12 (SD 2.92) kg/m2. The DIP-exposed neonates had a 
significantly higher mean z-score for birthweight than GDM-exposed infants [0.52 (SD 
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1.20) vs 0.11 (SD 0.97), respectively, p <0.001] but there were no significant 
differences in weight, height and BMI, between the two groups of children at preschool 
age (Table 7.2 and Fig 7.2).   
The prevalence of LGA at birth was 29.6% (95%CI 25.5 – 34.0), with a significantly 
higher prevalence in the neonates exposed to DIP, compared to those exposed to 
GDM (37.6% vs 24.8%, p =0.018, respectively). The prevalence of macrosomia was 
12.2% (95%CI 9.4% - 15.6%), with a higher prevalence in DIP-exposed compared to 
GDM-exposed, although not significant at a 5% significance level (Table 2). At 
preschool age, the combined prevalence of overweight and obesity was 26.5% (95%CI 
20.1 – 34.0), with no significant differences between DIP-exposed and GDM-exposed 
infants (Table 7.2).  
 
Table 7.2: Anthropometry at birth and preschool age, and comparison 
between children exposed to GDM and those exposed to DIP 
Variable Level Overall DIP GDM P 
Birth  N = 443 N = 165 N = 278  
Neonate 
birthweight (kg) 




3.3 [3.0, 3.6] 0.474 
Neonatal 
birthweight z-score  





category (n (%)) 
AGA 291 (65.69)  96 (58.18) 195 (70.14) 0.018 
SGA 21 (4.74) 7 (4.24) 14 (5.04) 




Macrosomia (n (%)) 54 (12.19) 27 (16.36) 27 (9.71) 0.117 
 LBW (n (%)) 33 (7.45) 12 (7.27) 21 (7.55)  
Preschool-age       







BMI at follow up 
(kg/m2) 




15.95 (2.55) 0.229 




20.06 (4.09) 0.057 
Child height z-
score  
 (Mean (SD)) -0.15 (1.02) -0.06 (1.09) -0.18 (0.99) 0.503 
Weight z-score   (Mean (SD)) 0.14 (1.51) 0.28 (1.77) 0.07 (1.39) 0.409 
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Child BMI z-score   (Mean (SD)) 0.34 (1.54) 0.35 (1.77) 0.33 (1.46) 0.937 
BMI category (n 
(%)), N = 155 
Underweight (z-
score <-1) 
26 (16.8) 7 (17.1) 19 (16.7) 0.935 
 Normal (-1≤z-score 
≤1) 
88 (56.8) 26 (52.0) 78 (66.7)  
 Overweight (1<z-
score≤2 
24 (15.5) 7 (17.1) 17 (14.9)  
 Obese (z-score>2) 17 (11.0) 5 (12.2) 12 (10.5)  
Combined 
overweight & obese 
category (n (%)) 
BMI z-score>1 41 (26.5) 12(29.3) 29 (25.4) 0.681 
 
NB: Neonates with birthweight percentile<10% were classified as small-for-gestational-age  
(SGA) while those with birthweight> 90% were classified as large-for-gestational-age (LGA). 
Neonates with birthweight<2500 grams were classified as low-birthweight (LBW) and neonates 
with birthweight>4000 grams as macrosomic.  
Abbreviations: LGA, large for gestational age, AGA, appropriate for gestational age, SGA, 
small for gestational age, BMI, body mass Index, FBG, fasting blood glucose, DIP, diabetes in 
pregnancy, GDM, gestational diabetes mellitus  
  
Fig 7.2. Prevalence of LGA at birth and overweight and obesity at 
preschool age and comparison between DIP and GDM exposures 
 
   
Abbreviations: DIP – diabetes in pregnancy, GDM, gestational diabetes, LGA, large for 




7.4.3. Maternal blood glucose during pregnancy and birth size and 
overweight and obesity at preschool age 
 
All maternal blood glucose values were consistently high for the neonates who were 
LGA, compared to those who were either AGA or SGA (Table 7.3). Postprandial blood 
glucose exhibited the strongest association with an increase in birth size, with the 
highest mean (SD) for LGA, followed by AGA and lastly SGA. Similarly, maternal blood 
glucose levels were significantly higher for LGA compared to AGA for both fasting and 
OGTT 2-hour glucose at diagnosis of HFDP but not for OGTT-1hour glucose. At 
preschool age, all mean maternal blood glucose parameters were high for offspring 
who were overweight and obese compared to those who had either normal BMI or 
underweight, although not statistically significant (Table 7.3).  
 Table 7.3. Maternal blood glucose and weight outcomes at birth and 
preschool age 
Birth size 






















30.71 (6.61) 0.854  






32.47 (9.81) 0.009 0.013 0.138 1.000 
FBG at HFDP 
diagnosis 
6.58 (1.85) 6.12 
(1.61) 
5.74 (1.77) 0.020 0.041 0.131 1.000 
OGTT 1-hour 






9.51 (2.30) 0.322  
OGTT 2-hour 











6.05 (1.03) 5.65 
(0.79) 
5.32 (0.61) <0.001 <0.001 0.001 0.264 
Overweight and obesity at preschool age 
 Overweight 
and obese, 















29.73 (5.64) 0.489 









FBG at HFDP 
diagnosis 
6.44 (2.05) 5.92 
(1.64) 
6.14 (1.73) 0.288 
OGTT 1-hour 






10.00 (2.05) 0.464 
OGTT 2-hour 








5.87 (0.74) 5.72 
(0.85)  
5.67 (1.06) 0.583 
 
*All tests carried out using one-way ANOVA  
Post hoc tests were done with Bonferroni correction and only out when omnibus ANOVA 
was significant at p=0.05  
Abbreviations: LGA, large for gestational age, AGA, appropriate for gestational age, SGA, 
small for gestational age, BMI, body mass Index, FBG, fasting blood glucose, HFDP, 
hyperglycaemia first detected in pregnancy, OGTT, oral glucose tolerance test  
 
7.4.4. Association between maternal blood glucose and offspring weight 
outcomes at birth and preschool age 
 
In multivariable analysis, maternal 2-hour postprandial glucose in the third trimester 
was significantly associated with weight z-score at birth (OR 1.23, 95%CI: 1.07 - 1.42, p 
= 0.005), at preschool age (OR 1.37, 95%CI: 1.03 - 1.81, p = 0.031), as well as weight 
z-score in longitudinal analysis (OR 1.26 (95%CI: 1.05 - 1.52, p = 0.014). Maternal 2-
hour postprandial blood glucose was also significantly associated with both SGA at 
birth (OR 0.41, 95%CI0.170.95) and LGA (OR 1.58, 95%CI 1.15-2.16) (Table 7.4), after 
multinomial logistic regression. Maternal fasting blood glucose at HFDP diagnosis was 
significantly associated with weight z-score at birth only (OR 1.11, 95%CI 1 -1.22, 
p=0.046). Notably, maternal BMI at booking of pregnancy was consistently associated 
with weight outcomes at both time points (Fig 7.3). There were no significant 
associations between maternal blood glucose during the pregnancy and preschool-age 




Fig 7.3: Association between maternal blood glucose and z-scores for 
weight at birth and preschool age – multiple variable linear regression 
   
Abbreviations: postprandial_gluc – Maternal 2-hour postprandial glucose during the third 
trimester  
OGTT_1hr_gluc – Maternal OGTT 1-hour glucose at HFDP diagnosis  
OGTT_2hr_gluc - Maternal OGTT 2-hour glucose at HFDP diagnosis  
Maternal_BMI – Maternal Body Mass Index at pregnancy booking  
Maternal_age – Maternal age at pregnancy booking  
FBG – Maternal fasting blood glucose at HFDP diagnosis  
Caesarian_delivery – Caesarian delivery at birth  
  
Table 7.4: Association between maternal blood glucose during 
pregnancy and size at birth and BMI category at preschool age – 
Multinomial logistic regression 
  
Preschool age  Birth  
















0.67 0.24 0.35 1.30 0.41 0.04 0.17 0.95 





0.85 0.35 0.60 1.20 0.90 0.47 0.67 1.21 
OGTT 2hr 
glucose 
1.06 0.71 0.79 1.42 0.91 0.54 0.67 1.23 
Maternal age 0.95 0.33 0.87 1.05 1.06 0.18 0.97 1.17 
Maternal BMI 1.06 0.08 0.99 1.13 0.96 0.30 0.88 1.04 
Female gender 0.45 0.14 0.16 1.31 0.34 0.07 0.11 1.11 
Caesarian 
delivery 
1.05 0.85 0.63 1.74 1.20 0.51 0.69 2.09 
SGA at birth 0.50 0.61 0.04 7.14  
LGA at birth 0.41 0.21 0.10 1.68 
 




1.16 0.57 0.69 1.97 1.58 0.01 1.15 2.16 
FBG 1.12 0.56 0.76 1.65 1.08 0.47 0.87 1.34 
OGTT 1-hr 
glucose 
0.94 0.67 0.69 1.27 1.00 0.97 0.95 1.06 
OGTT 2-hr 
glucose 
1.02 0.89 0.79 1.31 1.06 0.36 0.93 1.21 
Maternal age 1.00 0.94 0.92 1.09 1.00 0.86 0.96 1.05 
Maternal BMI 1.06 0.04 1.00 1.12 1.03 0.12 0.99 1.06 
Female gender 0.96 0.94 0.39 2.37 1.46 0.16 0.86 2.48 
Caesarian 
delivery 
1.44 0.10 0.93 2.24 1.46 0.01 1.10 1.92 
SGA at birth 1.85 0.56 0.23 14.82  
LGA at birth 1.21 0.69 0.46 3.17 
Abbreviations: LGA, large for gestational age, AGA, appropriate for gestational age, SGA, 
small for gestational age, BMI, body mass Index, FBG, fasting blood glucose at HFDP 
diagnosis, HFDP, hyperglycaemia first detected in pregnancy, OGTT, oral glucose tolerance 
test  
   
7.5. Discussion 
 
Birth weight outcomes 
 
At birth, we found that almost one third (29.6%) of children exposed to HFDP during 
pregnancy were LGA at birth; 12.2% had macrosomia and 7.5% LBW. Significantly 
higher proportions of neonates exposed to DIP were either LGA or had macrosomia at 
birth, compared to GDM-exposed neonates, although there were no significant 
differences in overweight and obesity at preschool age. We also found that maternal 
fasting blood glucose at HFDP diagnosis and maternal postprandial blood glucose 
during the third trimester were both associated with weight z-score at birth.  
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There are limited data on the effect of either HFDP or maternal blood glucose levels 
during pregnancy and offspring weight outcomes in Africa. In one study from Soweto, 
South Africa, out of 82 neonates born to women with GDM (defined using the IADPSG 
criteria), the prevalence of LGA was 6% while only 1% of the neonates had 
macrosomia (28). Our findings in a larger cohort show a high prevalence of both LGA 
and macrosomia at birth and suggest a need for interventions to either prevent GDM or 
treat more aggressively. LGA and macrosomia (birthweight >400 grams) are 
established risk factors for both childhood and adult overweight and obesity (5). On the 
other hand, LBW is a risk factor for developmental origins of adult cardiometabolic 
disease, with findings from several studies showing that infants with LBW have a higher 
risk for adult high blood pressure, diabetes and dyslipidaemia (6). In this study, 37.1% 
of the neonates were either LGA (29.6%) or LBW (7.5%). Apart from interventions to 
reduce risk of HFDP, and to improve treatment of HFDP, interventions may need to be 
targeted at these neonates, at an early age, to reduce risk of both childhood and 
adulthood overweight and obesity.  
We found that both maternal fasting blood glucose at HFDP diagnosis and 2-hour 
postprandial glucose during the third trimester were associated with z-score for 
birthweight. Besides, 2-hour postprandial glucose was associated with both SGA and 
LGA, after adjusting for other glucose indices and maternal BMI at booking of 
pregnancy. Our findings on the effect of fasting glucose on offspring birthweight agree 
with published data (10). However, in contrast to the HAPO study, we found that OGTT 
1-hour and 2-hour maternal glucose was not significantly associated with birth size. 
Instead, we found that postprandial exerted the strongest effect on weight outcomes. 
While data on the influence of postprandial glucose on offspring weight outcomes are 
sparse (29), data from trials have shown that tighter control of maternal blood glucose 
during the pregnancy reduces the risk of adverse perinatal outcomes, including both 
macrosomia and LGA (30), although data from Africa are scarce. Research is needed 
to provide evidence of Africa-specific interventions to improve maternal glucose.  
We found that neonates exposed to DIP had birthweight z-scores which were 5 
times higher than those for neonates exposed to GDM, with corresponding higher 
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proportions of LGA and macrosomia. Research comparing the effects of DIP and GDM 
on offspring weight outcomes is scarce. Women with DIP do not only have more severe 
dysglycaemia during the pregnancy but are more likely to have a higher risk of diabetes 
complications, during and after the pregnancy (8). In Africa, the high prevalence of 
undiagnosed diabetes of 69% (31) raises the possibility that some of the women with 
DIP may have had undiagnosed type 2 diabetes before the pregnancy (32). In South 
Africa, 83% of the mothers with DIP progressed to type 2 diabetes within 6 years (22), 
perhaps partly because a significant proportion of these women may have undiagnosed 
type 2 diabetes. By extension, offspring of women with DIP are more likely to have 
been exposed to hyperglycaemia for a longer period during the pregnancy, compared 
to the offspring of women with GDM. Our findings show a clear need to reduce 
exposure to untreated DIP in the offspring. One possible solution is to screen for 
diabetes earlier than the 24-28-week window recommended for GDM. An immediate 
drawback of the early screening using glucose testing, during the first trimester, for 
example, is the increased burden in costs and human resources required for glucose 
testing, as women who don’t have DIP at the initial screening will still need to be 
screened for GDM later in the pregnancy. One way of overcoming the costly 
implications of first-trimester glucose testing is by using non-invasive prediction models 
which use routine clinical data. However, there are currently no prediction models for 
Africa populations and most of the existing prediction models lack external validity (33). 
Recent data from Johannesburg suggest that the use of a dual-threshold fasting 
plasma glucose, ≥4.5mmol/L to rule out, and 5.1mmol/L to rule in GDM, may result in 
only 2.4% missed cases of GDM (19). Using fasting blood glucose only for the 
diagnosis of HFDP will be less costly than the standard OGTT, and maybe a useful 
solution in the meantime. The lack of universal screening in South Africa, due to 
resource limitations is also another limitation as the selective screening currently in use 
in many provinces in South Africa uses non-validated risk factors and may leave almost 
half of women with HFDP undiagnosed (14). A non-invasive screening tool for GDM 
could be equally useful as it can be deployed in a universal testing strategy without 
adding an extra burden to the health system.  
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Preschool age weight outcomes 
 
At preschool age, we found that more than a quarter (26.5%) children were either 
overweight or obese. This is almost twice as high as the 14% reported from recent 
South African national surveys (34, 35), and demonstrates a need for intervention in 
these children. Again, the lack of data from Africa in this area makes comparisons with 
published literature difficult. Evidence from a retrospective and prospective analysis of 
51 505 adults, showed that those children who were overweight and obese during 
adolescence experienced the highest increases in BMI during the preschool ages 2-6 
years, but not during the school years (4). Thus, the preschool age may be the critical 
time during childhood during which susceptibility to adulthood overweight and obesity 
occurs and when interventions may have the greatest impact.   
We found that maternal 2-hour postprandial glucose during the third trimester was 
associated with weight z-score at preschool age but no significant associations 
between maternal blood glucose levels during pregnancy and preschool age BMI z-
scores. In the HAPO follow-up study, there were no significant associations between a 
GDM diagnosis and child BMI at ages 10-14 years, although the authors found 
associations between GDM and other measures of adiposity (16). The 2-hour 
postprandial blood glucose is a measure of maternal blood glucose control during the 
third trimester and the possibility that poor glucose control during pregnancy could still 
exert an effect during preschool years has important clinical implications. More 
aggressive maternal blood glucose targets during the pregnancy may be required to 
reduce the risk of both LGA at birth and childhood overweight and obesity in the 
offspring.   
An important observation from our study is the consistent association between 
maternal BMI and child weight outcomes at birth and preschool age. This may be 
particularly important in the South African setting where the prevalence of overweight in 
women was 65% in 2015 (34) and therefore women are more likely to be either 
overweight at preconception. Intervening to reduce pre-conception overweight and 
obesity may have many benefits as overweight and obesity is also the strongest risk 
factor for HFDP.   
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A limitation of our study is the use of routinely collected clinical data for maternal 
blood glucose values and birthweight. Conversely, the measurement of maternal blood 
glucose and birthweight by clinicians unrelated to the study is a strength as clinicians 
were not aware of the study and these measurements would not have been affected by 
ascertainment bias. As is usual with all routinely collected data, missing data made it 
difficult to assess the effect of all variables, in particular, maternal fasting and 
postprandial 1-hour glucose during the pregnancy. The loss to follow up in our study 
was high at preschool age, typical for longitudinal studies in our setting where in-and-
out migration is high. Lastly, we did not include a comparison group of children who 




In offspring exposed to HFDP, there is a high prevalence of LGA and macrosomia 
at birth and overweight and obesity at preschool age, with higher prevalence in 
offspring exposed to DIP. Poor maternal blood glucose control during the pregnancy, 
represented by maternal postprandial 2-hour glucose increased the risk of both LGA 
and SGA at birth and was associated with weight z-score at preschool age. There is a 
need for earlier screening for HFDP in this setting, to allow earlier detection of DIP and 
intervention. Improved management of maternal blood glucose during pregnancy is 
needed to reduce the risk of both LGA and SGA at birth and overweight and obesity at 




Hyperglycaemia first detected in pregnancy (HFDP), gestational diabetes mellitus 
(GDM), diabetes in pregnancy (DIP), World Health Organization (WHO), 
Hyperglycaemia and Adverse Pregnancy Outcomes Study (HAPO Study), International 
Association of Diabetes and Pregnancy Study Groups (IADPSG), glycated 
haemoglobin A1C (HbA1c), oral glucose tolerance test (OGTT), low-to-middle-income 
207 
 
(LMIC), large-for-gestational-age (LGA), low birth weight (LBW), standard deviation 
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PART C. INTEGRATED 
DISCUSSION AND CONCLUSION 
 
 
“If we do discover a complete theory, it should be in time understandable in broad principle 
by everyone. Then we shall all, philosophers, scientists, and just ordinary people be able to 











CHAPTER 8. INTEGRATED DISCUSSION AND CONCLUSION 
 
This chapter summarises findings of the body of work, followed the emerging 
methodological and empirical themes, implications for policy, practice and future 
research. 
8.1 Principal findings and emerging themes 
 
8.1.1. Principal findings 
 
The findings of the body of work undertaken are summarized in Table 8.1.1. 
 
Table 8.1.1. Key findings 
 
Objective(s) Chapter Key findings 














The pooled prevalence of T2DM was 7.2%, impaired 
fasting glucose (IFG) 6.0%. The prevalence of 
impaired glucose tolerance ranged from 0.8% to 
37.0%  





• Almost half (48%) of the women progressed to 











the risk of 
postpartum 
T2DM in these 
women in Cape 
Town, South 
Africa 
• Risk factors associated with T2DM at follow up 
were; treatment with insulin and oral 
hypoglycemics during the pregnancy, fasting and 
OGTT 2-hour glucose at HFDP diagnosis and BMI, 
waist and hip circumference at follow-up. 
-Objective 3: To 
investigate the 
prevalence of 
CVD risk factors 
in women 6 
years after 





• There was a high prevalence of central obesity; 
(90%), measured using waist circumference 
≥88cm) and generalized obesity measured using 
BMI≥30kg/m2 (69%). 
• There was a high prevalence of insulin resistance 
(75%), dyslipidaemia (75%), and raised blood 
pressure (41%) 
• Almost two-thirds of the women (62%) had 
metabolic syndrome 









• The mean birthweight z-score for children exposed 
to DIP was 5 times higher than that for neonates 
exposed to GDM. 
• Maternal blood glucose at diagnosis of HFDP 
(fasting and OGTT 2-hour blood glucose) and 
postprandial 2-hour glucose during the third 










birthweight z-score and increased risk of LGA at 
birth. 
• At preschool age, the prevalence of overweight and 
obesity was 27%, with a slightly higher prevalence 
in children exposed to DIP compared to those 
exposed to GDM. 
• Postprandial glucose was significantly associated 
with a 37% increase in child weight z-score at 
preschool age but not with child BMI z-score.   
 
8.1.2. Emerging themes 
 
There were 2 main themes: the first being methodological and the second 
empirical. Two main quantitative study designs were employed to answer the 
prespecified specific objectives. The systematic review and meta-analysed method was 
used to estimate the prevalence of T2DM and impaired glucose metabolism in African 
women childbearing age. The systematic review and meta-analysis allowed us to 
understand the background prevalence of T2DM and the estimates from the meta-
analysis could be used to monitor trends and the success of intervention to prevent 
T2DM. However, several challenges were encountered. First, as discussed in Chapter 
4, is the lack of good quality gender and age-group specific data. This is particularly 
why the estimate of T2DM, and prediabetes included women between the ages 49-54 
years, outside the definition of childbearing age. Second, the unexplained 
heterogeneity in the prevalence estimates also poses a challenge, which could be 
explained by a combination of differences in setting, screening and diagnosis methods. 
However, limitations exist in the current meta-analysis regarding examining the effects 
of multiple variables on the prevalence of diabetes. These limitations include the lack of 
study-level data on some of the variables that could have helped explain the 
heterogeneity. Individual participant meta-analyses may provide a solution if data from 
individual studies can be accessed. 
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The PRO2D was a hybrid of a case series during pregnancy, followed by a 
cross-sectional study at follow-up. A cohort study, with a comparative group of 
unexposed women and their offspring, would have been best suited to study the 
cardiometabolic outcomes of women and their offspring after HFDP. The cohort study 
will have enabled us to compare the cardiometabolic outcomes between the two groups 
and make stronger inferences. However, a lack of resources and time constraints made 
such a design impractical at the time of the study. One possible solution could be to 
extend existing trials into cohorts, although there is a scarcity of trials in this area in 
Africa. 
Diabetes at this age affects a woman’s family, as African women play multiple 
critical roles in their families and has the potential to affect future generations through 
the transmission of T2DM risk to her offspring through epigenetic mechanisms. Our 
findings suggest that maternal blood glucose during pregnancy increased the risk of 
higher weight z-score at preschool age, which may contribute to increased risk of 
cardiometabolic disease for the offspring. Notably, our findings are not novel, as data 
from other parts of the world have shown a similar association between maternal blood 
glucose levels during pregnancy and child cardiometabolic outcomes, albeit with a 
great degree of heterogeneity from different settings. However, our findings are novel in 
the African context, a context where undernutrition and overnutrition are highly 
prevalent, and where social determinants of health and disease are complex and 
under-studied. The lack of research in this area is a challenge that needs to be 
addressed urgently in Africa.  
During the index pregnancy, women in our study were screen using risk-factor-
based screening, which may leave many women with HFDP undiagnosed. Further, this 
may mean that the women in our study are not entirely representative of the women 
with HFDP in the Western Cape. Universal screening may help arrive at a closer 
estimate of women who develop diabetes after HFDP. But the capacity to screen more 
women for HFDP or to introduce preventive programs for African women with HFDP is 
limited. Innovative use of the existing health resources so women can be screened for 
HFDP earlier and for T2DM and CVD after the pregnancy may provide a solution to the 
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problem. Both HFDP and T2DM are preventable and additional investment in this area 
would have high benefits to the individual women, the health system and the larger 
society. Some of the empirical themes are discussed in detail in the next sections. 
 
8.2. Implications for policy and practice 
 
Our findings have notable implication for policy and practice, as discussed below.  
8.2.1. Prevention of hyperglycaemia first detected in pregnancy is critical 
 
Findings from the PRO2D study, in the context of literature, have several 
ramifications for policy and practice. Although data from Africa continue to be sparse, 
several studies have already reported a high prevalence of HFDP, between 25-31%, in 
South Africa and Cameroon (9, 10). This implies that a large proportion of African 
women are potentially at risk of long-term cardiometabolic disease risk. Indications are 
that the prevalence will increase as the prevalence of obesity, one of the strongest 
drivers of HFDP, continues to increase across the African continent (14). Preventing 
HFDP itself may be the single most important intervention, as this will result in fewer 
pregnancy complications and reduce the risk of cardiometabolic disease in the women 
and their offspring.   
A yet unanswered question concerns the best interventions to prevent HFDP in 
Africa. Similar to the prevention of T2DM, prevention of HFDP could be done either 
through population-wide measures or targeted intervention. One of the population-wide 
interventions involves policies that mitigate against obesogenic environments. South 
Africa is one of the first African countries to implement a “sugar tax”. Life table-based 
models suggest that if the sugar tax is implemented over 20 years in South Africa, the 
prevalence of T2DM could be reduced by up to 4% (15). This reduction in T2DM 
prevalence will be mediated mainly by the reduction of body mass index (BMI) through 
reduced consumption of sugar-sweetened beverages (SSBs) (15).   
Although there are no projections on the possible impact of the sugar tax on 
HFDP prevalence in Africa, the prevalence may also decline as decreased 
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consumption of SSBs may result in a population-level decrease in BMI. However, 
whether the sugar tax will have the expected impact on either T2DM or HFDP remains 
debatable as the tax is in the early stages of implementation in South Africa. A 
systematic review of 17 studies found that purchases of SSBs decreased by 8% in 
California and 10% in Mexico (16). In California, the reduction in sugar-sweetened 
beverages intake was sustained over 3 years after the implementation of the sugar tax 
(17). However, in Chile, a low-to-medium-income country (LMIC) similar to South 
Africa, the reductions in SSBs intake after a year of implementation of a sugar tax in 
2014 were small and were not likely to change overweight and obesity profile at a 
population level (18, 19). This was partly explained by the availability of untaxed 
substitutes which were not affected by the sugar tax and remained available at cheap 
prices. The availability of untaxed substitutes may pose a similar problem in South 
Africa.   
Even if the population BMI does not decrease, the sugar tax will have benefit if 
the proceeds are channelled towards programs for the prevention of cardiometabolic 
disease in the population. Diabetes in women and HFDP have such wide-ranging 
consequences on the population health in the short and long term and could potentially 
affect generations after the initially exposed offspring (20). Therefore, a prime 
candidate for the use of the sugar tax could be the funding of programs to prevent and 
better screen for HFDP and mitigate against the risk of T2DM and CVD after the 
pregnancy.  
Interventions targeting women who are planning to be pregnant, or women in the 
early stages of pregnancies are another way that can be used to prevent HFDP. 
However, many previous meta-analyses of randomized controlled trials have 
demonstrated contradicting results from either lifestyle interventions (21) or 
pharmacological interventions (22) in preventing HFDP. One meta-analysis of 13 
randomized studies showed that structured physical activity throughout the pregnancy 
reduced risk of GDM by 36% (23). Another meta-analysis of 29 randomized controlled 
trials showed an 18% GDM risk reduction (24). On the hand, other meta-analyses have 
not found clinically significant effects from lifestyle interventions on either reducing 
excessive weight gain during pregnancy or reducing the risk of HFDP (25)(26).   
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The heterogeneous findings from the many existing clinical trials and meta-
analyses make it difficult to produce either evidence-based interventions or policy to 
prevent HFDP in Africa. There is evidence that a combination of both diet and exercise 
significantly reduced risk of HFDP by 23% (27). However, for these interventions to be 
effective, certain elements had to be present. The interventions were most effective 
when intensified diet and exercise were used during early pregnancy in women at high 
risk. Besides, interventions were successful when risk evaluation models were used to 
identify women at high risk and when the interventions targeted gestational weight gain. 
Notably, none of the aforesaid reviews included data from Africa, and it is doubtful 
whether these findings could be applied in the same way in Africa, where food 
insecurity is still prevalent and, in many cases, structured physical activity is not 
feasible due to time and resource limitations.  
 
8.2.2. Early screening for HFDP may help detect HFDP early and 
reduce the length of exposure to hyperglycaemia 
 
The SEMDSA in its 2017 guidelines, in line with the IADPSG, recommended that 
women with risk factors be screened for GDM at first booking using a 2-hour OGTT, to 
allow for earlier diagnosis of DIP (28). The 2-hour OGTT should then be repeated at 
24-28 weeks gestation for women without DIP at the initial screening (28). For the 
diagnosis of DIP during early pregnancy, the WHO (13), the IADPSG (29) and other 
international bodies recommend the use of criteria for diabetes diagnosis outside of 
pregnancy.  
Findings from our meta-analysis show that one in 14 women of childbearing age 
is affected by T2DM. In a continent where up to 69% of people living with diabetes are 
not diagnosed (1), early screening for HFDP would help detect women with 
undiagnosed diabetes. Further, findings from the PRO2D study showed that women 
with DIP and their offspring had worse outcomes. Some of the women could have had 
undiagnosed T2DM during the pregnancy and early screening would have helped 
detect this.   
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In the PRO2D study we found a high proportion of women with DIP, about 40% 
during the index proportion and it highly likely that undiagnosed pre-existing diabetes 
may have contributed to this. If undiagnosed diabetes and DIP in early pregnancy are 
to be detected efficiently during early pregnancy, an acceptable, accurate and relatively 
cheap screening method is needed. Currently, the OGTT is the accepted standard for 
testing for diabetes in pregnancy (13, 30-32), but it is resource intensive. Alternative, 
cheaper tests that have diagnostic accuracy comparable to the OGTT are therefore 
required. Random blood glucose can be used to diagnose DIP at a cut-off of 
11.1mmol/L (13) (33) but had a reported low sensitivity of 71% from one study (34) and 
therefore may leave many women with DIP undiagnosed. Using fasting blood alone has 
also been suggested but it also has poor sensitivity compared to the OGTT (35). The 
use of the HbA1c is also hampered by similar constrains of poor diagnostic accuracy 
compared to the OGTT (35). The use of prediction models, based on non-invasive risk 
factors, which identify women at high risk who then undergo an OGTT, may offer a 
solution. However, prediction models are usually context-specific (36-39) and research 
is needed to develop models that are specific to different Africa contexts.  
Early screening for HFDP can also be used to detect early onset GDM. Findings 
from a systematic review suggest that, depending on the setting, the screening strategy 
and methods used, between 15-70% of GDM can be detected before 24 weeks (40). 
Although there is consensus on the criteria for the diagnosis of DIP/ overt diabetes in 
early pregnancy (13, 29), debate on the optimum cut-offs for early GDM is still ongoing 
(35, 40). For example, the IADPSG (29) initially recommended that the same criteria 
used at 24-28 weeks’ gestation be used at the first antenatal visit. However, after 
findings from Italy (41) and China (42) showed that the fasting plasma glucose between 
5.1-6.9 mmol/L was a poor predictor of GDM during 24-28 weeks gestation, the 
IADPSG (43) subsequently cautioned against the use of fasting plasma glucose 
between 5.1-6.9 mmol/L for the diagnosis of early GDM. Other researchers have 
investigated the use of the glycated haemoglobin A1C (HbA1c) for the diagnosis of 
GDM during the first trimester (40). However, most of the studies have found low 
sensitivity, ranging from 13-29%, in predicting OGTT-diagnosed GDM when the HbA1C 
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cut-offs for prediabetes outside of pregnancy (5.7-5.9%) were used (34, 44-46). In our 
setting, policy on the diagnosis of early GDM is needed but requires more research to 
establish appropriate screening methods and criteria for diagnosis.  
Lastly, although universal screening for HFDP is recommended by many of the 
international bodies, it may not be feasible in African health systems as it would 
overburden healthcare systems. The SEMDSA recommends the use of universal 
screening, where resources are available. The National Guidelines for Maternity Care 
in South Africa (47) and the Western Cape province Diabetes in Pregnancy guidelines 
(48) both recommend a risk-factor-based approach. These risk factors include any of; 
repeated glycosuria, previous GDM, family history of diabetes, history of stillbirths, a 
previous baby with macrosomia, BMI≥30kg/m2, polycystic ovarian syndrome and 
history of perinatal death and South Asian descent. The limited evidence available 
suggests this risk factor-based screening is applied inconsistently across and within the 
provinces (49). Further, the risk factors used have not been evaluated fully to improve 
their diagnostic accuracy for HFDP in South African women. Findings from one study 
showed that the use of this risk factor-based approach in the Western Cape could 
result in half of the women with GDM being missed (50). If the risk-factor based 
approach is to be continued, then the risk factors need to be evaluated and 
appropriately weighted for the South Africa context.  
 
8.2.3. Screening for T2DM and CVD risk factors after HFDP needs to be 
improved 
 
We found that almost half of the women with T2DM, 80% with raised blood 
pressure and 91% of those with dyslipidaemia were undiagnosed. In line with 
international standards (13, 30, 51), the SEMDSA (12) recommends that women with 
HFDP should be assessed at delivery and diabetes treatment stopped if their blood 
glucose returns to normal after delivery. If a woman has persistent hyperglycaemia 
after the pregnancy, she must continue treatment. For women whose blood glucose 
returns to normal after delivery, the SEMDSA recommends that they must be assessed 
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for diabetes using a 2-hour OGTT 6-weeks after the pregnancy and screened for T2DM 
using HbA1c annually thereafter.  
In the Western Cape, women are given a referral letter to be screened for 
diabetes after 6 weeks at a primary health care facility close to their homes (49). The 
proportion of women who attend the 6-week OGTT is low, estimated to be below 30% 
(52). This could be because there are several barriers to women attending this 6-weeks 
screening. The health system is fragmented as the women have to go to a separate 
facility for the 6-weeks screening while at the same time taking their babies to a “Well 
baby clinic” for the mandatory 6-week check-up and immunization (49). This may 
discourage many women from attending the 6-weeks screening, as women naturally 
prioritize their babies’ appointments over theirs. Besides, because many of the primary 
care facilities are overburdened, even when the women go for the 6-week’s visit, they 
may not be screened as the OGTT is not offered routinely (49). Low perception of 
T2DM risk in women with GDM whose blood glucose returns to normal at delivery may 
also contribute to the low attendance for the 6-weeks diabetes screening (49). Other 
barriers against attendance are a lack of money to travel to the health facility and a lack 
of time as some women would have returned to work (49).   
The OGTT could impede women attending the 6-week visit due to the need for 
fasting, the time commitment and the discomfort associated with drawing blood (53). 
The use of HbA1c has been suggested (53) but the test has low sensitivity, 19% in one 
study 6-12 weeks post GDM (54) and poor concordance with the OGTT (Kappa = 
0.058) in another study (55). Using either fasting blood glucose only or with HBA1C, 
either alone or in a two-step way process, to screen for post-partum T2DM, could offer 
cost-effective and attractive alternatives to the OGTT. However, the use of the HBA1C 
as an alternative to the OGTT still requires more research and possibly requires moving 
the screening timing further than 3 months after the pregnancy, to avoid capturing 
pregnancy-related hyperglycaemia.   
Innovative solutions are needed so that screening for T2DM after HFDP could 
be improved but the dearth of context-specific evidence is an impediment. A currently 
ongoing trial (Trial registration: PACTR201805003336174) is investigating whether 
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integrating the post-partum care of the mother with the scheduled clinic visits for her 
offspring will improve screening rates. Another possible solution could be extending the 
screening period from 6 weeks to give women more time to get over early postpartum 
pressures. There is also a need for innovative solutions for women who go back to 
work soon after pregnancy.   
Poor follow-up for long term post-partum screening for T2DM is also a problem 
that needs to be addressed. There are sparse data about attendance for medium to 
long term screening for wither T2DM or the other CVD risk factors. Using the OGTT for 
medium to long term screening is likely to have the same limitation that the data for 6-
week screening has shown – health system constrains compounded by individual 
constrains. The HbA1C does not require prior fasting, is simple to use, costs less 
overally, can be done with capillary blood using a pin prick and can easily be done at 
the point of care. The advantages of the HbA1C in screening for T2DM in women with a 
previous history of GDM are many especially in resource limited settings, like Africa. 
Using either the FPG alone or the HbA1C may offer an alternative to the OGTT again 
but there are still unanswered research questions. These questions include; the 
proportion of women with T2DM who will be missed if either the FPG or the HbA1C are 
used, whether combining the two (FPG and HbA1C) is advisable, and whether 
combining the two tests is cost effective.  
Finally, our findings suggest the need to screen for other CVD risk factors during 
the postpartum period, specifically hypertension and dyslipidaemia. An advantage of 
this is that the additional screening would not significantly add to the burden on health 
workers and adds a small extra cost for laboratory testing for lipids. The lipids could be 
assessed from the same blood drawn for fasting blood glucose during screening for 
T2DM while blood pressure measurement is a relatively simple and quick process.  
 





Similar to the prevention of HFDP, prevention of T2DM and CVD during the 
postpartum period could be through either population-wide intervention such as the 
sugar tax discussed earlier or targeted intervention. Diabetes prevention programs 
(DPPs) have shown that lifestyle modification interventions can reduce the risk of 
T2DM in women after HFDP. A meta-analysis of 12 randomized controlled trials, with a 
median follow-up of 6 months, showed that postpartum interventions can reduce the 
risk of T2DM progression, reduce risk of insulin resistance and decrease weight (56). 
Further, a network meta-analysis of 44 DPPs in the USA (57), showed that the DPPs 
resulted in meaningful change in cardiometabolic health profile, apart from reducing 
diabetes risk. The pooled changes over a median follow-up of 9 months included a 
weight loss of 4kg, reductions of systolic and diastolic blood pressure of 4mmHg and 
2.6mmHg, respectively, an increase in HDL of 0.05 mmol/L and a decrease of total 
cholesterol of 0.3 mmol/L. These findings show that prevention of T2DM and CVD can 
be successfully achieved using the same intervention. Incorporating lifestyle 
modification counselling in postpartum settings may have benefit, although there is a 
need to test interventions that can work in Africa. 
There is also a need to address the barriers to lifestyle modification in women 
after HFDP. Considerable evidence from both international research (58) and data from 
Cape Town, South Africa (49, 59) suggests that women modify their diet and physical 
activity during the HFDP complicated pregnancy. However, the women revert to their 
lifestyles after the pregnancy (49, 58). In Cape Town, 6 months after the HFDP-
complicated pregnancy, women increased their intake of SSBs, added sugar, 
carbohydrates and energy-dense snacks, relative to their diet during the pregnancy 
(60). The failure to maintain the pregnancy lifestyle modification after the pregnancy 
could be partly due to two factors: for most women, the blood glucose returns to normal 
levels and the delivery of a healthy baby. These factors combined may make them feel 
that there is no longer a need to keep on with lifestyle modifications. Many studies have 
also reported a lower T2DM risk perception in women after delivery, once their blood 
glucose returns to normal (58). Other barriers to sustained lifestyle modification after 
the pregnancy include multiple roles in the family, demands of family life and raising the 
child, a lack of support from family and peers, and lack of information about diabetes 
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prevention (61-66). Lack of money and resources is also a frequently cited barrier as 
most women perceive healthy lifestyles as expensive (67). The format of interventions 
also affects their acceptability with many women preferring face-to-face interviews and 
flexible timing which allows them to attend to their jobs and families (63, 68, 69). 
Policies that address barriers to the maintenance of lifestyle modifications in the 
postpartum period are needed in Africa.  
Interventions for the prevention of HFDP itself or targeting an improved diet and 
physical activity are beneficial for the offspring but data are not conclusive. A meta-
analysis of 105 studies showed a 39% reduction in the odds of macrosomia in women 
who exercised during pregnancy, compared to those who did not (70). However, 
maternal exercise had no impact on childhood risk of overweight and obesity.   
Population-based approaches, such as the sugar tax, school-based nutritional 
and physical activity interventions may also have a positive effect on the 
cardiometabolic health of the children. In offspring at risk of overweight and obesity, 
there is a need for intervention as early as possible to reduce the risk of childhood 
overweight and obesity. However, an overview of meta-analyses found that 
interventions to reduce the risk of obesity in children have not shown much effect (71). 
More research is needed to study the interventions that can be effective in reducing the 
risk of adulthood overweight and obesity in children at risk.    
 
8.3. Implications for future research 
 
While our research presents some important findings, it also raises several 
pertinent research questions. These implications relate to the lack of data for 
monitoring trends and progress in reducing diabetes prevalence in Africa, and data 
about effective interventions for the prevention of HFDP, T2DM and CVD in women of 
childbearing age.  
 





There is a dearth of good quality data on T2DM prevalence in women of 
childbearing age, as we found data from 27 African countries only. Besides, data from 
nationally representative studies are also lacking. Further, three-quarter of the studies 
included in our systematic review and meta-analysis used FPG while the remainder 
used the the 2-hour OGTT. Given that the prevalence of T2DM was higher (10%) in 
studies which used the OGTT compared to those that used the FPG (6%), the 
prevalence estimate we found could be an underestimate of the true prevalence of 
T2DM in women of children bearing age. The issue of lack of good quality data could 
be addressed by using the WHO STEPWise approach, which would ensure similar 
rigorous research collection methods are used across different countries to obtain 
diabetes estimates. 
 
8.3.2. Effective interventions for the prevention of HFDP in Africa are not 
known 
 
To prevent HFDP, there is a need for interventions that are context-specific and 
informed by research findings from Africa. Research is also needed to investigate the 
best timing of these interventions, the core outcomes for the interventions and 
appropriateness to the African setting. Qualitative research may also help explain how 
women feel about the proposed interventions. Further, studies on the cost-
effectiveness of the interventions and their impact on offspring cardiometabolic 
outcomes are also needed.  
 
8.3.3. The most cost-effective screening methods for HFDP in early 




To our knowledge, there are no studies in Africa on long term cardiovascular risk 
that have been carried out in women who have HFDP detected using less stringent 
screening criteria. There is need to investigate outcomes for both offspring and mothers  
The case against universal screening for HFDP is strong due to the cost to the 
health system. However, the risk-factor based screening currently in use is based on 
factors that are not well tested in Africa. Studies are needed on risk factors for GDM 
and their relative contribution in the African context. Besides, more research is required 
to find the most cost-effective method for screening for HFDP that can be used in early 
pregnancy with good diagnostic accuracy, compared to the standard OGTT. A related 
research need is to establish criteria for the diagnosis of GDM in early pregnancy, 
preferably linked to maternal and foetal outcomes.   
8.3.4. Research on interventions to promote the uptake of the 
postpartum screening for T2DM and CVD of women with HFDP is 
needed 
 
Our findings suggest that many women could have benefitted from the postpartum 
follow-up, either with encouragement to maintain lifestyle modification or screening to 
detect diabetes early and reduce the risk of complications. Research on the best ways 
to encourage uptake of postpartum follow-up for women after HFDP is needed.  
 
8.3.5. Effective interventions to prevent or delay T2DM and CVD risk 
after HFDP in Africa are not known 
 
Apart from one ongoing trial (Trial registration: PACTR201805003336174), to our 
knowledge, there are no other data on effective interventions to reduce risk of both 
T2DM and CVD in women after HFDP. Research is needed to investigate the most 
cost-effective interventions to reduce T2DM and CVD risk in African women after 
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HFDP. Trials are also needed to investigate the best timing, type of interventions, 
length and dose and acceptability of these interventions.   
 
 
8.4. Strengths and limitations of this research study 
 
This research contributes data on the prevalence of T2DM and prediabetes in 
women of childbearing age in Africa, to date. Further, this research contributes to the 
understudied area of the effects of HFDP on the cardiometabolic health of the mother 
and her offspring in Africa.   
This research has several limitations. The lack of age-group specific data from 
many African countries resulted in the inclusion of only 27 countries in our estimate of 
the overall pooled prevalence of T2DM in women of childbearing age in Africa in the 
systematic review and meta-analysis. Further, poor data quality in some of the included 
studies in the systematic review and meta-analysis may have resulted in a T2DM 
estimate that may not be very accurate. Lastly, we found high unexplained statistical 
heterogeneity in our meta-analysis and again this affects the accuracy of the pooled 
estimates from the systematic review and meta-analysis.  
A key limitation of the PRO2D study was the absence of a control group, due to 
resource limitations. A control group would have enabled us to study the risk 
attributable to HFDP, for the future development of T2DM and CVD in women and risk 
for overweight and obesity in the offspring. Most of the women in our study were not 
assessed for T2DM at the recommended 6-week follow-up, and this could have 
contributed to the high prevalence of T2DM observed in the DIP group.   
We used routinely collected clinical data, for OGTT glucose results at HFDP, 
intra-pregnancy data and birthweight measurements. Apart from missingness in these 
data, one other disadvantage of using these data is that there may not be enough data 
quality control mechanisms in clinical settings. However, the measurement of key 
variables by clinicians who were not associated with this study was a strength as it 
reduced the risk of ascertainment bias.   
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Due to a lack of resources, we were only able to assess overweight and obesity 
in the offspring using weight and height, instead of comprehensive assessments. A 
further limitation of this research was the loss to follow-up at the 5-6 years assessment. 
However, this is typical of many longitudinal studies which have followed up women 




The high prevalence of T2DM and CVD risk factors in relatively young women 
and overweight and obesity in their offspring within 6 years of the index pregnancy 
demonstrates the need for context-specific interventions to prevent HFDP, to optimise 
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Appendix 4.1. Search Strategy 
PubMed Draft Search Strategy 
 
((((((("Diabetes Mellitus, Type 2"[Mesh]) OR Diabetes Mellitus, Type 2) OR diabetes 
type 2) OR T2DM) OR diabetes Type II) OR diabetes)) AND 
(((((((((("Adolescent"[Mesh]) OR "Young Adult"[Mesh]) OR "Adult"[Mesh]) OR "Middle 
Aged"[Mesh])) OR teenage*) OR adolescen*) OR young adult) OR adult) OR Middle 
Age*)) AND ((((((((("Prevalence"[Mesh] OR "Epidemiology"[Mesh] OR "Cross-Sectional 
Studies"[Mesh])) OR Prevalence) OR Epidemiology) OR Cross-Sectional Studies) OR 
"Longitudinal Studies"[Mesh]) OR "Cohort Studies"[Mesh]) OR Cohort Studies) OR 
Longitudinal Studies)) AND ((((((((((((Africa, Northern OR Algeria OR Libya OR Egypt 
OR Morocco OR Tunisia OR Northern Africa))) OR ((Benin OR Burkina Faso OR Cape 
Verde OR Cote d'Ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR 
Liberia OR Mali OR Mauritania OR Niger OR Nigeria OR Senegal OR Sierra Leone OR 
Togo))) OR ((Ethiopia OR Kenya OR Rwanda OR Somalia OR Sudan OR Tanzania OR 
Uganda OR Africa, Southern OR Angola OR Lesotho OR Mozambique OR Namibia OR 
South Africa OR Swaziland OR Zambia OR Zimbabwe OR Africa, Western))) OR Sub-
Saharan Africa) OR ((Africa OR Africa South of the Sahara OR Africa, Central OR 
Cameroon OR Central African Republic OR Chad OR Congo OR Democratic Republic 
of the Congo OR Equatorial Guinea OR Gabon OR Burundi OR Djibouti OR Eritrea))) 
OR (((((("Africa, Northern"[Mesh]) OR "Algeria"[Mesh]) OR "Libya"[Mesh]) OR 
"Egypt"[Mesh]) OR "Morocco"[Mesh]) OR "Tunisia"[Mesh])) OR africa) OR 
(((((((((((((((("Benin"[Mesh]) OR "Burkina Faso"[Mesh]) OR "Cape Verde"[Mesh]) OR 
"Cote d'Ivoire"[Mesh]) OR "Gambia"[Mesh]) OR "Ghana"[Mesh]) OR "Guinea"[Mesh]) 
OR "Guinea-Bissau"[Mesh]) OR "Liberia"[Mesh]) OR "Mali"[Mesh]) OR 
"Mauritania"[Mesh]) OR "Niger"[Mesh]) OR "Nigeria"[Mesh]) OR "Senegal"[Mesh]) OR 
"Sierra Leone"[Mesh]) OR "Togo"[Mesh])) OR ((((((((((((("Africa"[Mesh]) OR "Africa 
South of the Sahara"[Mesh]) OR "Africa, Central"[Mesh]) OR "Cameroon"[Mesh]) OR 
"Central African Republic"[Mesh]) OR "Chad"[Mesh]) OR "Congo"[Mesh]) OR 
"Democratic Republic of the Congo"[Mesh]) OR "Equatorial Guinea"[Mesh]) OR 
"Gabon"[Mesh]) OR "Burundi"[Mesh]) OR "Djibouti"[Mesh]) OR "Eritrea"[Mesh])) OR 
((((((((((((((((("Ethiopia"[Mesh]) OR "Kenya"[Mesh]) OR "Rwanda"[Mesh]) OR 
"Somalia"[Mesh]) OR "Sudan"[Mesh]) OR "Tanzania"[Mesh]) OR "Uganda"[Mesh]) OR 
"Africa, Southern"[Mesh]) OR "Angola"[Mesh]) OR "Lesotho"[Mesh]) OR 
"Mozambique"[Mesh]) OR "Namibia"[Mesh]) OR "South Africa"[Mesh]) OR 
"Swaziland"[Mesh]) OR "Zambia"[Mesh]) OR "Zimbabwe"[Mesh]) OR "Africa, 
Western"[Mesh]))) 
 
((((((((((((("Adolescent"[Mesh]) OR "Young Adult"[Mesh]) OR "Adult"[Mesh]) OR "Middle 
Aged"[Mesh])) OR teenage*) OR adolescen*) OR young adult) OR adult) OR Middle 
Age*)) AND ((((((((("Prevalence"[Mesh] OR "Epidemiology"[Mesh] OR "Cross-Sectional 
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Studies"[Mesh])) OR Prevalence) OR Epidemiology) OR Cross-Sectional Studies) OR 
"Longitudinal Studies"[Mesh]) OR "Cohort Studies"[Mesh]) OR Cohort Studies) OR 
Longitudinal Studies)) AND ((((((((((((Africa, Northern OR Algeria OR Libya OR Egypt 
OR Morocco OR Tunisia OR Northern Africa))) OR ((Benin OR Burkina Faso OR Cape 
Verde OR Cote d'Ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR 
Liberia OR Mali OR Mauritania OR Niger OR Nigeria OR Senegal OR Sierra Leone OR 
Togo))) OR ((Ethiopia OR Kenya OR Rwanda OR Somalia OR Sudan OR Tanzania OR 
Uganda OR Africa, Southern OR Angola OR Lesotho OR Mozambique OR Namibia OR 
South Africa OR Swaziland OR Zambia OR Zimbabwe OR Africa, Western))) OR Sub-
Saharan Africa) OR ((Africa OR Africa South of the Sahara OR Africa, Central OR 
Cameroon OR Central African Republic OR Chad OR Congo OR Democratic Republic 
of the Congo OR Equatorial Guinea OR Gabon OR Burundi OR Djibouti OR Eritrea))) 
OR (((((("Africa, Northern"[Mesh]) OR "Algeria"[Mesh]) OR "Libya"[Mesh]) OR 
"Egypt"[Mesh]) OR "Morocco"[Mesh]) OR "Tunisia"[Mesh])) OR africa) OR 
(((((((((((((((("Benin"[Mesh]) OR "Burkina Faso"[Mesh]) OR "Cape Verde"[Mesh]) OR 
"Cote d'Ivoire"[Mesh]) OR "Gambia"[Mesh]) OR "Ghana"[Mesh]) OR "Guinea"[Mesh]) 
OR "Guinea-Bissau"[Mesh]) OR "Liberia"[Mesh]) OR "Mali"[Mesh]) OR 
"Mauritania"[Mesh]) OR "Niger"[Mesh]) OR "Nigeria"[Mesh]) OR "Senegal"[Mesh]) OR 
"Sierra Leone"[Mesh]) OR "Togo"[Mesh])) OR ((((((((((((("Africa"[Mesh]) OR "Africa 
South of the Sahara"[Mesh]) OR "Africa, Central"[Mesh]) OR "Cameroon"[Mesh]) OR 
"Central African Republic"[Mesh]) OR "Chad"[Mesh]) OR "Congo"[Mesh]) OR 
"Democratic Republic of the Congo"[Mesh]) OR "Equatorial Guinea"[Mesh]) OR 
"Gabon"[Mesh]) OR "Burundi"[Mesh]) OR "Djibouti"[Mesh]) OR "Eritrea"[Mesh])) OR 
((((((((((((((((("Ethiopia"[Mesh]) OR "Kenya"[Mesh]) OR "Rwanda"[Mesh]) OR 
"Somalia"[Mesh]) OR "Sudan"[Mesh]) OR "Tanzania"[Mesh]) OR "Uganda"[Mesh]) OR 
"Africa, Southern"[Mesh]) OR "Angola"[Mesh]) OR "Lesotho"[Mesh]) OR 
"Mozambique"[Mesh]) OR "Namibia"[Mesh]) OR "South Africa"[Mesh]) OR 
"Swaziland"[Mesh]) OR "Zambia"[Mesh]) OR "Zimbabwe"[Mesh]) OR "Africa, 
Western"[Mesh]))) AND (((((("Diabetes Mellitus, Type 2"[Mesh]) OR Diabetes Mellitus, 
Type 2) OR diabetes type 2) OR T2DM) OR diabetes Type II) OR diabetes) 
Search filters  
a. human studies 
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[60.6%) 












both FPG 3688 
1891 
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DRC STEPS 
2005 [64] 
both FPG 1943 
1185 
[60.7%) 




rural FPG 3962 
2213 
[56.2%) 




both  FPG 9780 
4369 
[44.6%) 






















urban FPG 936 
196 
[20.9%) 
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Morocco  Tazi 2003 [85] both FPG 1802 
1047 
[58.1%) 
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[70.7%) 









































both OGTT 374 
137 
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South Africa  
SANHANES 
2014 [110] 
both HbA1C 4740 
3010 
[63.5%) 
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[52.5%) 



















both  FPG 1928 
1275 
[66.1%) 











































Appendix 4.3. Risk of bias of included studies 
Country Ye
ar 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 5.1. PRO2D Questionnaire 
 
 
PRO2D - The prevalence of Type 2 diabetes mellitus and associated risk factors 5 years after gestational 




Tawanda Chivese, Professor Shane Norris, Professor Naomi Levitt 
SECTION 1: GENERAL INFORMATION 
Participant study number: ……………………………………………… 




Participant suburb of residence… … … ………………… 
 
Consent has been read and obtained?               Yes, if yes continue 
 
                                                                             No, if no, STOP 
   
 Telephone………………………….. 
……………………………………………………………………………………………….. 
 2nd contact person’s details: 
 
Relationship…...………………………………..………………………….…………………..……… 
   
Telephone ……………………………………………………………………………………………. 
 Date of interview: 
 D D M M Y Y Y Y  
  
Age of participant at last birthday …………………..…………………………… 
 
 Participant date of birth: 





SECTION 2:  SOCIO-DEMOGRAPHIC INFORMATION 
 
  




What is the highest level of education 
that you have achieved? 
  
  Never went to school 1 
  Grade 1 to 7 (Primary school) 2 
  Grade 8 to 10 3 
  Matric  4 
  Tertiary / Diploma 5 
2B Are you … Employed, salaried 1 
  Self-employed 2 
  Unemployed 3 
  A full-time homemaker 4 
  A pensioner 5 
  On a disability grant 6 
  A student  
 
7 
2C Do you own a house? Yes …….. 1  No … 0 
2D What type of housing do you live in? Built formal unit 1 
  Informal shack / 
shelter/hostel/other 
2 
2E How many rooms does your house 
have? (don’t include bathroom & 




2F How many people, older than 18 years 





2G Does your household have: YES NO 
  Electricity? 1 0 
  A radio? 1 0 
  A television 1 0 
  A telephone 1 0 
  A refrigerator? 1 0 
  A personal computer (PC)? 1 0 
  A washing machine? 1 0 
            Access to tap water:  1 0 




QUESTIONS AND FILTERS 
 
CODING CATEGORIES 
            Tap outside house 1 0 
            Shared tap (4 houses) 1 0 
 Communal tap (5 or more houses) 1 0 
                 A toilet 1 0 
                 A motor car 1 0 
                 A bicycle (adults) 1 0 
2H What ethnicity do you identify yourself 
as? 
  
                  Black African 1 
  Coloured 2 
  White  3 
  Indian/Asian  4 
  Other  
 
5 
2I Are you……. Single 1 
  Married (civil) 2 
  Widowed/divorced 3 
  Other  4 
 If you answered other, please specify  
……………………………………… 
 





2N What was the result of the test, if you 
tested for diabetes? 
Diabetes ……….1 
 
No diabetes …….2 
 
Can’t remember ……3 
 
Not applicable ……..4 
 
 
SECTION 3: SELF-REPORTED REPRODUCTIVE HISTORY  
 




Would you say your health is poor, average, good, or very 
good/excellent?  
 
Poor ........................ 1 
Average .................. 2 
Good ....................... 3 






Do you personally think that you are underweight, normal 




Underweight ............. 1 
Normal weight .......... 2 
Overweight ............... 3 
Don’t know ............... 9 
3C How many times have you been pregnant?   
……………………… 
3D Have you ever had any miscarriages? Yes ………. 1 
No ……… 0 
 
3E How many children do you have?  
 






























       
       
       
       
       
3G Before your pregnancy in 2010/2011, were you ever told by 
a doctor or a nurse that you had diabetes? 
Yes……………1 
No………………0 
3H If you answered yes to question 3G, were you being treated 




3I If you were being treated for diabetes before your pregnancy 
in 2010/2011, what treatment were you on? 
Insulin only……1 
Orals pills only…2 
Insulin & oral pills…3 
Diet………………..4 
Not applicable…….5 
3J After your pregnancy in 2010/2011, were you given a 
referral letter to have your blood sugar checked? 
Yes………………1 
No………………0 
3K Did you go to have your blood sugar checked (for diabetes), 






3L If you went to be checked for diabetes, how many months 
after your pregnancy in 2010/2011 did you go? ……………….. 
3M If you went to be checked for diabetes after your pregnancy 
in 2010/2011, what test did you have? 
 
Oral Glucose 






Don’t remember ….4 
 
Not applicable ….5 
3N If you went be checked for diabetes after your pregnancy in 




No diabetes …….2 
 




3O If you did not go to be checked for diabetes after your pregnancy in 2010/2011, why 









Since your pregnancy in 2011 has a doctor or nurse or health worker at a clinic or 
hospital told you that you have or have had any of the following conditions: 
 
4A 
High Blood Pressure?  Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 
4B If you have high blood pressure, are 
you being treated?  
Yes…………1 
No…………..0  





Heart attack or angina (chest pains)? Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 
4D If you have had a heart attack, are you 
being treated?  
Yes…………1 
No………….0  






Stroke? Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 








High blood cholesterol or fats in the 
blood? 
Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 
4H If you have had high blood cholesterol, 
are you being treated?  
Yes…………1 
No………….0  




Diabetes  Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 
4J If you were told that you have diabetes, 
what treatment are you on?  
 
Diet only……………0 
Orals only…………. 1 
Insulin only ……….. 2 
Orals and insulin…..3 
No treatment ……….  4 






Yes .............................................................. 1 
No................................................................ 0 
Don’t know ................................................... 9 
4L If you have had kidney disease, are you 
being treated?  
Yes…………1 
No………….0  





Yes .............................................................. 1 
No………………….……………………………0 
Don’t know……………………………………..9 
4N If you have had cancer, are you being 
treated? 
 




Yes .............................................................. 1 
No………………….……………………….0 
Don’t know…………………………………9 
4P If you have had a chronic respiratory 
disease, are you being treated?  
Yes…………1 
No………….0  




QUESTIONS AND FILTERS 
 
CODING CATEGORIES 
 Now I want to ask you about any medication you take: 
 
4Q 
Do you use any medicine regularly or 
daily that a doctor or nurse has 
prescribed? 
 
Yes  ............................................................. 1 




QUESTIONS AND FILTERS 
 
CODING CATEGORIES 
 Don’t know ................................................... 9 
 









Diabetic medications (Insulin),      
Diabetic medications (Oral 
hypoglycaemics), e.g. 
 
    
Blood pressure medication 
 
    
Raised blood cholesterol 
medications e.g. Statins 
 
    
Others (Specify) 
 
    
 
SECTION 5: FAMILY MEDICAL HISTORY 
 
Now I would like to ask you about your family.  Do you have a close blood relative 
(father, mother, brother, sister or child) who has ever been diagnosed by a doctor or 
nurse with any of the following conditions: 






Pressure?   
 
Yes .......................................................... 1 
No ............................................................ 0 





Heart attack or 





Yes .......................................................... 1 
No ............................................................ 0 







Yes .......................................................... 1 
No ............................................................ 0 







Yes .......................................................... 1 
No ............................................................ 0 
Don’t know ............................................... 9 
 
SECTION 6: ALCOHOL USE 
 
In this section I would like to ask whether you drink alcohol or not and how you drink it 
263 
 
6A Have you ever consumed any alcohol such as beer, wine, 
spirits or sorghum beer?  
IF NO, GO TO SECTION 7 
Yes …………………..1 
No…………………….0 
6B Have you consumed any alcohol within the past 30 days?  Yes …………………..1 
No…………………….0 
6C If yes, during the past 30 days, how frequently have you 
had at least one standard alcoholic drink? 
 
Daily                               1 
5-6 days per week        2 
3-4 days per week        3 
1-2 days per week        4 
1-3 days per month         5 
Less than once a month    6 
6D IF NO, have you stopped drinking due to health reasons, 
such as a negative impact on your health or on the advice 
of your doctor or other health worker? 
Yes …………………..1 
No…………………....0 








6G Have people annoyed you by criticizing your drinking? Yes……………………..1 
No………………………0 
6H Have you ever felt bad or guilty about your drinking? Yes…………………….1 
No……………………..0 
6I Have you ever had a drink first thing in the morning to 
steady your nerves or get rid of a hangover? 
Yes……………………1 
No……………………..0 
SECTION 7: SMOKING HISTORY  
 
Now, I would like to ask you whether you smoke tobacco products or not and if you do, 
how you do so. 
7 
Have you ever smoked cigarette products? 
 


















How old were you when you first started smoking daily?        
Years old 
    
7D 
If you do not remember how old you were, do you remember how long ago you started 
smoking daily?                                                                                                     
 1 WEEKS AGO   
 2 MONTHS AGO   
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 3 YEARS AGO   
7E  On average, how many of the following items do you smoke each day? [NONE = 00] 
 1 Manufactured cigarettes?   
 2 Hand-rolled cigarettes?   
 3 Pipes full of tobacco?   
 4 Cigars/Cheroots/Cigarillos?   





7G How old were you when you first stopped smoking daily?  Years old   
 Don’t remember/not sure = 77 
7H 
If you do not remember how old you were, do you remember how long ago you stopped 
smoking daily?  
 1 Weeks Ago   
 2 Months Ago   
 3 Years Ago   
7I  
Before you stopped smoking, how many of the following items did you smoke each day?
 [NONE = 00] 
 1 Manufactured cigarettes?   
 2 Hand-rolled cigarettes?   
 3 Pipes full of tobacco?   
 4 Cigars/Cheroots/Cigarillos?   
 ASSESSING USE OF SMOKELESS TOBACCO 
7J 






 If No, go to question 7L 





 If No, go to question 7L 
7L  On average, how many times do you use each of the following items per day? [None = 00] 
 1 Snuff (by mouth)?   
 2 Snuff (by nose)?   
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 3 Chewing tobacco?   
7M 












During the past 30 days, did someone smoke in closed areas in your workplace 







SECTION 8: PSYCHOSOCIAL HEALTH  
We are now going to ask you questions relating to certain aspects of our lives. Some of the 
questions may seem the same but please bear with us because they are not exactly the same.  
A) ORIENTATION TO LIFE QUESTIONNAIRE (SOC-13) 
Below is a series of questions relating to various aspects of our lives. For each question, you 
SHOULD first select the response which most closely resembles how you feel.  Then, on a 
scale from 1 to 7, you SHOULD select the number closest to that response which best 
describes how you feel. You can choose any number between 1 and 7.  Please give only one 
answer to each question. 
   
1.  Do you have the feeling that you don't really care about what goes on around you? 
                    
           very seldom                  very often 
           or never 
     1               2                3               4               5               6              7 
 
 
 2.  Has it happened in the past that you were surprised by the behaviour of people 
whom you thought you knew well? 
                    
           never                  always 
           happened                 happened 





3.  Has it happened that people whom you relied/depended on disappointed you? 
                    
           never                  always 
           happened                 happened 
                  1               2                3               4               5               6               7 
 
   
4.  Until now your life has had: 
                    
        no clear direction               very clear 
direction 
        or purpose at all                           and purpose 
     1               2                3               4               5               6               7 
 
   
5.  Do you have the feeling that you're being treated unfairly? 
                    
            very often                 very seldom 
     1               2                3               4               5               6               7 
 
 
6.  Do you have the feeling that you are in an unfamiliar situation and don't know what to 
do? 
                     
            very often                very seldom  
or never 
     1               2                3               4               5               6               7 
 
  
7.  Doing the things you do every day is: 
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         a source of                  a source of frustration  
        deep pleasure                  and boredom 
        and satisfaction 
     1               2                3               4               5               6               7 
 
 
8.  Do you feel confused or have very mixed-up feelings and ideas? 
                
very often                  very seldom                           
                                                                                                                       or never 
      1               2                3               4               5               6               7 
 
 
9.  Does it happen that you have feelings inside that you don’t like or would rather not 
feel? 
           
             very often                   very seldom  
                                                                                                                      or never 
                  1               2                3               4               5               6               7 
 
 
10.  Many people--even those who are confident and successful--sometimes feel like 
losers in certain situations.  How often have you felt this way in the past? 
                                
   never                  very often 
     1               2                3               4               5               6               7 
 
11.  When something happened, have you generally found that: 
          
         you over-                   you saw things  
         estimated or                  in the right 
         underestimated                              perspective? 
         its importance? 





12.  How often do you have the feeling that there's little meaning in the things you do in 
your daily life?                          
 very often                 very seldom or never 
     1               2                3               4               5               6               7 
 
 
13.  Sometimes people have strong feelings that they cannot keep under control. How 
often do you have feelings that you're not sure you can keep under control? 
                       
  very often                 very seldom or never 








B) LOCUS OF CONTROL 
 





Disagree Neutral Agree 
Strongly 
agree 
a) At work, I feel I have control over 
what happens in most situations.  
     
b) I feel what happens in my life is 
often determined by factors beyond 
my control. 
     
c) Over the next 5-10 years, I expect 
to have more positive than negative 
experiences. 
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d) I often have the feeling I am being 
treated unfairly. 
     
e) In the past 10 years my life has 
been full of changes without my 
knowing what will happen next. 
     
f) I gave up trying to better my life a 
long time ago. 
     
 
    
C) LIFE EVENTS QUESTIONNAIRE   
 
Have any of the following life events or problems happened to you during the last 6 
months?  How about more than 6 months ago?  If so, please also rate the impact on 
you. 
1. You yourself suffered a serious illness, injury or an assault.      Yes/No.   If no, go to 
next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
2. A serious illness, injury or assault happened to a close relative.     Yes/No.   If no, go to 
next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 





Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
3. Your parent, child or spouse died.     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
4. A close family friend or another relative (aunt, cousin, Grandparent) died.     Yes/No.    
If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 




Did this occur in past 6 months?  
 
If yes, Impact:    
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
6. You broke off a steady relationship.     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
7. You had a serious problem with a close friend, neighbor or relative.     Yes/No.   If no, 
go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
Yes  No  
 





8. You became unemployed or you were seeking work unsuccessfully for more than one 
month. 
     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
9. You were fired from your job.     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
10. You had a major financial crisis.     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 





Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
11. You had problems with the police and a court appearance.     Yes/No.   If no, go to 
next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 
None  Some  Significant  
 
12. Something you valued was lost or stolen.     Yes/No.   If no, go to next question. 
 
Did this occur in past 6 months?  
 
If yes, Impact:    
 
 
Yes  No  
 
None  Some  Significant  
 
 
Did this occur more than 6 months ago?  
 
If yes, Impact:  
 
 
Yes  No  
 








The next questions are about the time you spend doing different types of physical 
activities.  This includes activities you do at home, at work, travelling from place to 
place and during your spare time.  You are requested to answer the questions even if 
you don’t consider yourself to be an active person. 
 
 
Occupation-Related Physical Activity (paid or unpaid work):  When answering the 




Does your work involve vigorous activities, (like heavy lifting, digging, or heavy 
construction) 





 If No, go to question 9D 
 
9B In a usual week, how many days do you do vigorous activities as part of your work? 
 DAYS:   
 
9C 
On a usual day on which you do vigorous activities, how much time do you spend doing 
such work? 
 1 HOURS:   
 2 MINUTES:    
 
9D 
Does your work involve moderate-intensity activities, (like brisk walking or carrying light 
loads) 





 If No, go to question 9G 
  
9E 
In a usual week, how many days do you do moderate-intensity activities as part of your 
work? 
 Days:   
9F 
On a usual day on which you do moderate-intensity activities, how much time do you 
spend doing such work? 
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 1 Hours:   
 2 Minutes:    
 
Travel-related physical activity: other than activities that you’ve already mentioned, i 
would like to ask you about the way you travel to and from places (to work, to shopping, 
to market, to church, etc.). 
9G 
Do you walk or use a bicycle (pedal cycle) for at least 9 minutes at a time to get to and 
from places? 





 If no, go to question 9J 
9H 
In a usual week, how many days do you walk or cycle for at least 9 minutes to get to and 
from places? 
 Days:   
9I On a usual day, how much time do you spend walking or cycling for travel? 
 1 Hours:   
 2 Minutes:    
 
Non-work related and leisure time physical activity:  the next questions ask about 
activities you do in your leisure or spare time, for recreation or fitness.  Do not include the 
physical activities you do at work or for travel already mentioned. 
9J In your leisure or spare time, do you do any vigorous activities (like running or strenuous  





 If no, go to question 9M 
9K 
In a usual week, how many days do you do vigorous activities as part of your leisure or 
spare time? 
 Days:   
9L How much time do you spend doing this on a usual day? 
  1 Hours:   
            2 Minutes:    
9M 
In your leisure or spare time, do you do any moderate-intensity activities (like brisk 
walking, cycling or 







 If no, go to question 9P 
9N 
In a usual week, how many days do you do moderate-intensity activities as part of your 
leisure  
 
Or spare time?           
Days: 
  
9O How much time do you spend doing this on a usual day? 
  Hours:   
  Minutes:    
 
Sitting / resting activity:  now I would like to ask you about the time spent sitting or 
resting, not including sleeping, in the past 7 days.  This may include time sitting at a 
desk, visiting friends, reading, or sitting down to watch television during working hours 
and leisure or spare time. 
9P 
Over the past 7 days, how much time did you spend sitting or reclining (lying) on a usual 
day (excluding sleeping)? 
  Hours:   
  Minutes:    
9Q 
On average, how much time, each day, do you spend 
watching television? 
    
  Hours:   









1. Are you on a special diet that has been prescribed for you e.g. by a doctor or one that you 





2. If NO, go to question 4. 




3. How long have you been on that diet?__________months/years. 
 




   
    IF YES, what do you take? 
 
 
 Name of product Amount/day 
(or how many tablets) 
Vitamins/vitamins and minerals   
Tonics   
Vitamin D   
Calcium   
Body building preparations   

















Don’t know 4 
 




8.  If yes, how much salt do you add to your food each day? 
¼ teaspoon 1 
½ teaspoon 2 
¾ teaspoon 3 
1 teaspoon 4 








10. If yes, how much Aromat do you add to your food each day? 
¼ teaspoon 1 
½ teaspoon 2 
¾ teaspoon 3 
1 teaspoon 4 









11. There are some factors which influence the choice of foods we eat.  Which of the following 
statements are true for you?  
 
 







13.  If YES, in an average month how often do you eat from these fast food shops? …………… 
 
 
Dietary intake assessment  
NB! Think back to the last two weeks and divide the food cards into two piles i.e. foods you did eat 
and foods you did not eat.  
Now go through the pile of cards that you did eat.  
Tell me how many times per day or per week did you eat …(complete column E or F) 
Describe the food item in column B (if applicable) 
Select the usual portion size in column D (encircle) and Indicate the amount consumed in column 
C 
A. Food Item (with FMP 
numbers) 














DAIRY – BLUE      
1. Sugar in tea/coffee   Tbs/tsp        
heaped/level 
  
1. Sugar in cooking (veg/ 
porridge) 





Agree Disagree Strongly 
Disagree 
I choose to eat certain foods because they taste 
good 
1 2 3 4 
The food I eat depends on whether it is expensive  1 2 3 4 
I choose to eat certain foods because it looks 
good 
1 2 3 4 
The food I choose to eat differs according to my 
mood (i.e. happy/sad) 
1 2 3 4 
My hunger level determines what type of food I 
eat. 
1 2 3 4 
I choose foods which are not time consuming to 
prepare 
1 2 3 4 
I consider whether a food is good for my health 
before eating the food. 
1 2 3 4 
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A. Food Item (with FMP 
numbers) 














2. Milk in tea/coffee Full cream / low fat 
(2%)/ fat-free 
 Little / milky              
2.Milk with porridge Full cream/ low fat 
(2%)/ fat-free 
 How much? 
Bowl  
  
3. Buttermilk/maas   Small or large 
glass 
  
4. Milk drinks Type: Steri-stumpie, 
etc. 
 Small or large 
glass or ml 
  
5. Yoghurt Plain / fruit & 
sweetened 
Full cream/low fat/fat 
free 




6. Cottage cheese Full fat/ low fat/ fat 
free 
 Heaped Tbs   
7. Hard Cheese   Slice / matchbox   
8. Processed cheese Type  Wedges/Tbs   
9. Ice cream & Ice lollies Type  Scoops or 
heaped Tbs or nr 
of lollies 
  
STARCH - BROWN      
1. Brown bread/rolls   Slice   
1. White bread/rolls   Slice   
1. Whole wheat /Low GI bread   Slice   
2. Fat cakes   Small = 1 
matchbox;  
Med = 2 
matchboxes 
Lrg = 3 
matchboxes 
  
3. Breakfast cereals Specify type 
 
 ½ or ¾ or full 
Bowl  
  
4. Maize porridge soft   ½ or ¾ or full 
Bowl 
  
4. Maize porridge stiff   ½ or ¾ or full 
Bowl  
  
4. Mabele/martabella soft   ½ or ¾ or full 
Bowl 
  





A. Food Item (with FMP 
numbers) 














4. Oats   ½ or ¾ or full 
Bowl 
  
5. Pasta without sauce White/ whole-wheat 
pasta 
 Heaped serving 
spoon 
  
6. Pasta dishes White/ whole-wheat 
pasta 
 Heaped serving 
spoon 
  
7. Rice White/brown  Heaped serving 
spoon 
½ cup dough 
model 
  
7. Samp/mealie meal   Heaped serving 
spoon 
½ cup dough 
model 
  
7. Wheat rice   Heaped serving 
spoon 
½ cup dough 
model 
  
8. Pizza and savoury tart Type  pic in booklet 
 
  
FATS - TAN      
1. Brick margarine Type  Tbs/tsp        
heaped/level 
  
1. Tub margarine Type  Tbs/tsp        
heaped/level 
  
1. White margarine Type  Tbs/tsp        
heaped/level 
  
1. Butter Type  Tbs/tsp        
heaped/level 
  
2. Animal fat i.e lard   Tbs/tsp        
heaped/level 
  
3. Cream and substitutes   Tbs/tsp 
heaped/level 
  
4. Oils Sunflower / fish oil / 




5. Salad dressing   Tbs/tsp 
heaped/level 
  





A. Food Item (with FMP 
numbers) 














SPREADS - PINK      
Cheese spread Type  Thin / med /thick   
Honey/syrup   Heaped Tbs/tsp   
Jam Regular/low sugar  Heaped Tbs/tsp   
Peanut butter Regular/no sugar  Heaped Tbs/tsp   
Sandwich spread Type  Heaped Tbs/tsp   
EGGS - YELLOW      
Boiled   1 egg   
Fried   1 egg   
Omelet   1egg   
Scrambled   1 egg   
FRUIT - ORANGE      
1. Apples, pears   Small / med 
/large 
  
2. Bananas   Small / med 
/large 
  
6. Grapes   Nr of grapes   
8. Mango/paw paw   ½ cup Slices / 
cubes 
  
9. Melons - sweet   ½ cup, pic per 
booklet 
  
11. Oranges, Naartjies   Small / med 
/large 
  
12. Peaches   Small / med 
/large 
  
16. Dried fruit   nr   
17. Fruit juice Type  ml or small glass 
or tall glass 
  
SOUP, LEGUMES, NUTS – 
pale green  
     
1. Soups   Ladle/bowl   
2. Legumes & lentils   ½ cup dough 
model 
  
3. Seeds & nuts, peanuts   Handful   
FISH AND SEAFOOD - 
BEIGE 
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A. Food Item (with FMP 
numbers) 














1. Fried fish   Picture in 
booklet 
  
2. Grilled/smoked/dried fish Type  Picture in 
booklet 
  
3. Plichards & sardines In oil/brine  Tin   
3. Tuna - tinned In oil/brine  Tin   
MEAT - RED      
1. Beef & Ostrich Cut  Matchbox   
2. Patties & mince Type: beef/ostrich 
Regular/lean/extra-
lean 
 Small/medium   
3. Burgers & take-aways Type     








5. Cold meat Type  slice   
7. Meat pies Type  Size - ruler   
8. Mutton Type  Line drawings   
9. Pork Type  Line drawings   
10. Sausage & vienna Type  Ruler and thick 
or thin 
  
11. Traditional & organ meats Type  Serving spoon   
13. Dry sausage & biltong Type  ½ cup/ length    
VEGETABLES - GREEN      
2. Avocado   ½ or ¼ etc.   
5. Orange/yellow veg 
(butternut, pumpkin, carrots, 
sweet potato, gem squash, 
mealies) 
  ½ cup dough 
model 
  
6. Green veg (spinach, peas, 
green beans, broccoli) 
  ½ cup dough 
model 
  
7. Cabbage, cauliflower, 
lettuce 





A. Food Item (with FMP 
numbers) 














12. Mixed vegetables   ½ cup dough 
model 
  
15. Potatoes   Nr med   
16. Potato chips   ½ cup   
20. Tomatoes   Nr or ½ cup   
BISCUITS, CAKES, 
PUDDINGS 
     
1. Biscuits/cookies Type  nr   
2. Biscuits/savoury Type  nr   
3. Muffins/scones Type  Picture in file   
4. Cakes and tarts Type  Line drawings   
5. Doughnuts/éclairs Type  nr   
6. Pancakes/waffles Type  nr   
7. Pudding/custard Type  bowl   
8. Rusks Type  nr   
SNACKS, SWEETS & COLD 
DRINKS - PINK 
     
1. Carbonated cold drinks Specify  ml or tin or small 
glass or tall 
glass 
  
1. Diet cold drinks Specify  ml or tin or small 
glass or tall 
glass 
  
2. Energy drinks Specify  ml or tin or small 
glass or tall 
glass 
  
2. Squashes Specify  ml or tin or small 
glass or tall 
glass 
  
3. Crisps Specify  small packet – 
40g 
  
4. Sweets  Specify  nr   
4. Chocolates Specify  50g bar or slab 
or nr of blocks 
from slab 
  
SAUCES AND CONDIMENTS 
- GRAY 
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A. Food Item (with FMP 
numbers) 














1. Cheese and white sauces Specify  Tbs   
2. Tomato sauce & other Specify  Tbs   
ALCOHOLIC DRINKS - 
GRAY 
     






2. Wine White/red/rose  Wine glass per 
booklet 
  
3. Spirits Type 
Mixed with? 




4. Liquers and fortified wine Type  Small glass   
Other      
 
SECTION 11A: MEASUREMENTS (MOTHER ANTHROPOMETRY AND BIOCHEMISTRY) 
Weight:       kg 
Height:      cm 
Waist circumference:      cm 
Hip circumference:      cm 
During the past two weeks, have you been treated for raised blood pressure with drugs 
(medication) prescribed by a doctor or other health worker? 
                                                           Yes 






Discard 1st blood pressure reading      
    1st Systolic blood pressure    mmHg 
1st Diastolic blood pressure :     mmHg           
1st Heart rate :      
2nd  Systolic blood pressure :     mmHg 
2nd  Diastolic blood pressure :     mmHg           
2nd Heart rate :      
3rd Systolic blood pressure :     mmHg 
3rd Diastolic blood pressure :     mmHg           
3rd Heart rate : 
    
 
 
SECTION 11B: MEASUREMENTS (CHILD ANTHROPOMETRY) 
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CHILD      
Weight at 5 years:       kg 
Height at 5 years:      cm 
At birth, head circumference:      cm 
At birth, length:      cm 
Birthweight:      gm 
Gestational age    weeks 
CHILD 2, IF TWINS     
Weight at 5 years:       kg 
Height at 5 years:      cm 
At birth, head circumference:      cm 
At birth, length:      cm 
Birthweight:      gm 
Gestational age     weeks 
 
 
BLOOD TEST RESULTS 
 Rapid 
test 
results Today, have you taken insulin or other drugs (medication) that have 





During the past two weeks, have you been treated for raised cholesterol 









Oral glucose tolerance test (OGGT) 
(mmol/ℓ) 
Fasting glucose 0 minutes  
  
 Blood glucose 120 minutes   
Insulin (MIU/mℓ)  0 minutes    
Insulin (MIU/mℓ) 120 minutes   
 Total cholesterol (mmol/ℓ)   
 HDL cholesterol (mmol/ℓ)   
 Triglycerides (mmol/ℓ)   
 LDL cholesterol (mmol/ℓ)   
    
 




The following questions relate to your usual sleep habits during the past month only.  Your 
answers should indicate the most         accurate reply for the majority of days and nights in the 
past month.  Please answer all questions.  
During the past month,  
1. What time have you usually gone to bed? ………………………. 
 
2. How long (in minutes) has it taken you to fall asleep each night?  ………………… 
 
3. What time have you usually gotten up in the morning?  …………………………… 
 
4. a. How many hours of actual sleep did you get at night? ……………….. 
 
          b.  How many hours were you in bed?  …………………………… 
 
5.  During the past month, how 
often have you had trouble 




Less than  





Three or more  
times a week  
(3) 
a.  Cannot get to sleep within 30 
minutes 
    
b.  Wake up in the middle of the 
night or early morning 
    
c.  Have to get up to use the 
bathroom 
    
d.  Cannot breathe comfortably     
e.  Cough or snore loudly     
f.  Feel too cold     
h. Have bad dreams     
i.  Have pain       
j.  Other reason (s), please 
describe, including how often you 
have had trouble sleeping 
because of this reason (s): 
    
6.  During the past month, how 
often have you taken medicine 
(prescribed or “over the   
counter”) to help you sleep? 
    
7.  During the past month, how 
often have you had trouble 
staying awake while driving, 
eating meals, or engaging in 
social activity? 
    
8.  During the past month, how 
much of a problem has it been for 
you to keep up enthusiasm to get 
things done? 
    
9.  During the past month, how 
would you rate your sleep quality 
overall?    
Very good  
(0)  





Very bad (3)  




SECTION 13: CHILD DATA 
 
Child’s name: …………………... 
 
Child’s date of birth …………         D D M  M Y Y Y Y 
 
Child age (years) ……         Child gender (male or female?) ………….  Race ..................... 
How was the child delivered at birth?                               Normal delivery……………1 
                                                                                          Caesarian section ………...2 
                                                                                          Breech ……………………...3 
                                                                                         Other, specify……………….4 
Is the child taking any medications?                                                           Yes……………….1 
                                                                                                                      No……………….0 
 
Has the child ever been hospitalized for at least 1 week with a serious illness?       Yes……1 
                                                                                                                                     No…….2 
 
If yes, list the medications below 
Medication Reason Date started Date stopped Prescribed by 
     
     
     
     
 
Further Study Participation 




THANK YOU FOR PARTICIPATING IN THE PRO2D STUDY. HAVE A GOOD DAY 
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Appendix 5.3. PRO2D participant consent 
 
  
Participant information leaflet and Consent Form 
Research Title: The prevalence of Type 2 diabetes mellitus and associated risk factors 
5 years after gestational diabetes mellitus in South Africa 
Principal Investigators: Professor Naomi Levitt, Professor Shane Norris, Professor 
Christina Zarowsky, Tawanda Chivese 
Contact Address:   Chronic Disease Initiative for Africa, J47 Room 86, Old Groote 
Schuur Hospital Building Observatory, 7935, Cape Town 
Telephone:   +27 21 4066572  
Fax:    +27 21 4486815  




You are being invited to take part in a research project which asks the question: How 
many women who had diabetes in their pregnancy have diabetes 5 years later?  
This research project is being conducted at the University of Cape Town and the 
University of the Witwatersrand in Johannesburg. A researcher from the University of 
Montreal (Christina Zarowsky) will also help with knowledge on how to carry out 
research properly.  
Most women who had diabetes during pregnancy recover from the diabetes after the 
birth of their babies, but they have a high chance of developing Type 2 diabetes 
sometime later. Type 2 diabetes is a chronic condition that affects the way your body 




diabetes earlier we can start treatment sooner and this may cause fewer long term 
problems.  
We do not know how many women with diabetes during pregnancy end up with type 2 
diabetes in South Africa. We also do not know what other factors lead to increased 
chance of diabetes in this situation. Knowing these factors will enable us to develop 
better programs to reduce the risk of diabetes in women. Additionally, knowing factors 
that increase the chance of their children being overweight can help lower the risk of 
them developing diabetes and heart disease later in their life. 
Ethical considerations  
This research has been approved by the University of Cape Town Human Research 
Ethics Committee (Ethics approval number 656/2015). The research will be carried out 
according to the Declaration of Helsinki, which protects people who take part in 
research (Fortaleza, Brazil 2013).  
You are free to say yes or to say no. If you say no, your medical care will continue just 
as before, and it will not be held against you. You are also free to withdraw from the 
study at any point, even if you do agree to take part. If you volunteer to take part in the 
study, you will only be included if you give written informed consent. 
Please ask the study staff any questions about any part of this project that you do not 
fully understand.  
Why have you been invited to participate? 
We are inviting all women who live in Cape Town and Soweto who received treatment 
for diabetes during pregnancy at Groote Schuur Hospital and Chris Hani Baragwanath 
Hospital to take part in the research.  
What will your participation entail? 
You have been asked to come to the Groote Schuur Hospital (or Chris Hani 
Baragwanath Hospital, delete inapplicable) in order to take part in the research. Your 
participation will be for two and a half hours. You will be asked to complete a 
questionnaire and have blood taken from a vein in your arm before and after drinking 
sugar water. In your blood, we will measure glucose, fats and other factors associated 
with diabetes. We will also store 5ml of your blood, in case we need to retest your blood 
or carry out additional tests related to the study. We will seek permission from the 
University of Cape Town Human Research Ethics Committee before we do any 
additional tests. This stored blood will be destroyed 2 years after the study is finished, if 
it has not been used.  
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For the diabetes test, you are requested to fast overnight before the test can be done. 
We will also measure your blood pressure (BP), height, weight and how wide your waist 
and hips are. We will also look for information about your pregnancy in your hospital 
folder. This information will include the sugar level that was in your blood when you 
were pregnant, any illnesses you had during the pregnancy, and how much your baby 
weighed when he/she was born. 
An interviewer will ask you some questions using a questionnaire. These question may 
help us identify a pattern of who is more likely to have diabetes. An example of the 
questions we are asking is whether you or any of your family members has ever been 
diagnosed with diabetes. 
 
Will you benefit from taking part in this research? 
If any illnesses (such as undiagnosed diabetes or high blood pressure) are identified 
during the research then you will be referred to a clinic for follow-up and management. 
You will also be told the results of all the tests that will be done. 
Are there any risks involved in your taking part in this research? 
We will take blood samples from the forearms. The risk are very small. Some of the 
potential risks in the blood collection include infection, delayed healing, bruising and 
some physical pain. The blood samples will be drawn using experienced nurses to 
minimize the risks. 
Your name and personal details will be kept strictly confidential and will not be given to 
anyone to minimise the risk of improper disclosure of information.  
What if Something Goes Wrong? 
The University of Cape Town (UCT) has insurance which will compensate you if you 
suffer injuries or harm during your participation in this research. This compensation will 
pay for reasonable medical charges and this will be according to the South African 
Good Clinical Practice Guidelines (DoH 2006), based on the Association of the British 
Pharmaceutical Industry Guidelines (ABPI) in the event of an injury or side effect 
resulting directly from your participation in the trial. You will not be required to prove 
fault on the part of the University. 
The University will not be liable for any loss, injuries and/or harm that you may sustain 
where the loss is caused by 
• The use of unauthorised medicine or substances during the study 
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• Any injury that results from you not following the protocol requirements or the 
instructions that the study doctor may give you 
• Any injury that arises from inadequate action or lack of action to deal adequately 
with a side effect or reaction to the study medication 
• An injury that results from negligence on your part 
 By agreeing to participate in this study, you do not give up your right to claim 
compensation for injury where you can prove negligence, in separate litigation. In 
particular, your right to pursue such a claim in a South African court in terms of 
South African law must be ensured. Note, however, that you will usually be 
requested to accept that payment made by the University under the SA GCP 
guideline 4.11 is in full settlement of the claim relating to the medical expenses.  
An injury is considered trial-related if, and to the extent that, it is caused by study 
activities. You must notify the study doctor immediately of any side effects and/or 
injuries during the trial, whether they are research-related or other related 
complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your 
injury came about because you chose not to follow the instructions that you were 
given while you were taking part in the study. Your right in law to claim 
compensation for injury where you prove negligence is not affected. Copies of these 
guidelines are available on request. 
If you do not agree to take part, what alternatives do you have? 
Not taking part in the study will not change your future care or treatment when you go to 
hospitals or clinics. You will be treated the same as other women who decide to 
participate in the study. The researchers are not the same people as your usual doctors. 
Who will have access to your medical records and what information will they 
collect? 
All personal information collected will be treated as confidential and access to it will be 
strictly controlled and limited to the researchers. The information collected from your 
medical records will include information about your pregnancy, whether you had any 
illnesses during that pregnancy, the level of sugar in your blood and blood pressure 
during that pregnancy and whether your child had any problems when they were born. 
Your name will be removed from all samples and information provided as soon as 




Will you be paid to take part in this study and are there any costs involved? 
We will give you a R150 food voucher redeemable at Shoprite to thank you for the time 
you spend during the study. You will not be able to buy alcohol and smoking products 
using this voucher. We will compensate you for your travelling expenses. 
Please ensure that you have carefully read and understood this information sheet and 
been given a copy to keep for yourself.  
Contact details of researchers: For any questions or concerns, please feel free to 
contact the researchers whose details are listed below: 
 
Tawanda Chivese                         Email: tchivese@gmail.com 
       Tel: 0216505131 
Professor Naomi Levitt    Email: Naomi.Levitt@uct.ac.za 
       Tel: 0216505110 
Professor Shane Norris    Email: san@global.co.za 
Professor Christina Zarowski   Email: czarowsky@gmail.com 
 
You may contact the University of Cape Town Human Research Ethics Committee if 
you have any questions or concerns your rights and welfare. The contact details are 
listed below    
Email: sumayahariefdien@uct.ac.za 
Tel: 021 406 6338 












PARTICIPANT CONSENT  
 
Study Title: The prevalence of Type 2 diabetes mellitus and associated risk factors 5 
years after gestational diabetes mellitus in South Africa 
By signing this document: 
I confirm that I have read the above information and understand it. I confirm that I have 
had an opportunity to ask questions and I am satisfied with the answers and 
explanations that have been given to me. 
I give my permission for the researchers to use the information in my medical chart for 
the purposes of this research. 
I agree to have left over serum from my blood sample kept and then frozen.  
I understand that my participation in this research is voluntary and I am free to withdraw 
at any time without having to give a reason. 
Please tick one of the boxes below: 
  YES, I would like to take part in this study 
  NO, I do not wish to take part in this study 
Name of research participant: ……………………………….   Signature………………….   
Date: ………………… 
 
Name of researcher: ……………………………….                    Signature………………….   
Date: ………………… 
 





If participant is not able to write: 
Thumbprint of participant………………………………………………………………………. 
Date ……………………… 






Postcode   
Telephone  
Cell   
Secondary cell  
Next of kin telephone  
Next of kin cell  
Next of kin address  
Date of birth  








Appendix 5.4. PRO2D Chapter 5 Supplementary materials 
S4 Table 1. Comparison of participants followed up 5-6 years later and the participants lost to follow-
up 
  Not followed-up, N 
= 278 
Followed-up, N = 
220 
Age at booking Median (IQR) years 31 (26-35) 31 (27-35) 
Number of pregnancies Median (IQR) 3 (2-4) 3 (2-4) 
Number of live births Median (IQR) 1 (1-2) 1 (0-2) 
Gestational age at booking  Median (IQR) weeks 17 (13-22) 15 (11-21) 
Syphilis (VDRL positive) n (%) 5 (1.8) 4(1.8) 
HIV positive n (%) 19 (6.9) 12 (5.5) 
CD4 count Median (IQR) cells/l 454 (406-545) 492.5 (364-774) 
BMI at booking Median (IQR) kg/m2 32.7 (27.6-38.4) 34.6 (28.8-41.4) 
Random blood glucose Median (IQR) mmol/l 12.7 (11.4-14.4) 12.7 (11.2-14.1) 
Fasting plasma glucose at HFDP 
diagnosis 
Median (IQR) mmol/l 5.9 (5.3-6.9) 5.8 (5.1-6.5) 
1-hour OGTT plasma glucose at GDM 
diagnosis 
Median (IQR) mmol/l 10.6 (9.4-12.2) 10.5 (9.2-11.5) 
2-hour OGTT plasma glucose at HFDP Median (IQR) mmol/l 12 (11.2-12.8) 9 (8.2-10) 
Treated with metformin during HFDP n (%) 99 (35.6) 61 (28.4) 
Treated with glibenclamide during 
HFDP 
n (%) 9 (3.3) 7 (3.3) 
Treated with insulin during HFDP n (%) 80 (28.8) 52 (24.1) 
Treated with both orals and insulin 
during HFDP 
n (%) 4 (1.4) 3 (1.4) 
Number of hospital admissions during 
HFDP 
Median (IQR) 2 (1-3) 2 (1-3) 
HbA1c at booking Median (IQR) % 6.4 (5.9-7.2) 6.5 (6-7.4) 
Type of birth delivery  Caesarian section, n (%) 144 (52.8) 120 (56.3) 
 Normal virginal, n (%) 129 (47.3) 93 (43.7) 
Fetal outcome Stillborn or miscarriage, 
n (%) 
10 (3.6) 6 (2.8) 
Admitted to NICU n (%) 2 (0.7) 3 (1.4) 
Fetal birthweight Median (IQR) grams 3230 (2805-3620) 3292 (2925-3610) 
*NICE 2008 guidelines were used. GDM referred to women with the following glucose concentrations at 
diagnosis: fasting>7.0mmol/l and OGTT 2-hours ≥11.1mmol/l. IGT referred to women with the following 
glucose at diagnosis: fasting between 5.6-6.9mmol/l and OGTT between 7.8-11.0mmol/l. in the WHO 
2013 GDM diagnosis guidelines, the “GDM” group in the NICE guidelines is now the diabetes in 
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NR* - not reported 
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Appendix 6. PRO2D Chapter 6 Supplementary materials 
Online only supplemental material 
 
Supplemental Table 1.  Comparison of participants followed up 5-6 years later and the participants 
lost to follow-up 
  Lost to follow-
up, N = 278 




Age at booking, years Median (IQR)  31 (26-35) 31 (27-35) 0.879 
Number of pregnancies Median (IQR) 3 (2-4) 3 (2-4) 0.375 
Number of live births Median (IQR) 1 (1-2) 1 (0-2) 0.339 
Gestational age at booking, weeks Median (IQR)  17 (13-22) 15 (11-21) 0.004* 
HIV positive n (%) 19 (6.9) 12 (5.5) 0.545 
CD4 count, cells/dl Median (IQR)  454 (406-545) 492.5 (364-774) 0.725 
BMI at booking, kg/m2 Median (IQR)  32.7 (27.6-
38.4) 
34.6 (28.841.4) 0.041* 
Random blood glucose at HFDP 
diagnosis, mmol/l 
Median (IQR)  12.7 (11.4-
14.4) 
12.7 (11.2-14.1) 0.963 
Fasting plasma glucose at GDM 
diagnosis, mmol/l 
Median (IQR)  5.9 (5.3-6.9) 5.8 (5.1-6.5) 0.054 
1-hour OGTT plasma glucose at 
HFDP diagnosis, mmol/l 
Median (IQR)  10.6 (9.4-12.2) 10.5 (9.2-11.5) 0.064 
2-hour OGTT plasma glucose at 
HFDP diagnosis, mmol/l 
Median (IQR)  12 (11.2-12.8) 9 (8.2-10) 0.011* 
Type of HFDP* DIP, n (%) 122 (43.9) 70 (31.8) 0.008 
 GDM, n (%) 156 (56.1) 150 (67.7) 
Treated with metformin or other 
orals during HFDP  
n (%) 99 (35.6) 61 (28.4) 0.089 
Treated with insulin during HFDP  n (%) 80 (28.8) 52 (24.1) 0.241 
Treated with both orals and insulin 
during HFDP  
n (%) 4 (1.4) 3 (1.4) 0.93 
Number of hospital admissions 
during HFDP  
Median (IQR) 2 (1-3) 2 (1-3) 0.104 
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HbA1c at booking, % Median (IQR) 6.4 (5.9-7.2) 6.5 (6-7.4) 0.327 
Type of birth delivery  Caesarian 
section, n (%) 
144 (52.8) 120 (56.3)  
 
0.439  Virginal, n (%) 129 (47.3) 93 (43.7) 
Gestational age at delivery Median (IQR) 
weeks 
38 (37-38) 38 (37-39) 0.038 
Fetal outcome Stillborn or 
miscarriage, n 
(%) 
10 (3.6) 6 (2.8) 0.598 





*HFDP classified post-hoc, using WHO 2013 criteria 
Supplemental Table 2. Anthropometry and biochemical characteristics at follow-up 
  Overall, n = 220  
Waist circumference (cm) Mean (SD) 110.5 (17.6) 
Hip circumference (cm) Mean (SD) 117.3 (16.1) 
Waist-hip ratio median (IQR) 0.94 (0.89-0.99) 
Waist-height ratio median (IQR) 0.68 (0.61-0.75) 
BMI (kg/m2) Mean (SD) 34.9 (8.7) 
Systolic blood pressure (mmHg) Mean (SD) 114 (14.6) 
Diastolic blood pressure (mmHg) Mean (SD)) 79.7 (10.6) 
Fasting blood glucose (mmol/l) Median (IQR) 5.8 (5.0-8.1) 
OGTT 2-hour glucose (mmol/l) Median (IQR) 8.0 (6.2-11.7) 
HbA1c (%, DCCT units) Median (IQR) 6.0 (5.3-7.8) 
Total cholesterol (mmol/l) Median (IQR) 3.8 (3.2-4.5) 
HDL-cholesterol (mmol/l) Median (IQR) 1.2 (1.0-1.4) 
LDL-cholesterol (mmol/l) Median (IQR) 2.9 (2.3-3.6) 
Triglycerides (mmol/l) Median (IQR) 0.76 (0.55-1.06) 
Fasting insulin (uIU/mL), N = 108 Median (IQR) 13.4 (9.3-20) 
HOMA-IR, N = 108 Median (IQR) 3.0 (1.9 – 5.1) 
 
Supplemental Table 3. CVD risk factors, insulin resistance and metabolic syndrome prevalence 5-6 
years post HFDP and comparison between DIP and GDM groups 
Cardiometabolic risk factor  Overall, 
N = 220 
 DIP**, N = 70 GDM***, 
N = 150 
p-value 
 n (%) 95%CI of 
prevalence 
n (%) n (%)  
Metabolic syndrome 134 
(60.9) 
54.3-67.2 52 (74.3) 82 (54.7) 0.010 
Obese (30≤BMI<40kg/m2) 104 
(47.3) 
40.7-53.9 33 (46.5) 71 (47.7) 0.879 







85.6-93.7 62 (89.9) 135 (90.6) 0.862 
Dysglycaemia 
Fasting glucose≥5.6mmol/l 
or/and 2-hour glucose≥8.5mmol/l 
137 
(62.3) 
55.6-68.5 62 (88.6) 75 (50.0) <0.001* 
Any dyslipidaemia 164 
(74.6) 
68.3-79.9 52 (74.3) 112 (75.2) 0.759 
Triglycerides ≥1.7mmol/l 17 (7.7) 4.8-12.1 9 (12.7) 8 (5.4) 0.058 
Total cholesterol ≥5.2mmol/l 21 (10.9) 20.9-32.6 10 (17.5) 11 (8.1) 0.054 
HDL<1.3mmol/l 139 
(63.2) 
56.6-69.3 41 (58.5) 98 (65.3) 0.249 
BP≥130/85mmHg 91 (41.4) 35.0-48.0 30 (42.9) 61 (40.7) 0.565 
Insulin resistance 
HOMA-IR >1.95, N = 108 




Supplemental Table 4a. Multivariate analysis of factors associated with dysglycaemia, raised blood 
pressure and dyslipidaemia 






























Age at follow-up (years) 1.1 
0.0
79 
0.316 1.0 1.2 1.0 
0.6
35 
1 0.9 1.1 
Follow-up period (years) 0.9 
0.0
02 
0.008 0.9 1.0 1.0 
0.6
88 
1 1.0 1.1 





0.508 0.3 1.2 1.2 
0.7
4 
1 0.5 2.7 
                 Others (vs black) 0.5 
0.3
58 
1 0.1 2.3 0.6 
0.5
25 
1 0.1 3.2 











                    Secondary 




1 0.6 4.9 2.2 
0.1
11 
0.444 0.8 5.7 
Employed (vs unemployed) 0.3 
0.0
02 
0.008 0.2 0.7 0.8 
0.5
68 
1 0.4 1.7 





0.172 1.0 4.8 2.0 
0.0
84 
0.336 0.9 4.3 
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1 0.4 1.7 0.7 
0.3
67 
1 0.3 1.6 





1 1.0 1.0 1.0 
0.3
22 
1 1.0 1.1 





1 0.5 2.3 1.7 
0.3
05 
1 0.6 4.3 
Waist circumference (cm) 1.1 
0.0
09 
0.036 1.0 1.1 1.1 
0.0
08 
0.032 1.0 1.1 
Hip circumference (cm) 1.0 
0.4
49 
1 1.0 1.0 0.9 
0.0
08 
0.032 0.9 1.0 
Weight gain (kg) 1.0 
0.7
01 
1 1.0 1.0 1.0 
0.4
97 
1 1.0 1.1 
Overweight at booking 0.7 
0.5
32 
1 0.2 2.4 2.1 
0.2
41 
0.964 0.6 7.1 
Obese at booking 0.8 
0.6
9 






Morbid obese at booking 1.0 
0.9
65 











1 0.7 1.2 1.0 
0.8
11 
1 0.8 1.3 





1 0.9 1.3 0.9 
0.1
87 
0.748 0.7 1.1 





1 0.4 2.7 0.5 
0.1
4 
0.56 0.2 1.3 
GPAQ total physical activity 1.0 
0.7
74 
1 1.0 1.0 1.0 
0.8
04 










                      
                      
































































NB: For the Bonferroni adjustment – for each outcome, the p-value was multiplied by the number of tests (4 
outcomes – 4 tests). Significance was set at p = 0.05 
 
Supplemental Table 4b. Multivariate analysis of factors associated with dysglycaemia 
and insulin resistance 
 





























Age at follow-up (years) 1.0 
0.44
3 
1 1.0 1.1 
1.
1 
0.533 1 0.9 1.2 
Follow-up period (years) 1.0 
0.24
4 
0.976 0.9 1.0 
1.
0 
0.516 1 0.9 1.1 





0.636 0.8 4.4 
4.
5 
0.051 0.204 1.0 
20.
3 
                 Others (vs black) 0.3 
0.18
2 
0.728 0.1 1.8 
1.
3 
0.817 1 0.1 
12.
6 





1 0.2 6.1 
0.
2 
0.409 1 0.0 8.6 
                    Secondary 




1 0.4 3.0 
0.
5 
0.394 1 0.1 2.3 
Employed (vs unemployed) 0.9 
0.78
1 
1 0.4 1.9 
1.
4 
0.61 1 0.4 5.1 





1 0.4 2.2 
1.
0 
0.964 1 0.3 3.6 





0.5 0.2 1.2 
0.
2 
0.021 0.084 0.0 0.8 





1 1.0 1.0 
1.
0 
0.375 1 1.0 1.1 





1 0.3 1.8 
2.
1 
0.363 1 0.4 9.8 
Waist circumference (cm) 1.1 0 0 1.0 1.1 
1.
1 
0.078 0.312 1.0 1.1 
Hip circumference (cm) 0.9 
0.01
1 
0.044 0.9 1.0 
0.
9 
0.158 0.632 0.9 1.0 
Weight gain (kg) 1.0 
0.19
1 
0.764 1.0 1.1 
1.
1 
0.138 0.552 1.0 1.1 
Overweight at booking 0.5 
0.28
6 
1 0.1 1.9 
3.
5 





Obese at booking 1.0 
0.97
3 
1 0.3 4.3 
6.
7 
0.08 0.32 0.8 
55.
4 
Morbid obese at booking 1.1 
0.92
4 
1 0.1 8.6 
10
.4 
0.127 0.508 0.5 
211
.8 





0.072 1.1 2.4 
2.
3 
0.051 0.204 1.0 5.2 





0.052 1.1 1.7 
1.
0 
0.889 1 0.6 1.7 













    
GPAQ total physical activity 1.0 
0.59
4 
1 1.0 1.0 
1.
0 




0.048 0.0 0.2 
0.
0 
0.233 0.932 0.0 
77.
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NB: For the Bonferroni adjustment – for each outcome, the p-value was multiplied by the number of 


















Consent for Child Participation in research 
Research Title: The prevalence of Type 2 diabetes mellitus and associated risk factors 
5 years after gestational diabetes mellitus in South Africa 
Principal Investigators: Professor Naomi Levitt, Professor Shane Norris, Professor 
Christina Zarowsky, Tawanda Chivese 
Contact Address:   Chronic Disease Initiative for Africa, J47 Room 86, Old Groote 
Schuur Hospital Building Observatory, 7935, Cape Town 
Telephone:   +27 21 4066572  
Fax:    +27 21 4486815  




Your child is invited to take part in a research project which asks the question: How 
many 5-6-year-old children born to women who had diabetes in their pregnancy are 
overweight?  
This research project is being conducted at the University of Cape Town and the 
University of the Witwatersrand in Johannesburg. A researcher from the University of 




This research will be carried out according to the Declaration of Helsinki, which protects 
people who take part in research.  
Most women who had diabetes during pregnancy recover from the diabetes after the 
birth of their babies, but their children may be overweight when growing up. This makes 
it easy for them to become sick with type 2 diabetes and other illnesses like heart 
disease. Type 2 diabetes is a chronic condition that affects the way your body uses 
sugar (glucose), your body's source of fuel. If we can find that someone has type 2 
diabetes earlier, we can start treatment sooner and this may cause fewer long term 
problems.  
We do not know how many 5-6-year-old children born to women with diabetes during 
pregnancy are overweight in South Africa. Knowing this will enable us to develop better 
programs to look after children born to mothers who had diabetes during pregancy. 
Additionally, knowing factors that increase the chance of their children being overweight 
can help lower the risk of them developing diabetes and heart disease later in their life. 
Please ask the study staff any questions about any part of this project that you do not 
fully understand. You are free to say yes or to say no. If you say no, your child’s medical 
care will continue just as before, and it will not be held against you. You are also free to 
withdraw your child from the study at any point, even if you do agree to take part. 
Why has your child been invited to participate? 
We are inviting all 5-6 year-old children who live in Cape Town and Soweto whose 
mothers received treatment for diabetes during pregnancy at Groote Schuur Hospital 
and Chris Hani Baragwanath Hospital to take part in the research.  
What will your child’s participation entail? 
Your child has been asked to come to the Groote Schuur Hospital (or Chris Hani 
Baragwanath Hospital) in order to take part in the research. The participation will be no 
more than 30 minutes. You will be asked some questions about your child in a 
questionnaire. Some of the questions will be to see if your child has been sick, if he/she 
is taking any medicines for any illness and whether you breast fed your child. 
Your child will also be weighed on a scale and have his/her height measured. 
 Will your benefit from taking part in this research? 
If any illnesses are identified during the research then your child will be referred to a 
clinic for follow-up and management. You will also be told the results of the weight and 
height measurements of your child. 
Are there any risks involved in your child taking part in this research? 
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Your child will only have his/her height and weight measured. He/she will not have any 
bloods taken and will not be given any medicines during this study. If your child does 
not want to have their weight and height measured, we will not force him/her. 
Your child’s name and personal details will be kept strictly confidential and will not be 
given to anyone to minimise the risk of improper disclosure of information.  
 
If you do not want your child to take part, what alternatives do you have? 
Not taking part in the study will not change your child’s future care or treatment if and 
when you take him/her to hospitals or clinics. Your child will be treated the same as 
other children who participate in the study. The researchers are not the same people as 
your child’s usual doctors. 
Please ensure that you have carefully read and understood this information sheet and 
been given a copy to keep for yourself.  
Contact details of researchers: For any questions or concerns, please feel free to 
contact the researchers whose details are listed below: 
 
Tawanda Chivese                         Email: tchivese@gmail.com 
       Tel: 0216505131 
Professor Naomi Levitt    Email: Naomi.Levitt@uct.ac.za 
       Tel: 0216505110 
Professor Shane Norris    Email: san@global.co.za 
Professor Christina Zarowski   Email: czarowsky@gmail.com 
 
You may contact the University of Cape Town Human Research Ethics Committee if 
you have any questions or concerns about your child’s rights and welfare. The contact 
details are listed below    
Email: sumayahariefdien@uct.ac.za 
Tel: 021 406 6338 








PARENTAL CONSENT  
 
Study Title: The prevalence of Type 2 diabetes mellitus and associated risk factors 5 
years after gestational diabetes mellitus in South Africa 
By signing this document: 
I confirm that I have read the above information and understand it. I confirm that I have 
had an opportunity to ask questions and I am satisfied with the answers and 
explanations that have been given to me. 
I give my permission for my child (Insert child’s name………) to have their height and 
weight measured. 
I agree to answer question about my child’s (Insert child’s name………) health 
I understand that my participation in this research is voluntary and I am free to withdraw 
my child (Insert child’s name………) at any time without having to give a reason. 
Please tick one of the boxes below: 
 
  YES, I would like my child (Insert child’s name………) to take part in this study 
  NO, I do not wish my child (Insert child’s name………) to take part in this study 
 





Name of researcher: ……………………………….                    Signature………………….   
Date: ………………… 
 
Name of witness……………………..    Signature………………… 
Date …………………….. 
 
If participant is not able to write: 













Postcode   
Telephone  
Cell   
Secondary cell  
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Next of kin telephone  
Next of kin cell  
Next of kin address  
Date of birth  







Appendix 7.2. PRO2D Chapter 7 Supplementary materials 
 
Online only material  
The influence of maternal blood glucose during pregnancy on weight outcomes 
at birth and preschool age in offspring exposed to hyperglycemia first detected 
during pregnancy, in a South African cohort  
Supplementary Table 1 – comparison of maternal and child characteristics of children followed up and 
those lost to follow up at 5-6 years age 
variable level Lost to follow up, N = 276 Followed up, N = 167 p-value  
Birthweight (mean (SD)) 3320.85 (583.35) 3303.47 (554.96) 0.757 
Birthweight z-score (mean 
(SD)) 
0.30 (1.08) 0.19 (1.07) 0.294 
Maternal age at booking (mean 
(SD)) 
30.55 (6.11) 30.41 (6.29) 0.813 
Maternal BMI at booking 
(mean (SD)) 
33.99 (8.40) 35.20 (8.78) 0.193 
Child gender (n 
(%)) 
Female  145 (52.5) 80 (47.9) 0.397 
 
Male  131 (47.5) 87 (52.1) 
 
Birth delivery 
method (n (%)) 
Caesarian 
Section 




Vaginal  128 (46.5) 82 (49.4) 
 
Maternal HIV 
infection (n (%)) 
POS 21 (7.6) 6 (3.6) 0.129 
CD4 (median [IQR]) 453.00 [360.00, 543.50] 492.50 [382.50, 729.25] 0.75 
HFDP type (n 
(%)) 
DIP 115 (41.7) 50 (29.9) 0.018 
 
GDM 161 (58.3) 117 (70.1) 
 
Insulin during 
HFDP (n (%)) 






YES 91 (33.0) 50 (30.1) 0.605 
Gestational age at delivery 
(median [IQR]) 
38.00 [38.00, 38.00] 38.00 [38.00, 39.00] 0.221 
Gravida (median [IQR]) 3.00 [2.00, 4.00] 3.00 [1.00, 4.00] 0.65 
Parity (median [IQR]) 1.00 [1.00, 2.00] 1.00 [0.00, 2.00] 0.472 
Gestational age at booking 
(median [IQR]) 
17.00 [13.00, 23.00] 15.00 [12.00, 21.00] 0.006 
Fasting blood glucose at HFDP 
diagnosis (median [IQR]) 
5.80 [5.35, 6.75] 5.80 [5.00, 6.40] 0.136 
OGTT 2-hour glucose at HFDP 
diagnosis (median [IQR]) 
9.20 [8.30, 10.90] 8.90 [8.20, 10.00] 0.046 
Hemoglobin (median [IQR]) 12.00 [11.20, 12.80] 12.10 [11.40, 13.10] 0.163 
HbA1C (median [IQR]) 6.40 [5.80, 7.15] 6.40 [6.00, 7.40] 0.379 
Average maternal random 
blood glucose during 
pregnancy (median [IQR]) 
5.60 [5.00, 6.20] 5.60 [5.10, 6.10] 0.824 
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